



Title	Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
Author(s)	Chan, JFW; Lau, SKP; To, KKW; Cheng, VCC; Woo, PCY; Yuen, KY
Citation	Clinical Microbiology Reviews, 2015, v. 28 n. 2, p. 465-522
Issued Date	2015
URL	http://hdl.handle.net/10722/211848
Rights	Clinical Microbiology Reviews. Copyright © American Society for Microbiology.

1 **Title:** Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing
2 severe disease

3

4 **Running title:** Middle East respiratory syndrome coronavirus

5

6 **Authors:** Jasper F. W. Chan,^{a,b,c} Susanna K. P. Lau,^{a,b,c} Kelvin K. W. To,^{a,b,c} Vincent C. C.
7 Cheng,^b Patrick C. Y. Woo,^{a,b,c} and Kwok-Yung Yuen^{a,b,c*}

8

9 **Affiliations:**

10 State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong
11 Kong Special Administrative Region, China^a;

12 Department of Microbiology; The University of Hong Kong, Hong Kong Special Administrative
13 Region, China^b; and

14 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong
15 Special Administrative Region, China^c.

16

17 ***Corresponding author:** Kwok-Yung Yuen. Mailing address: Carol Yu Centre for Infection,
18 Department of Microbiology, The University of Hong Kong, 102 Pokfulam Road, Pokfulam,
19 Hong Kong Special Administrative Region, China. E-mail: kyyuen@hku.hk. Phone:
20 +85222554892. Fax: +85228551241.

21 **Word Count:** summary, 211; text, 15637.

22 **Keywords:** MERS, Middle East respiratory syndrome, coronavirus, SARS, severe acute
23 respiratory syndrome

24	SUMMARY
25	INTRODUCTION: FROM SARS TO MERS
26	TAXONOMY, NOMENCLATURE, AND GENERAL VIROLOGY
27	VIRAL REPLICATION CYCLE
28	SEQUENCE OF EVENTS IN THE MERS EPIDEMIC
29	EPIDEMIOLOGY
30	Risk Factors for Severe Disease
31	Seroepidemiology
32	Animal Surveillance
33	Molecular Epidemiology
34	Mathematical Modeling
35	CLINICAL MANIFESTATIONS
36	HISTOPATHOLOGY AND PATHOGENESIS
37	Histological Changes
38	Innate Immune Response
39	Adaptive Immune Response
40	Organ-Specific Pathology and Systemic Virus Dissemination
41	LABORATORY DIAGNOSIS
42	Specimen Collection
43	Nucleic Acid Amplification Assays
44	Antibody Detection Assays
45	Antigen Detection Assays
46	Viral Culture

47	CLINICAL MANAGEMENT AND ANTIVIRALS
48	INFECTION CONTROL AND LABORATORY SAFETY
49	VACCINATION
50	Active Immunization
51	Passive Immunization
52	ANIMAL MODELS AND ANIMALS SUSCEPTIBLE TO MERS-CoV
53	CONCLUSIONS
54	ACKNOWLEDGEMENTS
55	REFERENCES
56	AUTHOR BIOS

57 **SUMMARY**

58 The source of the SARS epidemic was traced to wildlife market civets and ultimately to bats.
59 Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human
60 and over 40 animal CoVs, including the prototype lineage C betacoronaviruses, *Tylonycteris* bat
61 CoV HKU4 and *Pipistrellus* bat CoV HKU5, which are phylogenetically closely related to the
62 Middle East respiratory syndrome coronavirus that has affected >900 patients with >35% fatality
63 since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the
64 Middle East. Some had contacted camels which shed virus and/or had positive serology. Most
65 secondary cases are related to healthcare-associated clusters. The disease is especially severe in
66 elderly men with comorbidities. Clinical severity may be related to MERS-CoV's ability to infect
67 a broad range of cells with DPP4 expression, evade host innate immune response, and induce
68 cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary
69 specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane
70 oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent
71 *in-vitro* activities include neutralizing monoclonal antibodies, antiviral peptides, interferons,
72 mycophenolic acid, and lopinavir. They should be evaluated in better animal models before
73 clinical trials. Developing camel MERS-CoV vaccine and implementing appropriate infection
74 control measures may control the expanding epidemic.

75 **INTRODUCTION: FROM SARS TO MERS**

76 Frequent mixing of different animal species in markets in densely populated areas and human
77 intrusions into the natural habitats of animals have facilitated the emergence of novel viruses.
78 Examples with specific geographical origins include severe acute respiratory syndrome
79 coronavirus (SARS-CoV) and avian influenza A/H7N9 and H5N1 in China, Nipah virus in
80 Malaysia and Bangladesh, and Ebola and Marburg viruses in Africa (1-8). The Middle East is a
81 region encompassing the majority of Western Asia and Egypt that contains 18 countries with
82 various ethnic groups. It is one of the busiest politicoeconomic centers in the world with many
83 unique religious and cultural practices such as the annual Hajj along with a reliance on camels
84 for food, business, and travel in both rural and urban areas. These distinct regional characteristics
85 have provided favorable conditions for new and rapidly mutating viruses to emerge. Similar to
86 the first decade of the new millennium during which the world witnessed the devastating
87 outbreak of SARS caused by SARS-CoV, the beginning of the second decade was plagued by the
88 emergence of another novel CoV, Middle East respiratory syndrome coronavirus, that has caused
89 an outbreak of severe respiratory disease in the Middle East with secondary spread to Europe,
90 Africa, Asia, and North America since 2012 (3, 9). MERS-CoV is similar to SARS-CoV in being
91 a CoV that is likely to have originated from animal reservoirs and crossed interspecies barriers to
92 infect humans (1). The disease, Middle East respiratory syndrome (MERS), was initially called a
93 “SARS-like” illness at the beginning of the epidemic as both are human CoV infections that
94 manifest as severe lower respiratory tract infection with extrapulmonary involvement and high
95 case-fatality rates (10, 11), whereas the other four CoVs that cause human infections, namely
96 human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-HKU1, and HCoV-NL63, mainly cause
97 mild, self-limiting upper respiratory tract infections such as the common cold (10). MERS-CoV,

98 like SARS-CoV, is considered by the global health community as a potential pandemic agent
99 since person-to-person transmission occurs and effective therapeutic options are limited.
100 However, unlike the SARS epidemic, which rapidly died off after the intermediate amplifying
101 hosts were identified and segregated from humans by closure of wild animal markets in Southern
102 China, the MERS epidemic has persisted for **more than** two years with no signs of abatement (3,
103 12). Detailed analysis of the epidemiological, virological, and clinical aspects of MERS and
104 SARS reveals important differences between the two diseases, and identifies unique aspects of
105 MERS-CoV that may help to explain the evolution of the MERS epidemic. A summary of the
106 key differences between the MERS and SARS epidemics is provided in Table 1. In this article,
107 we review the biology of MERS-CoV in relation to its epidemiology, clinical manifestations,
108 pathogenesis, laboratory diagnosis, therapeutic options, immunization, and infection control, and
109 identify key research priorities that are important for the control of this evolving epidemic.

110

111 **TAXONOMY, NOMENCLATURE, AND GENERAL VIROLOGY**

112 MERS-CoV belongs to lineage C of the genus *Betacoronavirus* (β CoV) in the family
113 *Coronaviridae* under the order *Nidovirales* (Fig. 1A). Prior to the discovery of MERS-CoV, the
114 only known lineage C β CoVs were two bat coronaviruses that are phylogenetically closely
115 related to MERS-CoV, namely *Tylonycteris* bat CoV HKU4 (Ty-BatCoV-HKU4) and *Pipistrellus*
116 bat CoV HKU5 (Pi-BatCoV-HKU5) discovered in *Tylonycteris pachypus* and *Pipistrellus*
117 *abramus* respectively in Hong Kong in 2006 (Fig. 1B) (13-15). MERS-CoV is the first lineage C
118 β CoV and the sixth CoV known to cause human infection. It was designated as a novel lineage C
119 β CoV based on the International Committee on Taxonomy of Viruses (ICTV) criteria for CoV
120 species identification using rooted phylogeny. Calculation of pairwise evolutionary distances for

121 seven replicase domains showed that MERS-CoV had an amino acid sequence identity of <90%
122 when compared to all other known CoVs at the time when MERS-CoV was discovered (16).
123 Before the virus was formally named MERS-CoV by the Coronavirus Study Group of ICTV, it
124 was also known by other names including “novel coronavirus”, “human coronavirus EMC”,
125 “human betacoronavirus 2c EMC”, “human betacoronavirus 2c England-Qatar”, “human
126 betacoronavirus 2C Jordan-N3”, and “betacoronavirus England 1”, which represented the places
127 where the first complete viral genome was sequenced (Erasmus Medical Center, Rotterdam, the
128 Netherlands) or where the first laboratory-confirmed cases were identified or managed (Jordan,
129 Qatar, England) (9, 17-20). Similar to other CoVs, MERS-CoV is an enveloped positive-sense
130 single-stranded RNA virus (16). Its **single-stranded RNA** genome has a size of **approximately** 30
131 kb, G+C content of 41%, and contains 5'-capped, polyadenylated, polycistronic RNA (16, 20,
132 21). The genome arrangement of **5'-replicase-structural proteins (spike-envelope-membrane-**
133 **nucleocapsid)-poly(A)-3'** [ie: **5'-ORF1a/b-S-E-M-N-poly(A)-3'**] is similar to that of other
134 β CoVs, and unambiguously distinguishes MERS-CoV from lineage A β CoVs, which universally
135 contain the characteristic hemagglutinin-esterase (HE) gene (16, 20-22). Many of these genes
136 and their encoded proteins are useful diagnostic, therapeutic, or vaccination targets (Fig. 2).
137 There are 10 complete, functional open reading frames (ORFs) expressed from a nested set of
138 seven subgenomic mRNAs carrying a 67-nt common leader sequence in the genome, eight
139 transcription-regulatory sequences, and two terminal untranslated regions (16, 20, 21). The
140 putative roles and functions of the ORFs and their encoded proteins are derived by analogy to
141 other CoVs (Table 2). Proteolytic cleavage of the large replicase polyprotein **pp1a/b** encoded by
142 the partially overlapping 5'-terminal ORF1a/b within the 5' two-thirds of the genome produces
143 16 putative non-structural proteins (nsp), including two viral cysteine proteases, namely nsp3

144 (papain-like protease) and nsp5 (chymotrypsin-like, 3C-like, or main protease), nsp12 (RNA-
145 dependent RNA polymerase; RdRp), nsp13 (helicase), and other nsps which are likely involved
146 in the transcription and replication of the virus (16, 20, 21). The membrane anchored trimeric S
147 protein is a major immunogenic antigen involved in virus attachment and entry into host cell, and
148 has an essential role in determining virus virulence, protective immunity, tissue tropism, and host
149 range (23). The other canonical structural proteins, namely E, M, and N proteins, are encoded by
150 ORF6, -7, and -8 respectively, and are involved in the assembly of the virion. The M protein, as
151 well as the papain-like protease and accessory proteins 4a, 4b, and 5, exhibit *in vitro* interferon
152 antagonist activities that may modulate *in vivo* replication efficiency and pathogenesis (24-28).

153

154 **VIRAL REPLICATION CYCLE**

155 The replication cycle of MERS-CoV consists of numerous essential steps that can be efficiently
156 inhibited by antiviral agents *in vitro* (Fig. 3). CoVs are so named because of their characteristic
157 solar corona (*corona soli*) or “crown-like” appearance observed under electron microscopy,
158 which represents the peplomers formed by trimers of S protein radiating from the virus lipid
159 envelope. The MERS-CoV S protein is a class I fusion protein composed of the amino N-
160 terminal receptor-binding S1 and carboxyl C-terminal membrane fusion S2 subunits (Fig. 2). The
161 S1/S2 junction is the location of a protease cleavage site which is required to activate membrane
162 fusion, virus entry, and syncytia formation. The S1 subunit consists of the C-domain, which
163 contains the receptor binding domain (RBD), and an N-domain (29). The RBD of MERS-CoV
164 has been mapped by different groups to a 200 to 300-residue region spanning residues 358 to
165 588, 367 to 588, 367 to 606, 377 to 588, or 377 to 662 (29-36). Among these RBD-containing
166 fragments, the one that encompasses residues 377 to 588 appears to be the most stable and

167 neutralizing fragment in structural analysis and virus neutralization assays (36). Neutralizing
168 monoclonal antibodies against the RBD potently inhibit virus entry into host cells and receptor-
169 dependent syncytia formation in cell culture, and vaccines containing the RBD induce high
170 levels of neutralizing antibodies in mice and rabbits (31, 34, 36-43). The S2 subunit contains the
171 heptad repeat 1 and 2 (HR1 and HR2) domains, a transmembrane domain, and an intracellular
172 domain that form the stalk region of S protein which facilitates fusion of the viral and cell
173 membranes necessary for virus entry (44, 45). The binding of the S1 subunit to the cellular
174 receptor triggers conformational changes in the S2 subunit which inserts its fusion peptide into
175 the target cell membrane to form a six-helix bundle fusion core between the HR1 and HR2
176 domains that approximates the viral and cell membranes for fusion. This fusion process can be
177 inhibited by HR2-based antiviral peptide fusion inhibitors **which prevent the interaction between**
178 **the HR1 and HR2 domains** (44, 45).

179 The key functional receptor of the host cell attached to by the MERS-CoV S protein is
180 dipeptidyl peptidase-4 (DPP4), which is also known as adenosine deaminase complexing protein
181 2 or CD26 (46). MERS-CoV is the first coronavirus that has been identified to use DPP4 as a
182 functional receptor for entry into host cells (1, 46). DPP4 is a multifunctional 766-amino-acid-
183 long type II transmembrane glycoprotein presented as a homo-dimer on the cell surface which is
184 involved in the cleavage of dipeptides (46, 47). It has important roles in glucose metabolism and
185 various immunological functions including T cell activation, chemotaxis modulation, cell
186 adhesion, and apoptosis (46, 47). In humans, it is abundantly expressed on the epithelial and
187 endothelial cells of most organs including lung, kidney, small intestine, liver, and prostate, as
188 well as immune cells, and exists as a soluble form in the circulation (46-48). This broad tissue
189 expression of DPP4 may partially explain the extrapulmonary manifestations seen in MERS.

190 Adenosine deaminase, which is a natural competitive antagonist, and some anti-DPP4
191 monoclonal antibodies exhibit inhibitory effects on *in vitro* MERS-CoV infection (49, 50).

192 The energetically unfavorable membrane fusion reaction in endosomal cell entry is
193 overcome by low pH and the pH-dependent endosomal cysteine protease cathepsins, and can be
194 blocked by lysosomotropic agents such as ammonium chloride, bafilomycin A, and cathepsin
195 inhibitors in a cell type-dependent manner (23, 51). Additionally, various host proteases, such as
196 transmembrane protease serine protease-2 (TMPRSS2), trypsin, chymotrypsin, elastase,
197 thermolysin, endoproteinase Lys-C, and human airway trypsin-like protease, cleave the S protein
198 into the S1 and S2 subunits to activate the MERS-CoV S protein for endosomal-independent host
199 cell entry at the plasma membrane (23, 51-53). Inhibitors of TMPRSS2 can abrogate this
200 proteolytic cleavage and partially block cell entry (23, 51, 52). In some cell lines, MERS-CoV
201 demonstrates the ability to utilize both the cathepsin-mediated endosomal and the TMPRSS2-
202 mediated plasma membrane pathways to enter host cells (51, 52).

203 In addition to these cellular proteases, furin has recently been identified as another
204 protease that has essential roles in the MERS-CoV S protein cleavage activation (54). Furin and
205 furin-like proprotein convertases are broadly expressed serine endoproteases that cleave the
206 multibasic motifs RX(R/K/X)R and processes proproteins into their biologically active forms
207 (55). Proprotein convertases including furin have been implicated in the processing of fusion
208 proteins and therefore cell entry of various viruses including human immunodeficiency virus,
209 avian influenza A/H5N1 virus, Marburg virus, Ebola virus, and flaviviruses (55-57). The MERS-
210 CoV S protein contains two cleavage sites for furin at S1/S2 (₇₄₈RSVR₇₅₁) and S2' (₈₈₄RSAR₈₈₇)
211 and exhibits an unusual two-step furin-mediated activation process (Fig. 2) (54). Furin cleaves
212 the S1/S2 site during S protein biosynthesis and the S2' site during virus entry into host cell (54).

213 Furin inhibitors such as dec-RVKR-CMK block MERS-CoV entry and cell-cell fusion (54).
214 Treatment of MERS-CoV infection with a combination of inhibitors of the different cellular
215 proteases utilized by MERS-CoV for S activation should be further evaluated in *in vivo* settings.

216 After cell entry, MERS-CoV disassembles to release the inner parts of the virion
217 including the nucleocapsid and viral RNA into the cytoplasm for translation of the viral 1a and
218 1b polyproteins and replication of genomic RNA (Fig. 3). The characteristic replication
219 structures of CoVs including double-membrane vesicles and convoluted membranes are formed
220 by the attachment of the hydrophobic domains of the MERS-CoV replication machinery to the
221 limiting membrane of autophagosomes (58). These structures can be observed at the perinuclear
222 region of the infected cells under electron microscopy (58). The viral papain-like protease and
223 3C-like protease co-translationally cleave the large replicase polyproteins pp1a and pp1b
224 encoded by ORF1a/b into nsp1 to nsp16 (16, 59, 60). These nsps form the replication-
225 transcription complex where transcription of the full length positive genomic RNA yields a full
226 length negative strand template for synthesis of new genomic RNAs as well as a series of
227 overlapping subgenomic negative strand templates for synthesis of subgenomic 3' co-terminal
228 mRNAs that will be translated to make viral structural and accessory proteins (58). The relative
229 abundance of the subgenomic mRNAs of MERS-CoV is similar to those of other CoVs, with the
230 smallest mRNA, which encodes the N protein, being the most abundant (58). After adequate
231 viral genomic RNA and structural proteins have been cumulated, the N protein assembles with
232 the genomic RNA in the cytoplasm to form the helical nucleocapsid. The nucleocapsid then
233 acquires its envelope by budding through intracellular membranes between the endoplasmic
234 reticulum and Golgi apparatus. The S, E, and M proteins are transported to the budding
235 compartment where the nucleocapsid probably interacts with M protein to generate the basic

236 structure and complexes with the S and E proteins to induce viral budding and release from the
237 Golgi apparatus (61). The viral replication cycle is completed when the assembled virion is
238 released through exocytosis to the extracellular compartment.

239

240 **SEQUENCE OF EVENTS IN THE MERS EPIDEMIC**

241 On 23 September 2012, the World Health Organization (WHO) reported two cases of acute
242 respiratory syndrome with renal failure associated with a novel CoV in two patients from the
243 Middle East (Table 3). The viral strains obtained from the respiratory tract specimens of these
244 two epidemiologically-unlinked patients shared 99.5% nucleotide identity with each other, with
245 only one nucleotide mismatch in partial replicase gene sequencing (18). In the following week,
246 the WHO and other collaborative healthcare authorities rapidly responded to the outbreak by
247 providing a unified interim case definition, making the complete genome sequence publicly
248 available in GenBank, and establishing a laboratory diagnostic protocol for real-time **reverse**
249 **transcription (RT)**-PCR using the upE (upstream of E gene) and ORF1b assays (16, 62). With
250 these important tools, sporadic cases were increasingly detected in the Middle East over the
251 subsequent six months, including two retrospectively diagnosed cases that occurred in a
252 healthcare-associated cluster of severe respiratory disease in Zarqa, Jordan, in April 2012 (19,
253 63-66). Additional cases were also reported in Europe and Africa among patients with recent
254 travel to the Arabian Peninsula and their close hospital and household contacts (18, 67-74). The
255 fear of person-to-person transmission was further heightened by the occurrence of a large-scale
256 outbreak involving over 20 patients in four interrelated hospitals in Al-Hasa, the Kingdom of
257 Saudi Arabia (KSA), from April to May 2013 (75).

258 In view of the significant epidemiological link of all the reported cases to the region, the

259 ICTV formally named the novel virus MERS-CoV on 15 May 2013 (17). However, the epidemic
260 was not contained within the Middle East as its name implied, and the number of patients and
261 countries involved continued to escalate over the following years (76-81). In particular, there was
262 a sudden surge of over 400 cases in KSA and the United Arab Emirates (UAE) within just two
263 months from mid-March to May 2014 as a result of both an increased number of primary cases
264 possibly related to the weaning season of dromedary camels, a probable zoonotic source of
265 MERS-CoV, and an amplification of the number of secondary cases by several healthcare-
266 associated outbreaks in the region during the same period (82,
267 http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf)
268 . As of 17 December 2014, the WHO has reported a total of 938 laboratory-confirmed cases of
269 MERS including 343 deaths. The affected countries with primary cases include KSA, Qatar,
270 Jordan, UAE, Oman, Kuwait, Egypt, Yemen, Lebanon, and Iran in the Middle East. The
271 countries with imported cases include the United Kingdom, Germany, France, Italy, Greece, the
272 Netherlands, Austria, and Turkey in Europe, Tunisia and Algeria in Africa, Malaysia and the
273 Philippines in Asia, and the United States in North America.

274

275 **EPIDEMIOLOGY**

276 Among the first 699 laboratory-confirmed cases of MERS, 63.5% were male and the median age
277 was 47 years, with a range of 9 months to 94 years
278 ([http://www.who.int/csr/disease/coronavirus_infections/MERS-](http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf)
279 [CoV_summary_update_20140611.pdf](http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf)). The persistence of the epidemic is postulated to be
280 related to repeated animal-to-human transmissions from at least one type of animal reservoir that
281 is in frequent contact with residents in the region, which are amplified by non-sustained person-

282 to-person transmission in multiple large-scale healthcare-associated outbreaks and limited
283 household clusters (67, 68, 70, 71, 73-75, 83, 84,
284 [http://www.who.int/csr/disease/coronavirus_infections/MERS-](http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf)
285 [CoV_summary_update_20140611.pdf](http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf)). Human infection has been linked to the contacts with
286 dromedary camels (*Camelus dromedarius*) or other humans infected with MERS-CoV, but
287 alternative sources of infection are possible as many patients did not have epidemiological link to
288 infected camels or humans. All primary MERS cases were epidemiologically linked to the
289 Middle East and all secondary cases in other countries were linked to primary cases imported
290 from the Middle East. The incubation period is estimated to be 5.2 days, with a range of 1.9 to
291 14.7 days, and 95% of infected patients have symptom onset by day 12.4 (63, 75). The serial
292 interval, representing the time between the case's symptom onset and the contact's symptom
293 onset, is estimated to be 7.6 days with a range of 2.5 to 23.1 days, and is less than 19.4 days in
294 95% of the cases (63, 75). The rate of secondary transmission among household contacts of
295 MERS patients is estimated to be about 4% (85).

296

297 **Risk Factors for Severe Disease**

298 Among the first 536 laboratory-confirmed cases reported by the WHO, 62% were severe cases
299 that required hospitalization (77). Severe cases requiring hospitalization were more commonly
300 seen among primary cases which mainly consist of older patients with comorbidities. The
301 secondary cases were mostly younger patients and healthcare workers without comorbidities, but
302 severe nosocomial infection among patients sharing contaminated equipment with improper
303 barrier controls have also been reported (75,
304 http://www.who.int/csr/disease/coronavirus_infections/MERS-

305 [CoV_summary_update_20140611.pdf](#)) (Table 4). In a clinical cohort from KSA with 47 severe
306 cases requiring hospitalization, the patients' median age was 56 years. There was a male
307 predominance with a male to female ratio of 3.3 to 1 (63). About 96% of the patients had
308 comorbidities, with the most common being diabetes mellitus (68%), chronic renal disease
309 (49%), hypertension (34%), chronic cardiac disease (28%), and chronic pulmonary disease
310 (26%). Smoking and obesity were also reported in 23% and 17% of the patients respectively. The
311 predominance of older males with comorbidities among severe cases was also reported in other
312 case series at variable rates, depending on the size and setting of the studies (63, 66, 75, 80, 86-
313 89). Furthermore, age of over 50 years, male sex, and the presence of multiple comorbidities
314 were associated with a higher fatality rate (63, 87, 90). Some of these conditions are highly
315 prevalent among residents in the Middle East, for example, diabetes mellitus in nearly 63% of
316 persons at or older than 50 years in KSA (91). Their relative risk of developing severe MERS
317 requires further evaluation in large-scale case-control studies. Patients who develop
318 complications such as acute respiratory distress syndrome requiring hospitalization and/or
319 intensive care are also at risk of fatal outcome (87).

320

321 **Seroepidemiology**

322 The interim WHO case definition used early in the epidemic was criticized for being focused on
323 identifying severe cases which might have over-estimated the clinical severity and significance
324 of MERS (92). This was supported by the increasing number of asymptomatic and mild cases
325 identified in subsequent enhanced surveillance among contacts of MERS patients in various
326 clusters. It was thus suggested that the genuine epidemiology of MERS-CoV might be more
327 similar to that of HCoV-HKU1 rather than SARS-CoV in that the infection is prevalent in the

328 general population, but only manifests severely in the elderly and immunocompromised (93-96).
329 However, seroepidemiological studies conducted so far have refuted this hypothesis as there is
330 little evidence of past infection among the general population in the Middle East. Serum anti-
331 MERS-CoV antibodies were not detected in archived serum samples of 2400 control in- or out-
332 patients without MERS in KSA, suggesting that MERS-CoV was unlikely to be circulating in the
333 general population during the preceding two years (9, 90). Similarly, serum neutralizing anti-
334 MERS-CoV antibodies were not detected among 158 children hospitalized for lower respiratory
335 tract infections and 110 adult male blood donors in KSA between May 2010 and December 2012
336 (97). Even among 226 slaughterhouse workers who had contact with various livestock species
337 that might serve as zoonotic sources of MERS-CoV, neutralizing anti-MERS-CoV antibodies
338 were not detected in serum samples collected in October 2012 (98). Additional region-wide
339 seroepidemiological studies that include large collections of archived samples from earlier
340 timepoints may determine the true prevalence and clinical severity of MERS among residents in
341 the affected areas.

342

343 **Animal Surveillance**

344 Given the sudden emergence of MERS-CoV without definite serological evidence of past
345 exposure in the general population, a novel episode of interspecies transmission of the virus was
346 postulated. An intense hunt for animal reservoirs of MERS-CoV was sparked by the early
347 recognition of the close phylogenetic relationship between MERS-CoV and the prototype lineage
348 C β CoV, Ty-BatCoV-HKU4 and Pi-BatCoV-HKU5, which suggested the possibility of MERS-
349 CoV being a zoonotic agent (9, 13, 14, 21, 99). Subsequent functional studies showed that Ty-
350 BatCoV-HKU4 also utilizes DPP4 as a functional receptor for cell entry in pseudotyped virus

351 assay (100, 101). These findings concur with the existing notion that bats are the likely gene
352 sources of most α CoVs and β CoVs including SARS-CoV (1, 15, 102-107). Recent reports also
353 show a high nonsynonymous (d_N) to synonymous (d_S) nucleotide substitutions per site ratio in
354 the bat DPP4-encoding genes (108). This adaptive evolution on the bat DPP4 is suggestive of
355 long-term interactions between bats and MERS-CoV-related viruses (108). In addition to Ty-
356 BatCoV-HKU4 and Pi-BatCoVHKU5 which are found in bats in Hong Kong and Southern
357 China, other lineage C β CoVs closely related to MERS-CoV were also identified in different bat
358 species in the Middle East, Africa, Europe, and Central America after the MERS epidemic
359 started (Table 5). The virus that is most closely related to MERS-CoV phylogenetically was a
360 β CoV detected in the fecal pellet of a *Taphozous perforatus* bat caught in Bisha, KSA, near the
361 home of a patient with laboratory-confirmed MERS, which shared 100% nucleotide identity with
362 MERS-CoV by partial RdRp gene sequencing (109). However, this study was limited by the
363 short length of the gene fragment analyzed (182 nucleotides) and its detection in only one of 29
364 (3.4%) *T. perforatus* bats caught at the same location. Furthermore, no live virus was isolated
365 from any of these bats. Subsequent studies identified a closely related virus, NeoCoV, in the
366 feces of a *Neoromicia capensis* bat in South Africa which had a complete genome sequence
367 sharing 85.6% nucleotide identity with those of MERS-CoV from infected humans and
368 dromedary camels (110, 111). Based on the estimated evolutionary rate of MERS-CoV, the most
369 recent common ancestor between NeoCoV and human MERS-CoV strains was proposed to exist
370 in bats more than 44 years ago (112). As the same lineage of CoVs are usually found and
371 originate from closely related bat species, the likelihood of MERS-CoV originating from both *T.*
372 *perforatus* (superfamily *Emballonuroidea*) and vespertilionid bats (*Neoromicia capensis*,
373 *Pipistrellus* sp., and *Tylonycteris pachypus* in the superfamily *Vespertilionoidea*), which belong

374 to two distantly related superfamilies of insectivorous bats, is low (20, 110, 111). Interestingly,
375 European hedgehogs (*Erinaceus europaeus*) belonging to the order *Eulipotyphla*, which is
376 closely related to bats phylogenetically, also carry high concentrations of a MERS-CoV-related
377 lineage C β CoV, *Erinaceus* CoV, in their feces and intestines (113). Further surveillance and full
378 virus genome sequencing involving a larger population of different bat and bat-related species is
379 required to confirm these preliminary findings.

380 Besides the possibility of direct interspecies transmission of SARS-CoV from bats to
381 humans, it is postulated that intermediate amplifying animal hosts such as civets and raccoon
382 dogs might also have been important in the transmission of SARS. Therefore, specific
383 intermediate animal hosts of MERS-CoV with frequent contact with infected humans were
384 sought since the early phase of the MERS epidemic (3, 114, 115). In *in vitro* studies, MERS-CoV
385 can replicate efficiently not only in a variety of bat cell lines, but also in cell lines originating
386 from other animal species including camelid, goat, pig, rabbit, and civet (116-118) (Table 6). The
387 host range is mainly determined by the binding of the MERS-CoV S protein to the host receptor
388 DPP4, which is relatively conserved among mammalian species (30, 48, 49, 119, 120). The first
389 *in vivo* evidence to support the presence of an intermediate animal reservoir of MERS-CoV
390 emerged when high-titer of serum neutralizing IgG against the MERS-CoV S1 RBD were
391 detected in dromedary camels (121). All 50 Omani dromedary camels were seropositive as
392 compared to less than 10% of the Spanish dromedary camels and none of the other common
393 livestock species in the study. This suggested that widespread circulation of MERS-CoV or a
394 closely related virus was present among dromedary camels in this Middle Eastern country.
395 Numerous seroepidemiological studies also demonstrated serological evidence of MERS-CoV
396 infection in dromedary camels in other Middle Eastern countries including KSA, Qatar, UAE,

397 and Jordan, and also in African countries including Egypt, Kenya, Nigeria, Ethiopia, Tunisia,
398 **Somalia, and Sudan** where most of the camels found in the Middle East have originated from
399 (Table 5). Serological evidence of infection among camels was detected in archived specimens
400 collected in as early as **1992 and 1983 in KSA and eastern Africa** respectively, and was
401 especially prevalent in areas of high dromedary population density (122-133). These findings
402 suggested that unrecognized primary human cases of MERS might also be present outside the
403 Middle East. On the other hand, studies in Qatar and several other countries showed that anti-
404 MERS-CoV antibodies were not detected in the sera of other livestock species tested including
405 goats, sheep, cows, water buffaloes, swine, and wild birds
406 (http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf).

407 Furthermore, it was also shown that the percent seropositivity of neutralizing anti-MERS-CoV
408 antibodies was much lower in juvenile than adult dromedary camels, suggesting that acutely
409 infected juvenile dromedary camels without neutralizing antibodies might be a more important
410 source for transmission to humans than adult dromedary camels (123, 127).

411 The significance of camels as the major source of animal-to-human transmission required
412 further virological studies on the pattern of viral shedding in camels and their relationship to
413 laboratory-confirmed human cases (Fig. 4). An investigation of a disease outbreak in dromedary
414 camels in Qatar demonstrated MERS-CoV in nasal swabs, but not rectal swabs or fecal samples,
415 of three of 14 (21.4%) camels by RT-PCR sequencing (133). The nucleotide sequences of a 940-
416 nucleotide ORF1a fragment and a 4.2 kb concatenated gene fragment of these camel strains were
417 very similar to those of two epidemiologically-linked human strains. This study, however, was
418 not able to conclusively establish the direction of transmission or exclude the presence of a third
419 source of infection. Subsequently, the detection of MERS-CoV in dromedary camels was

420 reported in a number of studies conducted in different areas in the Middle East, which provided
421 further insights into the viral shedding kinetics in camels (123, 128, 129, 131, 134). In agreement
422 with the lower frequency of neutralizing anti-MERS-CoV antibodies in juvenile camels, the rate
423 of detection of MERS-CoV RNA in the nasal and/or rectal swabs of juvenile camels was higher
424 than those of adult camels (123). These findings may partially explain the absence of serum
425 neutralizing anti-MERS-CoV antibodies among camel abattoir workers who have predominantly
426 contacted adult camels (135, 136). These serological surveys should be confirmed by virus
427 neutralization assays. Nevertheless, infected adult camels might still be a source of human
428 infection. **Similar to HCoVs and other respiratory viruses that can cause repeated infections in**
429 **humans over a lifetime, MERS-CoV shedding could be** observed in camels with pre-existing
430 serum antibodies, suggesting that prior infection and passively acquired maternal antibodies
431 might not provide complete protection from MERS-CoV infection and/or re-infection in camels
432 (129). The fact that the majority of amino acid residues critical for receptor binding are identical
433 between most human and camel strains further supports the potential of the dromedary MERS-
434 CoVs to infect humans despite differences in clinical manifestations of infected humans and
435 camels (129, 131). The higher positivity rate of MERS-CoV RNA in nasal swabs than in rectal
436 swabs or fecal samples, and the isolation of MERS-CoV from cultures of nasal swabs but not
437 rectal swabs of camels in Vero E6 cells correlated with the predominantly upper respiratory tract
438 symptoms in acutely infected symptomatic camels (129, 137). Together with the genetic stability
439 of MERS-CoV in camels, these serological and virological data from animal surveillance support
440 the hypothesis that MERS-CoV has likely originated from bats in Africa and then crossed species
441 barriers to infect camels in the greater Horn of Africa many years ago. Infected camels were then
442 transported to the Middle East where they transmitted the virus to non-immune humans to cause

443 the epidemic (111).

444 The strongest evidence of direct cross-species transmission of MERS-CoV from camels
445 to humans was provided in a study reporting the isolation of the virus from a dromedary camel
446 which had a complete genome sequence identical to that of a human strain from a patient who
447 developed MERS after close contact with sick camels that had rhinorrhea (138). Serological tests
448 showed seropositivity in the camels but not in the patient before the human infection occurred
449 (138). The air sample collected from the camel barn on the same day when a sick camel tested
450 positive for MERS-CoV, but not on the subsequent two days, was also positive for MERS-CoV
451 RNA by RT-PCR (139). This suggests that the virus may persist in the air surrounding infected
452 animals or humans for less than 24 hours, although viral infectivity is uncertain because the virus
453 was not culturable from the air sample. Another similar study also reported a human case of
454 MERS that developed after the patient had contact with sick camels with respiratory symptoms
455 (128). Comparison of eight RT-PCR fragments, constituting 15% of the virus genomes derived
456 from the infected camel and from an epidemiologically-linked patient, showed nearly 100%
457 nucleotide identity (128). The genomes of both the camel and human strains of MERS-CoV
458 contained unique nucleotide polymorphism signatures not found in any other known MERS-CoV
459 sequences and therefore supported direct cross-species transmission (128). Preliminary results
460 from an ongoing investigation in Qatar showed that people working closely with camels,
461 including farm workers, slaughterhouse workers, and veterinarians, may be at higher risk of
462 developing MERS than those who do not have regular contact with camels
463 (http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf).

464 Notably, while these studies support camel-to-human transmission, a bidirectional mode of
465 transmission cannot be completely excluded at this stage.

466 In spite of these examples that support the hypothesis of direct camel-to-human cross-
467 species transmission of MERS-CoV, a number of important questions remain unresolved at this
468 stage. Firstly, it is uncertain whether camels are intermediate amplification hosts or the natural
469 reservoirs of MERS-CoV. Although bats are postulated to be the natural host of most β CoVs
470 including MERS-CoV, the detection of anti-MERS-CoV antibodies in archived sera of camels
471 dating back to **more than 28 years ago in eastern Africa** and more than 20 years ago in KSA, the
472 high genetic stability of MERS-CoV in camels, and the high sequence nucleotide identities
473 between camel and human strains of MERS-CoV suggest that the virus was well adapted and
474 circulating in camels for a long time (123, 129). The reason why human infection has not been
475 reported until 2012 remains elusive. Notably, a different novel lineage A β CoV, named
476 dromedary camel CoV UAE-HKU23, has also been discovered in the fecal samples of
477 dromedary camels in Dubai, UAE recently (140). Further surveillance studies may provide novel
478 insights into the role of this unique camelid species, which also have heavy-chain antibodies as
479 humoral defense, in the emergence of novel CoVs (141). Another unresolved question is whether
480 an alternative source may be present but undetected at this stage. It is noteworthy that a
481 significant proportion of laboratory-confirmed human cases did not have a clear history of
482 contact with camels (83, 142). Evaluation of other animal species endemic in the region using
483 validated serological and virological assays should be conducted. Finally, the route of
484 transmission of MERS-CoV from camels to humans remains unknown at this stage. Droplet
485 transmission appears likely as evidenced by the high viral loads in the nasal and conjunctival
486 swabs of camels and the surrounding air samples. However, viral shedding in nasal secretions is
487 usually short-lasting during acute infection, which may limit viral transmission by this route
488 (129). Direct contact with other infected bodily fluids including blood and feces is also possible,

489 but viral shedding in these samples is also transient in acute infection (129). Food-borne
490 transmission through ingestion of infected unpasteurized camel milk, in which MERS-CoV can
491 survive for at least 48 hours at 4°C or 22°C, has also been suggested. But it has yet to be
492 definitively proven that camels actively shed MERS-CoV in their milk as contamination by
493 feces, nasal secretions, or calf saliva containing the virus cannot be completely excluded (143).
494 The presence of neutralizing antibody in milk may also limit the virus' infectivity *in vivo* (144).
495 In human MERS cases without direct exposure to camels, contact with environments
496 contaminated with infected camel secretions and aerosol transmission are other possibilities that
497 warrant further investigations (139, 145).

498

499 **Molecular Epidemiology**

500 Detailed analysis of the molecular evolution and spatiotemporal distribution of genomes
501 of human and animal strains of MERS-CoV provides useful information for detecting viral
502 adaptation to animal-to-human and person-to-person transmissions, identifying zoonotic and
503 other sources of human infections, and assessing the pandemic potential of the virus.
504 Comparative analysis of 65 complete or near-complete genomes of human MERS-CoV strains
505 identified early in the epidemic from June 2012 to September 2013 estimated the evolutionary
506 rate of the coding regions of the viral genome to be 1.12×10^{-3} (95% confidence interval, $8.76 \times$
507 10^{-4} to 1.37×10^{-3}) substitutions per site per year (146). The time to the most recent common
508 ancestor (TMRCA) of MERS-CoV was estimated to be March 2012 (95% confidence interval,
509 December 2011 to June 2012) (112, 146). Compared with the genome of one of the earliest
510 human MERS-CoV strains, the genomes of the MERS-CoV strains obtained from patients
511 diagnosed between October 2012 and June 2013 showed various nucleotide changes in the last

512 third of the genomes, which represent potential amino acid changes in the accessory proteins and
513 the S protein encoded at nucleotide positions 21,000-25,500 (112). Specifically, codon 1020 at
514 the HR1 domain of the S gene was identified to be under strong episodic selection among
515 different geographical lineages with either a histidine or arginine at this position (112, 146).
516 Although the amino acid variations are not predicted to change the alpha helical structure of this
517 region, the histidine and arginine provide an endosomal protonated residue and a potential
518 endosomal protease cleavage site respectively that may affect the S protein membrane fusion
519 activity (146). Codon 158 at the N-terminal domain and codon 509 at the RBD of the S gene are
520 also noted to be under weaker positive selection (146). As mutations in the RBD of the S protein
521 of CoVs may be associated with changes in the transmissibility across and within species, the
522 phenotypic changes associated with these genomic variations should be ascertained (3, 29, 147-
523 149).

524 In addition to the results of animal surveillance studies and investigations of human
525 MERS outbreaks, genomic analysis also supports the hypothesis that MERS-CoV is transmitted
526 from both animal-to-human and person-to-person. Among genomes of sporadic human MERS
527 cases, numerous distinct phylogenetic clades and genotypes exist, which likely represent separate
528 instances of incursions from animals to human (112). Indeed, at least four clades of MERS-CoV
529 were identified in KSA, with three of them apparently no longer widely circulating during May
530 to September 2013 (146). In a large healthcare-associated outbreak in Al-Hasa, person-to-person
531 transmissions were supported by genomic analysis in at least 8 of 13 patients (75, 112). Two
532 phylogenetically distinct MERS-CoV strains were detected in a family cluster in Riyadh, KSA,
533 in October 2012, suggesting that at least two distinct lineages of MERS-CoV were circulating in
534 Riyadh during this time period and that human clusters might involve multiple sources with more

535 than one virus lineage (112). The genomic diversity of MERS-CoV detected in patients from the
536 same locality and the geographical dispersion of MERS-CoV lineages in the Middle East suggest
537 the presence of **multiple** mobile infection sources such as animal reservoirs, infected animal
538 products, and/or infected patients in the epidemic regions (146). This hypothesis fits well with
539 the evidence of MERS-CoV infection in dromedary camels, which are an important vehicle for
540 transportation of goods and travelers, as well as food source in the Middle East. Notably,
541 quasispecies of MERS-CoV within single samples have been detected in samples from
542 dromedary camels but not humans or Vero cell isolates from the same animal (137). Further
543 studies using next-generation high throughput sequencing are required to confirm the presence of
544 quasispecies and clonal virus populations within individual human cases, **which may help**
545 **identify specific genotypes that can pass the bottleneck selection** to cause cross-species
546 transmission from camels to humans, and help to explain the relative rarity of human cases
547 despite the widespread circulation of MERS-CoV in dromedary camels for prolonged periods in
548 the Middle East and North Africa (137).

549

550 **Mathematical Modeling**

551 Mathematical **modeling** has been widely used to predict the spread and pandemic potential of
552 emerging viruses. Although the interval for data accumulation may diminish the predictive value
553 of mathematical **modeling** and its impact on epidemiological control or policy setting, these
554 studies provide a preliminary estimate of the pandemic potential of emerging viruses if enough
555 data are included in the calculations. Three real-time predictions of the spread of MERS-CoV
556 have been conducted for the current epidemic and have estimated the basic reproduction number
557 (R_0), the number of secondary cases per index case in a fully susceptible population, to be 0.30-

558 0.77 (150), 0.60-0.69 (90), or 0.8-1.3 (151), as compared to about 0.8 for pre-epidemic SARS-
559 CoV. These estimates imply the occurrence of a subcritical epidemic in the Middle East, which is
560 unlikely to sustain person-to-person transmission of MERS-CoV, especially when infection
561 control measures are implemented (150). The estimated daily rate of MERS-CoV introductions
562 into the human population in the Middle East is 0.12-0.85 and the expected yearly incidence of
563 MERS introduction was estimated to be between 160 and 320 cases per year (90, 150). Clearly,
564 these estimations are at most only modestly accurate for a number of reasons. Firstly, these
565 studies were conducted early in the epidemic when the total number of laboratory-confirmed
566 cases was only less than one-eighth of that reported by the WHO as of 17 December 2014 (90,
567 150, 151). This low number limited the accuracy of the predictions as sufficient caseload is
568 required to calculate the basic parameters for estimation of the worst- and best-case scenarios to
569 gauge the magnitude of the epidemic. The omission of large clusters may underestimate the R_0
570 (90). Secondly, most of the cases reported in the early period of the epidemic were biased
571 towards including more severe cases. The increasingly recognized number of asymptomatic or
572 mildly symptomatic cases identified through enhanced surveillance programmes may further
573 underestimate the R_0 (90). Finally, the R_0 may also be affected by community demographics,
574 contact structure, large gatherings such as the Hajj, and exportation of patients from the
575 relatively less populated Middle East to densely populated areas such as Southeast Asia (78, 90).
576 Updated mathematical modeling using the latest available epidemiological and virological data
577 may increase the accuracy of these estimates.

578

579 **CLINICAL MANIFESTATIONS**

580 The early reports of MERS have focused on severe cases which typically presented as acute

581 pneumonia with rapid respiratory deterioration and extrapulmonary manifestations (Table 7).
582 Few clinical and radiological features can reliably differentiate MERS from acute pneumonia
583 caused by other microbial agents (80). The common presenting symptoms of MERS are non-
584 specific, and include feverishness, chills, rigors, sore throat, non-productive cough, and dyspnea.
585 Other symptoms of respiratory tract infections including rhinorrhea, sputum production,
586 wheezing, chest pain, myalgia, headache, and malaise may also be present. Rapid clinical
587 deterioration with development of respiratory failure usually occurs within a few days after these
588 initial symptoms (80). Physical signs at the time of deterioration may include high fever,
589 tachypnea, tachycardia, and hypotension. Diffuse crepitations may be present on chest
590 auscultation, but they may be disproportionately mild compared with radiological findings (68).

591 Chest radiograph abnormalities are found in nearly all severe cases and often progress
592 from a mild unilateral focal lesion to extensive multifocal or bilateral involvement especially of
593 the lower lobes as the patient deteriorates (63). The radiological changes are non-specific and
594 indistinguishable from other viral pneumonias associated with acute respiratory distress
595 syndrome (ARDS), and include air-space opacities, segmental, lobar or patchy consolidations,
596 interstitial ground glass infiltrates, reticulonodular shadows, bronchial wall thickening, increased
597 bronchovascular markings, and/or pleural and pericardial effusions (Table 7). Rarely, pneumonia
598 may be an incidental finding in chest radiograph and precede the sudden deterioration in
599 respiratory function in patients who are harboring a “walking pneumonia” with minimal
600 respiratory tract symptoms (63, 68). The most common thoracic computerized tomography (CT)
601 scan features are bilateral, predominantly basilar and subpleural airspace involvement, with
602 extensive ground-glass opacities, and occasional septal thickening and pleural effusions (152).
603 Tree-in-bud pattern, cavitation, and lymph node enlargement have not been reported. Fibrotic

604 changes including reticulation, traction bronchiectasis, subpleural bands, and architectural
605 distortion may be found in thoracic CT scans performed three weeks after symptom onset. These
606 different changes in thoracic CT scan throughout the course of disease are suggestive of
607 organizing pneumonia and may mimic those seen in other viral pneumonias such as influenza (4,
608 8, 153-156).

609 Various extrapulmonary manifestations involving multiple body systems have been
610 reported in MERS (Table 7). Acute renal impairment was the most striking feature in the early
611 reports (9, 18). This finding was confirmed in subsequent sporadic reports and at least three case
612 series that provided specific details on renal function, in which more than half of the patients
613 developed acute renal impairment at a median time of around 11 days after symptom onset, with
614 most requiring renal replacement therapy (88, 152, 157). This is unique among CoV infections of
615 human. For SARS, only around 6.7% of patients developed acute renal impairment mainly due
616 to hypoxic injury at a median duration of 20 days after symptom onset and 5% required renal
617 replacement therapy (158, 159). The exceptionally high incidence of this distinctive
618 manifestation of MERS is likely multi-factorial. These include the high prevalence of
619 background chronic renal impairment among severe cases and the renal tropism of MERS-CoV
620 (63, 116, 157). The presence of MERS-CoV RNA in urine also supports the possibility of direct
621 renal involvement, but the exact incidence and prognostic significance of this finding is unknown
622 at present (72).

623 As in humans infected with SARS-CoV and animals infected with other CoVs, patients
624 infected with MERS-CoV may have enteric symptoms in addition to respiratory tract
625 involvement (3, 160, 161). Gastrointestinal symptoms are found in more than a quarter of
626 hospitalized cases in a large cohort in KSA (63). Diarrhea is the most common symptom and

627 occurs in 6.7% to 25.5% of severe cases. Nausea, vomiting, and abdominal pain may also occur.
628 The detection of viral RNA in fecal samples has been reported, but longitudinal studies on the
629 pattern of viral shedding are lacking (72). It remains to be determined whether cases of acute
630 abdomen presenting as ischemic bowel or negative findings on laparotomy result from hypoxic
631 damage or direct viral invasion of the gastrointestinal tract (88).

632 Other extrapulmonary features of MERS include hepatic dysfunction, pericarditis,
633 arrhythmias, and hypotension (66). Hematological abnormalities include leukopenia or
634 leukocytosis, usually accompanied by lymphopenia with normal neutrophil count, and
635 thrombocytopenia. Compared to other patients with pneumonia, patients with MERS are more
636 likely to have a normal leukocyte count on admission (80). Anemia, coagulopathy, and
637 disseminated intravascular coagulation have also been reported (64, 72, 162). Elevated levels of
638 serum transaminases, lactate dehydrogenase, potassium, creatine kinase, troponin, C-reactive
639 protein, and procalcitonin, and reduced levels of serum sodium and albumin are seen
640 occasionally.

641 Complications of MERS include bacterial, viral, and/or fungal co-infections, ventilator-
642 associated pneumonia, septic shock, delirium, and possibly stillbirth (9, 69, 71, 73) (Table 7).
643 Respiratory failure with ARDS and multiorgan dysfunction syndrome is not uncommon, and the
644 majority of such patients require admission to the intensive care unit at a median of 2 to 5 days
645 from symptom onset. The median time from symptom onset to invasive ventilation and/or
646 extracorporeal membrane oxygenation (ECMO) in these patients is 4.5 to 7 days, which is at
647 least 6 days earlier than that of SARS (63, 75, 88, 162, 163). The duration of stay in the intensive
648 care unit is often prolonged with a median of 30 days (range: 7 to 104 days). The case-fatality
649 rate is up to 25.0% to 76.5% in various cohorts (Table 7).

650 With enhanced surveillance of healthcare-associated and family contacts of MERS
651 patients, an increasing number of asymptomatic and mild cases have been identified. Most of
652 these patients are young, healthy female healthcare workers or children who do not have any
653 comorbidities (65, 164). Among 402 patients identified in the recent clusters that occurred in
654 KSA between 11 April 2014 and 9 June 2014, 109 (27.1%) were healthcare workers. Of note,
655 though many were either asymptomatic or mildly symptomatic, more than one-third developed
656 moderate to severe disease requiring hospitalization and nearly 4% died
657 ([http://www.who.int/csr/disease/coronavirus_infections/MERS-
658 CoV_summary_update_20140611.pdf](http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf)). Severe and even fatal cases have also been reported
659 among infected children, especially in those who have underlying diseases such as cystic fibrosis
660 and Down's syndrome with congenital heart disease and hypothyroidism (164). Therefore, even
661 healthcare workers and children with MERS should be monitored closely for clinical
662 deterioration.

663

664 **HISTOPATHOLOGY AND PATHOGENESIS**

665 The pathogenesis of MERS is under-studied and poorly understood. Serial sampling for
666 characterization of the innate and adaptive immune responses is lacking in human cases of
667 MERS. Due to religious and cultural reasons, post-mortem examination was seldom performed
668 in Islamic patients who died of MERS and no post-mortem findings have been reported so far.
669 Thus, the current understanding on the histopathology and pathogenesis of MERS is limited to
670 findings in *in vitro*, *ex vivo*, and animal experiments.

671

672 **Histological Changes**

673 In rhesus macaques infected with MERS-CoV, macroscopic changes of acute pneumonia
674 including multifocal to coalescent bright red palpable nodules with congestion occurred
675 throughout the lower respiratory tract in necropsy lung tissues collected on day 3 post-infection
676 (165-167). On day 6 post-infection, these inflamed areas progressed into dark reddish purple
677 lesions. Microscopically, the changes resembled those seen in mild to severe acute interstitial
678 pneumonia, characterized by alveolar infiltration by small to moderate numbers of macrophages
679 and fewer neutrophils with occasional multinucleate syncytia, and thickening of alveolar septae
680 by edema fluid and fibrin on day 3 post-infection. Lesions similar to those described in early
681 bronchiolitis obliterans with organizing pneumonia consisting of aggregations of fibrin,
682 macrophages, and sloughed pulmonary epithelium that occluded small airways, and multifocal
683 perivascular infiltrates of inflammatory cells within and adjacent to the affected areas of lungs
684 were also reported. On day 6 post-infection, moderate to marked microscopic changes including
685 type II pneumocyte hyperplasia, alveolar edema, and hyaline membranes of fibrin were observed
686 (166). In situ hybridization and immunohistochemistry demonstrated viral RNA and antigen
687 respectively in type I and II pneumocytes, alveolar macrophages, and occasionally round
688 mononuclear cells and stellate cells within the cortex of the mediastinal lymph nodes, but not in
689 pulmonary endothelial cells, on both days 3 and 6 post-infection (166, 167). Infected cells were
690 not observed in the kidney, brain, heart, liver, spleen, and large intestine of the infected rhesus
691 macaques (167). Common marmosets infected with MERS-CoV showed similar but more severe
692 histological findings. In necropsied lungs of common marmosets euthanized on days 3 to 4 post-
693 infection, extensive transcriptional evidence of pulmonary fibrosis was present (168). In
694 immunosuppressed rhesus macaques using cyclophosphamide and dexamethasone with depleted
695 T and B cells and disrupted splenic and mesenteric lymph node architectures, MERS-CoV

696 replicated more efficiently and affected more tissues as compared to non-immunosuppressed
697 controls. Interestingly, the immunosuppressed animals had fewer histological changes associated
698 with infection despite having higher virus replication in the lungs, suggesting that
699 immunopathology might also play a key role in MERS (169).

700

701 **Innate Immune Response**

702 Immune evasion is an important strategy utilized by CoVs to overcome the innate immune
703 response for efficient replication in the host. MERS-CoV is capable of inhibiting recognition,
704 delaying interferon induction, and dampening interferon-stimulated genes (ISGs) expression in
705 polarized human bronchial epithelia (Calu-3) cells until peak viral titers have been reached (170).
706 While MERS-CoV triggers an activation of pattern recognition receptors that is similar to SARS-
707 CoV, their subsequent levels of interferon induction in Calu-3 cells are markedly different (171).
708 This may be related to the different structural and accessory proteins of the two viruses that act
709 as interferon antagonists. Instead of the papain-like protease, **accessory proteins 3b and 6, nsp1,**
710 **M, and N proteins** which are the major putative interferon antagonists of SARS-CoV, the papain-
711 like protease encoded by nsp3 of ORF1a/b, M protein encoded by ORF7, and accessory proteins
712 **4a and 4b** encoded by ORF4a and -4b respectively of MERS-CoV antagonize interferons *in vitro*
713 (3, 24, 25, 27, 28, 172). Among them, the MERS-CoV **accessory protein 4a**, a double-stranded
714 RNA-binding protein, exhibits potent antagonistic activity at multiple levels of the interferon
715 response including the prevention of interferon- β synthesis through the inhibition of interferon
716 promoter activation and interferon regulatory factor 3 (IRF3) function, and inhibition of the
717 interferon-stimulated response element (ISRE) promoter signaling pathway in human (HEK-
718 293T) and/or primate kidney (Vero) cells (24). Specifically, it inhibits PACT-induced activation

719 of retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated protein 5
720 (MDA5), which are key cytosolic recognition receptors of virus-derived RNAs (25).
721 Furthermore, preliminary data show that MERS-CoV, but not SARS-CoV, may employ an
722 additional mechanism to antagonize ISG via altered histone modification which affects a diverse
723 spectrum of biological processes including gene regulation (170). With the attenuated interferon
724 response at the cellular level, the virus may then employ the deISGylating and deubiquitinating
725 activities of its papain-like protease to take over the host metabolic apparatus (28, 172, 173).
726 Efficient viral replication may follow and result in cell damage through direct virus-induced
727 cytolysis or immunopathology via dysregulated pro-inflammatory cytokine induction.

728 In addition to these *in vitro* data, the roles of the different branches of the innate immune
729 response have been assessed in a limited number of animal models and patients. MERS-CoV
730 infection is more severe in knockout C57BL/6 and BALB/c mice with impaired type I interferon
731 or Toll-like receptor signaling than those with impaired RIG-I-like receptor signaling, suggesting
732 that the former signaling pathways are more important for controlling the infection (174). The
733 depletion of natural killer cells, a major cellular component of the innate immune response, does
734 not significantly affect the clinical disease severity or viral clearance kinetics (174). In rhesus
735 macaques, the innate immune response occurs and resolves very rapidly after MERS-CoV
736 inoculation. A type I interferon response is observed on days 1 and 2 and disappears on day 3
737 after infection (166, 175). Robust but transient up-regulation of the expression levels and
738 elevated serum levels of proinflammatory cytokines and chemokines including interleukin-6 (IL-
739 6), chemokine (C-X-C motif) ligand 1 (CXCL1), and matrix metalloproteinase 9 (MMP9) are
740 associated with chemotaxis and activation of neutrophils as evidenced by increased numbers of
741 neutrophils in the blood and lungs of the infected animals (166). In humans who develop severe

742 MERS, significant differences are noted between the innate immune responses of fatal and non-
743 fatal cases. Compared to a patient who survived, a patient who died from MERS induced lower
744 expression levels of RIG-I and MDA-5, which led to decreased expression levels of IRF3 and
745 IRF7 (176). This was associated with a major decrease in the amount of mRNA and protein of
746 interferon- α in serum and bronchoalveolar lavage. Additionally, the antigen presentation
747 pathway was broadly down-regulated and affected types I and II major histocompatibility
748 (MHC) genes which were associated with significantly lower expression levels of the key
749 cytokines involved in the activation of lymphocytes into CD4+ Th1 cells, including IL-12 and
750 interferon- γ (176, 177). Increased levels of IL-17A and IL-23 in the serum and bronchoalveolar
751 lavage within the first week after symptom onset, and persistent uncontrolled secretion of the
752 type-1 interferon-triggered CXCL10 and IL-10 beyond the first week after symptom onset, were
753 noted in fatal MERS cases and might be associated with poor outcome as in SARS and other
754 respiratory viral infections (176, 178-181). A poorly coordinated innate immune response with
755 ineffective activation of the adaptive immune response that failed to clear MERS-CoV viremia
756 appeared to be associated with fatal outcome (176, 182).

757

758 **Adaptive Immune Response**

759 Systematic study on the adaptive immune response to MERS in large cohorts of human cases is
760 lacking. T-cell or combined T- and B-cell deficiencies, but not B-cell deficiency, were found to
761 be associated with persistent infections and lack of virus clearance in C57BL/6 and BALB/c
762 mice transduced with adenoviral vectors expressing human DPP4, highlighting the important
763 role of T cells in acute clearance of MERS-CoV (174). In terms of antibody-mediated immunity
764 which is essential for protection against subsequent challenge by the virus, the CD8 T-cell

765 response to the immunodominant epitopes located in the MERS-CoV S protein is shown to peak
766 at days 7 to 10 post-infection and exhibits only low level of cross-reactivity with the T-cell
767 response to SARS-CoV infection (174). In rhesus macaques infected with MERS-CoV, serum
768 neutralizing antibodies are detected on as early as day 7 post-infection, reaching a peak titer on
769 day 14 post-infection, and decreasing slightly in titer on day 28 post-infection. In patients with
770 MERS, high titers of serum neutralizing antibodies can be detected on day 12 and persist for at
771 least 13 months after symptom onset (66, 72, 81, 183). Both IgM and IgG against S and N
772 proteins are detectable in the sera of infected patients on day 16 after symptom onset, with the
773 titer of IgG being at least 10 times higher than that of IgM, suggesting that the initial IgM
774 antibody response is likely mounted before this time period (72). IgG titers peaked at three
775 weeks after symptom onset, while IgM titers remained elevated between two to five weeks after
776 symptom onset in a patient (184). Notably, serum anti-MERS-CoV antibodies were undetectable
777 in a patient who died on days 26 and 32 after symptom onset, suggesting that inadequate
778 antibody response may be associated with poor clinical outcome (66). The exact onset and
779 changes in titer of serum neutralizing anti-MERS-CoV antibodies should be further evaluated in
780 subsequent clinical cohorts consisting of patients with different severities and outcomes.
781 Moreover, given the *in vitro* observation that the viral fitness and evolution may be restricted by
782 the immunodominance of the anti-MERS-CoV-RBD neutralizing antibody response that blocks
783 binding to human DPP4, B cell-associated antibodyome studies from MERS patients should be
784 performed to further assess the role that immunoglobulin polymorphisms play in determining the
785 protective antibody repertoire and clinical outcomes (40).

786

787 **Organ-Specific Pathology and Systemic Virus Dissemination**

788 Although *in vitro* cell line studies and even *ex vivo* organ cultures may not completely represent
789 *in vivo* scenarios, they have provided insightful clues to explain the pathogenesis involved in the
790 pulmonary and extrapulmonary manifestations of MERS, before findings from animal models
791 and post-mortem examination are available (Table 6). The *in vitro* observation that MERS-CoV
792 replicates more efficiently in a variety of lower respiratory tract cell lines than in upper
793 respiratory tract cell lines, and the inability of the human bronchial epithelium to mount a timely
794 and adequate innate immune response against MERS-CoV infection in the absence of
795 professional cytokine-producing cells including dendritic cells and macrophages may partially
796 explain the high incidence of severe cases in MERS (116, 157, 171, 185-188). The finding in *ex*
797 *vivo* culture systems that MERS-CoV is capable of infecting most cell types of the human
798 alveolar compartment including non-ciliated and possibly ciliated epithelial cells, types I and II
799 pneumocytes, and endothelial cells of pulmonary vessels further supports the notion that all the
800 host cell factors necessary for viral replication are available in the human lung (187, 189-191).
801 Additionally, MERS-CoV can also infect pulmonary vascular endothelial cells and lung
802 macrophages, which corroborates with the clinical observation of systemic dissemination of the
803 virus with viremia in severe cases (191).

804 Besides lower respiratory tract cells, MERS-CoV also exhibits a peculiar tropism for
805 renal cells that is not seen in any other CoVs associated with human infections and not
806 explainable by the expression of their respective host cell receptors. Avian nephropathogenic
807 infectious bronchitis virus may cause lymphoplasmacytic interstitial nephritis, but rarely
808 pneumonia, in broiler chickens (192). MERS-CoV replicates efficiently to about 5 logs above the
809 baseline titer with abundant N protein expression and prominent cytopathic effects (CPE) within
810 72 hours after infection in human embryonic kidney cells (116). In primary kidney epithelial

811 cells and primary bronchial epithelial cells infected with either MERS-CoV or SARS-CoV,
812 pronounced CPE with rounding, detachment, and death of the majority of cells occur only in
813 primary kidney epithelial cells infected with MERS-CoV, although viral replication was
814 detectable with both viruses (157). The concentration of infectious MERS-CoV progeny in
815 primary kidney epithelial cells was almost 1000-fold higher than that in primary bronchial
816 epithelial cells (157). Together with the clinical observation that MERS-CoV RNA may be
817 detectable in the urine without viremia after almost 2 weeks of symptom onset, these *in vitro*
818 findings suggest that the kidney may be a potential site of autonomous virus replication (72,
819 157). Comparable findings are also observed in many bat and primate kidney cell lines, although
820 clinical disease in these animals is much milder than in humans and viral RNA is not detectable
821 in the kidneys of infected rhesus macaques (116, 117). As in the case of *ex vivo* lung cultures, it
822 would be important to elucidate the specific pathways involved in virus-host cell interactions
823 affecting different cell types such as podocytes in the renal cortex and others in the medulla
824 which are often involved in renal disease pathogenesis.

825 In view of the pronounced systemic inflammatory response with multi-organ involvement
826 and hematological abnormalities seen in patients with MERS, the specific roles of immune cells
827 in the pathogenesis of the disease have been investigated. Among the immune cells, human
828 histiocytes efficiently support viral replication with N protein expression *in vitro* on as early as
829 day 1 post-infection, while increased viral RNA levels without N protein expression are
830 detectable in human monocyte and T lymphocyte cell lines (116). Correspondingly, *ex vivo*
831 culture systems of human monocyte-derived dendritic cells and macrophages confirm that
832 MERS-CoV can productively infect both of these important professional antigen-presenting cell
833 types with high-level and persistent induction of immune cell-recruiting cytokines (191, 193).

834 This leads to recruitment and infiltration of a large number of immune cells into the infected lung
835 tissues as is seen clinically. Moreover, the sequestration of lymphocytes at infected tissues
836 resulting from the induction of CXCL10 and monocyte chemotactic protein 1 (MCP-1) may also
837 explain marked peripheral lymphopenia that is commonly seen in MERS (191). Together with
838 the wide distribution of DPP4 in different human cell types, the ability of MERS-CoV to hijack
839 these professional antigen-presenting cells as vehicles for systemic dissemination to and
840 induction of immunopathology at various organs may help to explain the unusually severe multi-
841 organ involvement in MERS.

842

843 **LABORATORY DIAGNOSIS**

844 There are no pathognomonic clinical, biochemical, or radiological features that reliably
845 differentiate MERS from other causes of acute community- or hospital-acquired pneumonia. Due
846 to the lack of Biosafety Level 3 (BSL-3) containment, nucleic acid amplification assays are the
847 most widely used method to provide laboratory confirmation of MERS with a short turn-around
848 time using a unified testing protocol that was established early on in the epidemic. The WHO
849 criteria for a laboratory-confirmed case include either a positive RT-PCR result for at least two
850 different specific targets on the MERS-CoV genome, or one positive RT-PCR result for a specific
851 target on the MERS-CoV genome and an additional different RT-PCR product sequenced,
852 confirming identity to known sequences of MERS-CoV (Table 8)
853 ([http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)
854 [a=1](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)). Isolation of infectious MERS-CoV from respiratory tract specimens, and possibly also
855 blood, urine, and fecal samples, also provides laboratory confirmation, but virus isolation has a
856 longer turn-around time than nucleic acid amplification assays, requires experienced staff for

857 interpretation of CPE and confirmation of infection by RT-PCR or immunostaining. Serological
858 assays for detection of specific neutralizing anti-MERS-CoV antibodies in paired sera, taken at
859 the acute and convalescent phases 14 to 21 days apart, also provides evidence of infection, but
860 none of the serological assays developed so far has been thoroughly validated or compared
861 against each other. Furthermore, viral culture and neutralizing antibody detection assays using
862 whole virus require BSL-3 containment, which is not widely available in standard clinical
863 microbiology laboratories.

864

865 **Specimen Collection**

866 The ideal clinical specimen for laboratory diagnosis is one which can be readily obtained by non-
867 invasive means and contains a large number of infected cells with high viral load. Although
868 lower respiratory tract specimens including tracheal aspirate and bronchoalveolar lavage contain
869 higher viral loads and genome yields than upper respiratory tract specimens and sputum, they
870 require invasive procedures for collection and may not be easily obtainable in the early phase of
871 illness (71, 72, 194). Therefore, upper respiratory tract specimens including nasopharyngeal
872 aspirate or swabs, and oropharyngeal swabs are the most commonly collected specimens in
873 suspected cases of MERS. Clinical specimens from extrapulmonary sites, especially urine, feces,
874 blood, and/or tissues, may occasionally be positive and should also be collected if available,
875 especially for their possible impact on infection control implementation (71, 72, 81, 176, 182).
876 Notably, the diagnosis of MERS in a Tunisian patient was established by RT-PCR targeting the
877 upE and N genes followed by nucleotide sequencing of RNA from a serum sample collected 10
878 days after symptom onset, whereas his mini-bronchoalveolar lavage tested negative (74). As for
879 the optimal timing of specimen collection, there is a lack of data on the viral shedding kinetics of

880 MERS-CoV in infected humans over time. Analysis of a limited number of laboratory-confirmed
881 MERS cases suggests that the pattern may be more similar to that of SARS than that of other
882 HCoV infections (195). Thus, the viral load of MERS-CoV in nasopharyngeal specimens may
883 also peak in the second week of illness rather than at symptom onset (163, 182, 196, 197).
884 Repeated testing of upper and preferably lower respiratory tract specimens at different time
885 points should be performed in suspected cases of MERS even when the first samples have tested
886 negative (77,
887 [http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)
888 [=1](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)). Virus shedding in the upper respiratory tract may be found in up to 30% of case contacts
889 with minimal symptoms (198). Severe cases appear to have more prolonged virus shedding than
890 mild cases (198). In critically ill patients who may have detectable MERS-CoV RNA in
891 respiratory tract specimens and/or blood for more than three weeks, continued compliance with
892 infection control measures is required during patient-care procedures as a precautionary measure
893 despite the presence of serum neutralizing antibody (88, 176, 182, 184). Aerosol-generating
894 procedures for specimen collection should be performed under strict compliance with droplet
895 precautions along with additional measures including the wearing of a N95 respirator, eye shield,
896 long-sleeved gown and gloves in an adequately ventilated room
897 (http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1).
898 The specimens should be sent to the laboratory in viral transport medium as soon as possible
899 after collection, or be stored at -80°C if delay in transfer was expected
900 ([http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)
901 [a=1](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)).
902

903 **Nucleic Acid Amplification Assays**

904 With the successful isolation and propagation of MERS-CoV and sequencing of its complete
905 genome early in the epidemic, specific primers and a standardized laboratory protocol were
906 rapidly developed and evaluated (199). Several gene targets can be used for RT-PCR as
907 screening and/or confirmatory testing for MERS-CoV (Table 8). The most widely adopted
908 approach uses the upE assay as a screening test, followed by the ORF1a or the ORF1b assays as
909 confirmation. If the ORF1a assay or the ORF1b assay is negative or equivocal despite a positive
910 upE assay, further testing of other specific gene targets, including the N, RdRp, and/or S genes,
911 followed by amplicon sequencing, should be performed. If further testing is not available, but the
912 patient had a compatible epidemiological and clinical history, then the case is considered to be a
913 probable case of MERS
914 ([http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)
915 [a=1](http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1)). Notably, assays targeting the abundant N gene may be more sensitive than those targeting
916 the other genes, although direct comparison with the upE assay in human clinical specimens has
917 not been performed (133). However, a 6-nt deletion was found in N gene of the strain from the
918 second laboratory-confirmed patient when compared to the one obtained from the first patient,
919 and therefore potential false-negative results due to mutations in this region may occur (62). For
920 all positive cases, a second sample should preferably be tested to exclude false-positive results
921 due to amplicon carryover. Other novel diagnostic approaches for MERS which have short
922 turnaround times, high sensitivities and specificities include reverse transcription loop-mediated
923 isothermal amplification and reverse transcription isothermal recombinase polymerase
924 amplification assays which may be useful in areas without easy access to laboratories equipped
925 with RT-PCR and/or sequencing technologies (200, 201). Further validation using more clinical

926 specimens is required to assess their field performance.

927

928 **Antibody Detection Assays**

929 A number of assays for detection of non-neutralizing and neutralizing antibodies to MERS-CoV
930 proteins have been developed but require further validation because some antibodies against
931 β CoVs are generally known to cross-react within the genus (Table 9). Indeed, cross-reacting
932 antibodies have been found not only in immunofluorescence assays, but also in virus
933 neutralization tests, which are considered to be the most specific method of antibody detection
934 (202, 203). Therefore, the European Centre for Disease Prevention and Control recommends
935 against testing for immunofluorescent antibodies unless convalescent plasma is available to look
936 for 4-fold increase in antibody titer because false positive results may arise in single tests. Cases
937 with positive serology in the absence of PCR testing or sequencing should be considered
938 probable only if they meet the other criteria of the case definition
939 (http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u
940 [a=1](#)). Nevertheless, antibody detection assays are important for retrospective diagnosis in
941 clinically and epidemiologically suspicious cases with negative molecular test results,
942 particularly in those with only upper respiratory tract specimens being tested. It can also be used
943 for monitoring the evolution of epidemics in human and animal seroepidemiological studies, and
944 contact tracing in outbreak investigations (126). The development of high throughput, non-whole
945 virus-based assays such as enzyme-linked immunosorbent and pseudoparticle neutralization
946 assays that do not required BSL-3 containment facilities may increase their utility especially in
947 rural parts of the Middle East and other affected areas.

948

949 **Antigen Detection Assays**

950 The development of antigen detection assays for MERS-CoV has only been reported in
951 histopathological confirmation in infected tissues of animals and in cell cultures with positive
952 CPE (166, 167, 174). Possible approaches include antigen detection with monoclonal antibodies
953 or monospecific polyclonal antibodies against the abundantly expressed N protein using either
954 enzyme immunoassay or immunofluorescence assay. These methods were found to be highly
955 sensitive and specific for the laboratory diagnosis of SARS from sera and nasopharyngeal
956 samples, and have the potential advantages of being non-labor-intensive and relatively high
957 throughput without requiring a BSL-3 containment facility (3). More information on the timing
958 of serum neutralizing antibody kinetics and viral shedding patterns in different clinical
959 specimens is required to optimize these antigen detection assays.

960

961 **Viral Culture**

962 In contrast to other CoVs causing human infections, which are difficult to culture in *in vitro*
963 systems, MERS-CoV grows rapidly in a wide range of human and non-human cell lines (Table
964 6) (116-118). Indeed, the first identification of MERS-CoV was achieved by inoculation of the
965 patient's sputum sample in monkey kidney cell lines, including LLC-MK2 and Vero cell lines,
966 for detection of CPE, before specific nucleic acid amplification assays were developed (9).
967 MERS-CoV produces focal CPE with rounded refractile cells in various susceptible cell lines on
968 day 5 after inoculation during primary isolation, and on as early as day 1 on subsequent passage
969 (116). These changes then spread throughout the cell monolayers, leading to rounding and
970 detachment of cells within 24 to 48 hours. Additionally, syncytium formation caused by fusion
971 activity of the viral spike protein at neutral pH may be observed in LLC-MK2, Calu-3, Caco-2,

972 and Huh-7 cell lines, and Vero cells expressing TMPRSS2 (9, 52, 58, 116). Transmission
973 electron microscopy of MERS-CoV-infected cells shows CoV-induced membrane structures that
974 support RNA synthesis, including convoluted membranes surrounded by double-membrane
975 vesicles measuring 150 to 320 nm with dense inner cores, in the perinuclear region, which is
976 typical of cellular changes of CoV infection (58). Although the clinical use of viral culture for
977 MERS-CoV is limited by the lack of BSL-3 facilities in most satellite hospitals, the ease of
978 growing the virus in cell culture systems has greatly facilitated study on its pathogenesis and
979 development of antiviral agents in reference research laboratories.

980

981 **CLINICAL MANAGEMENT AND ANTIVIRALS**

982 As in the case of other human CoV infections including SARS, specific antiviral agents with
983 proven efficacy in randomized controlled trials are lacking for MERS (204, 205). Supportive
984 care remains the mainstay of treatment for severe MERS cases with respiratory failure and
985 extrapulmonary complications. ECMO has been increasingly used in severe viral pneumonia
986 including some cases of MERS (18, 71, 153, 154, 156, 206). However, procedure-related factors
987 such as the requirements of technical expertise and specific equipment, and patient factors
988 including the presence of multiple comorbidities and coagulopathy may limit its use especially
989 among patients in rural parts of the Middle East and Africa. Other forms of assisted ventilation
990 and pulmonary rescue therapy, including mechanical ventilation using a lung protective strategy
991 with a small tidal volume, non-invasive positive pressure ventilation, and inhaled nitric oxide
992 have been tried for SARS and influenza with ARDS (3, 153). However, data on their efficacies in
993 MERS are lacking (88, 207). Due to the apparently high incidence of acute and acute-on-chronic
994 renal failure in patients with severe MERS, renal replacement therapy has been frequently used,

995 and was essential for tiding the patient over the oliguric phase (64, 88, 207). Circulatory failure
996 is supported by the use of inotropes and volume expansion (207). Broad-spectrum antibacterials
997 and neuraminidase inhibitors against influenza are used empirically before the diagnosis of
998 MERS is established (207). Antimicrobials guided by interval surveillance or sepsis work-up
999 should be used to treat secondary nosocomial infections in those with prolonged hospitalization
1000 and invasive ventilation, and opportunistic infections in patients who are immunocompromised,
1001 especially those who receive corticosteroid for immunomodulation. As in SARS,
1002 immunosuppressive dose of corticosteroid therapy should not be given because of its potential
1003 side effects and immunosuppression. Only stress dose of corticosteroid should be considered in
1004 patients with refractory shock and relative adrenal insufficiency
1005 ([http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement](http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf?ua=1)
1006 [NovelCoronavirus_11Feb13u.pdf?ua=1](http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf?ua=1)).

1007 The improvement in outcome of MERS with a case-fatality rate of over 30% depends on
1008 the development of effective antiviral treatment for suppression of viral load. Candidate antiviral
1009 agents are identified using three general approaches (Table 10). The first and fastest approach is
1010 to test drugs with broad-spectrum antiviral activities including those with reported activities
1011 against other CoVs associated with human infection, particularly SARS-CoV. This approach has
1012 identified numerous agents with known antiviral mechanisms. Examples include interferons,
1013 ribavirin, and cyclophilin inhibitors (58, 208, 209). Type I interferons, which are important in the
1014 innate immunity against CoV infection, exhibit anti-MERS-CoV activity in various cell lines and
1015 also rhesus macaques. MERS-CoV is 50 to 100 times more sensitive to pegylated interferon- α
1016 than SARS-CoV in cell culture (58). Moreover, the combination of interferon- α 2b and ribavirin,
1017 a purine nucleoside analogue that inhibits guanosine triphosphate synthesis and viral RNA

1018 polymerase activity that has been widely used to treat SARS, has exhibited synergistic effects
1019 against MERS-CoV in cell cultures (209, 210). In rhesus macaques infected with MERS-CoV,
1020 this combination reduces virus replication, moderates host inflammatory response, and improves
1021 clinical outcome (175). However, the regimen's efficacy in humans remains uncertain. In a small
1022 cohort of MERS cases in KSA, all five patients who received a combination of interferon- α 2b,
1023 ribavirin, and corticosteroid died. The delayed commencement of the antiviral regimen of at least
1024 two weeks after symptom onset in these patients might have reduced treatment benefit, as
1025 another patient who received treatment early on the day of admission survived, though MERS-
1026 CoV RNA remained detectable in his sputum samples until day 12 of treatment (211). A more
1027 recent retrospective cohort study showed that 20 severe adult MERS patients who received oral
1028 ribavirin and pegylated interferon- α 2a (Pegasys; Roche Pharmaceuticals, Basel, Switzerland) for
1029 8 to 10 days (initiated on a median of 3 days after diagnosis) had significantly better survival
1030 rates at 14 days but not at 28 days after diagnosis as compared to 28 historical controls who
1031 received supportive care only (207). Possible reasons for the lack of long-term survival benefit in
1032 the treatment group include the small number of patients in the study and the fact that both
1033 ribavirin and pegylated interferon have high EC_{50} against MERS-CoV relative to their peak
1034 serum concentrations achievable at clinically relevant dosages. Cyclophilin inhibitors, such as
1035 cyclosporine A, are known to have antiviral activity against numerous human and animal
1036 coronaviruses including SARS-CoV. However, the clinical relevance of cyclosporin A for
1037 treating MERS is likely limited as the drug's peak serum level achievable with clinically relevant
1038 dosages is below its EC_{50} for MERS-CoV (58).

1039 The second approach to identify candidate antivirals for MERS involves screening of
1040 chemical libraries that comprise large numbers of existing drugs or databases that contain

1041 information on transcriptional signatures in different cell lines. The advantages of this approach
1042 include the commercial availability, known pharmacokinetics, and well-reported safety profiles
1043 of the identified drugs. The first agent with potent *in vitro* anti-MERS-CoV activity identified by
1044 this method was mycophenolic acid, an anti-rejection drug used in organ transplantation with
1045 broad-spectrum antiviral activities that acts by inhibiting inosine-5'-monophosphate
1046 dehydrogenase and depleting the lymphocyte guanosine and deoxyguanosine nucleotide pools
1047 (210). The combination of mycophenolic acid and interferon- β 1b shows synergistic activity
1048 against MERS-CoV in Vero cells. The desirable pharmacokinetics of mycophenolic acid
1049 compared to ribavirin warrants further evaluation, although the potential inhibitory effect on the
1050 immune system and therefore neutralizing antibody production should be fully assessed in
1051 animal models before use in humans. The very low EC₅₀ when compared with the peak serum
1052 level achieved at routine clinical dosages suggests that even a very low dose may be effective
1053 without inducing significant immunosuppression. A fatal case of MERS was reported in a renal
1054 transplant recipient who was receiving anti-rejection therapy consisting of prednisone,
1055 mycophenolate mofetil, and cyclosporine, but the dosage, serum drug level of mycophenolate
1056 mofetil, and the resulting lymphocyte count were not reported (68, 176). Following the
1057 identification of mycophenolic acid as an inhibitor of MERS-CoV replication *in vitro*, many
1058 other drugs have been found to exhibit *in vitro* anti-MERS-CoV activity in Vero and/or Huh-7
1059 cells using a similar drug discovery approach. These drugs belong to a number of major
1060 pharmacological categories including peptidic or small-molecule HIV entry inhibitors,
1061 antiparasitics, antibacterials, and inhibitors of clathrin-mediated endocytosis, neurotransmitters,
1062 estrogen receptor, kinase signaling, lipid or sterol metabolism, protein processing, and DNA
1063 synthesis or repair (41, 177, 212-215). However, none of them has been tested in animal models

1064 for MERS, and many of them have doubtful clinical relevance in human infection because of
1065 unachievable peak serum levels in relation to their EC₅₀ against MERS-CoV. Two notable
1066 exceptions which warrant further evaluation in clinical trials are lopinavir and chloroquine.
1067 Lopinavir, which is routinely available as a lopinavir/ritonavir combination, shows inhibitory
1068 effects on MERS-CoV infection *in vitro* in Huh-7 cells at concentrations observed in blood
1069 during clinical use and has a well established toxicity profile (212, 213,
1070 http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416). Moreover,
1071 lopinavir/ritonavir has been used successfully in the treatment of SARS in a case-control study
1072 (216). Viremia resolved after two days of combinational lopinavir/ritonavir, pegylated interferon,
1073 and ribavirin therapy in a MERS patient (184). However, virus shedding in **the** airway was
1074 persistent despite treatment (184). Chloroquine is an anti-malarial drug that inhibits MERS-CoV
1075 *in vitro* in Huh-7 and Vero E6 cells at a concentration achievable by standard clinical oral dosage
1076 through multiple possible mechanisms including inhibition of the pH-sensitive cathepsin L cell
1077 entry pathway through elevation of endosomal pH (212, 213, 217,
1078 http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416). However, previously
1079 chloroquine has not been shown to work in BALB/c mice infected by SARS-CoV, possibly due
1080 to the lack of inhibition of other cell entry pathways utilized by the virus (218).

1081 The third approach to identify treatment for MERS requires the development of
1082 specific antiviral agents based on novel insights into the viral genome and structural biology of
1083 MERS-CoV (219, 220). Understandably, the development of such candidate drugs is more time-
1084 consuming than that of the first two approaches. However, these tailor-made antiviral agents
1085 represent the most specific and possibly most effective therapeutic options against MERS-CoV.
1086 Of particular interests are agents that target the MERS-CoV S protein, which has essential roles

1087 in virus-host cell receptor interaction and immunogenicity. A number of potent monoclonal
1088 antibodies targeting different epitopes on the RBD in the S1 subunit of the MERS-CoV S protein
1089 have been identified by biopanning of ultra-large non-immune human antibody libraries
1090 displayed in yeast or phage baited by the RBD (37-40). These monoclonal antibodies bind to the
1091 RBD with 10- to 450-fold higher affinity than does the RBD to the human DPP4, conferring
1092 broader and higher neutralizing activity. The production of these monoclonal antibodies in high
1093 titers may help to overcome the potential cultural hurdle in collecting large amounts of
1094 convalescent plasma from patients in the Middle East and the possibility of adverse outcomes
1095 associated with immune enhancement with low antibody titer previously observed in *in vitro* and
1096 animal experiments on SARS (221, 222). Moreover, possible selection of virus mutants capable
1097 of escaping from antibody-mediated neutralization may be mitigated by using divergent
1098 combinations of two or more synergistically acting neutralizing monoclonal antibodies that target
1099 non-cross-resistant epitopes on the RBD (40). *In vitro* inhibition of S protein-mediated cell-cell
1100 fusion and virus entry into host cell can also be achieved by specially designed antiviral peptides
1101 that span the sequence of the HR2 domain of the S2 subunit of the MERS-CoV S protein.
1102 Analogous to the HIV fusion inhibitor Enfuvirtide which binds to glycoprotein 41 of HIV to block
1103 membrane fusion and virus entry, the MERS-CoV antiviral peptides block the fusion process of
1104 MERS-CoV by preventing the interaction between the HR1 and HR2 domains required for the
1105 formation of the heterologous six-helix bundle in viral fusion core formation (44, 45). Other drug
1106 candidates that target specific enzymes of MERS-CoV include inhibitors of viral proteases and
1107 helicase. The rapid determination of crystal structure for these enzymes have facilitated the
1108 development of candidate drugs to be further tested in animal studies to evaluate their
1109 pharmacokinetics and *in vivo* inhibitory effects, especially in view of the reported mutations in

1110 the papain-like protease of recently circulating MERS-CoV strains (146, 223-226). Inhibition of
1111 MERS-CoV infection can also be achieved by agents that target the functional host cell receptor
1112 DPP4. Because of the abundance of DPP4 in epithelial and endothelial cells, high titers of
1113 monoclonal antibodies against specific binding regions of DPP4, but not the commercially
1114 available reversible, competitive DPP4 antagonists such as sitagliptin, vildagliptin, and
1115 saxagliptin, efficiently inhibit virus-cell receptor interaction (46, 50). Agents that manipulate the
1116 levels of adenosine deaminase, a natural DPP4 antagonist, may also be considered (49). The
1117 clinical efficacy of anti-DPP4 monoclonal antibodies and adenosine deaminase analogues
1118 remains uncertain because expression of catalytically inactive DPP4 still allows for MERS-CoV
1119 infection *in vitro* (227). Furthermore, the risk of physiological disturbances, immunopathology,
1120 and T cell suppression should be assessed in animal studies given the wide distribution of DPP4
1121 in different human cell types and its multiple essential metabolic and immunological functions
1122 (228, 229). Alternatively, inhibitors of host cellular proteases including TMPRSS2 and
1123 cathepsins, which affect virus entry into host cells, may be considered. However, the recent
1124 finding that cathepsin activity is essential for Ebola virus infection in cell lines but not for viral
1125 spread and pathogenesis in mice highlights the necessity to confirm the roles of cellular protease
1126 inhibitors in *in vivo* spread of MERS-CoV (230, 231). Alternative host proteases that cleave the
1127 MERS-CoV S protein should also be searched to broaden the range of existing antiviral options
1128 (51).

1129

1130 **INFECTION CONTROL AND LABORATORY SAFETY**

1131 Similar to epidemics caused by other novel emerging respiratory viruses with no herd immunity
1132 in the general population and limited effective treatment and immunization options, infection

1133 control measures to interrupt the chain of transmission remains the cornerstone to control the
1134 MERS epidemic (3, 4, 153, 232-234). Based on the available epidemiological data, the scenario
1135 is most compatible with a combination of animal-to-human and person-to-person transmission.
1136 In endemic regions, multi-source sporadic animal-to-human transmissions occur in the
1137 community, which may be amplified under special circumstances such as the breeding seasons of
1138 dromedary camels. These primary infections may be followed by limited non-sustained person-
1139 to-person transmission among unprotected household contacts (67, 70, 73). When the patients are
1140 hospitalized, the infection is introduced into the healthcare setting where lapses in infection
1141 control measures culminate in large healthcare-associated outbreaks (66, 68, 71, 75, 235). The
1142 infection can then be disseminated beyond the Middle East by air travel of infected patients
1143 seeking medical care in other non-endemic countries (150, 236, 237).

1144 In the community setting, the primary goals of infection control are to identify and
1145 segregate all zoonotic reservoirs and infected humans from immunologically naive persons.
1146 Besides dromedary camels, bats, and hedgehogs, other livestock species prevalent in the Middle
1147 East should be further surveyed by validated serological and virological tests to exclude
1148 unrecognized MERS-CoV infection. Before these data are available, residents in and travelers to
1149 the endemic regions should generally avoid contacting sick animals and especially camels.
1150 Contact with environments contaminated with animal bodily fluids, tissues, or feces should be
1151 avoided as MERS-CoV may be transmitted via direct contact or fomite due to prolonged
1152 environmental survival lasting for at least 48 hours at 20°C in 40% relative humidity, and 24
1153 hours at 30°C in 30% relative humidity (145, 238). Consumption of unpasteurized camel milk
1154 should be cautioned against, as MERS-CoV may possibly be shed and survive in the milk of
1155 camels with active nasal or fecal virus shedding (143, 144). Early recognition of human cases

1156 can be achieved by public education and dissemination of diagnostic tests to healthcare facilities.
1157 Testing should be performed even among asymptomatic or mildly symptomatic persons with
1158 known exposures to potential animal reservoirs or laboratory-confirmed human cases. They
1159 should also undergo medical surveillance and quarantine in healthcare facilities or at home until
1160 the incubation period is over
1161 (http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1).
1162 Air travel should be restricted for laboratory-confirmed cases unless it is necessary to transfer the
1163 patient to other countries for medical care. In such cases, compliance with infection control
1164 measures including hand hygiene, wearing of personal protective equipment, and standard and
1165 transmission-based precautions should be applied by the aircraft staff and accompanying medical
1166 personnel. Though there is no documented in-flight transmission of MERS-CoV so far, the risk is
1167 estimated to be one new infection in a five-hour flight in first class, and 15 infections from a
1168 “super-spreader” in a 13-hour flight in economy class (236). Temperature checks at borders and
1169 health declarations for travelers are used in some regions, but their value in controlling
1170 international spread is unproven. The Hajj, which attracts millions of pilgrims from over 180
1171 countries to gather in Mecca every year, poses a theoretical risk of causing massive outbreaks of
1172 MERS as in the super-spreading events of SARS. Though MERS has not been reported among
1173 pilgrims attending the annual Hajj in 2012 and 2013, the small number of subjects tested and the
1174 lack of samples collected during the pilgrimage are major limitations of the few surveillance
1175 studies conducted so far (239-241). Thus, persons at risk of developing severe infection should
1176 consider postponing the Hajj until the epidemic is under control (242, 243).

1177 In the hospital setting, triage, early diagnosis, compliance with appropriate infection
1178 control measures, prompt isolation of suspected cases, and timely contact tracing of case contacts

1179 are the key strategies to prevent nosocomial transmission. Indeed, the disappearance of the three
1180 clades of MERS-CoV found earlier in the epidemic suggests the possible effects of enhanced
1181 surveillance and early isolation of human cases in successfully interrupting person-to-person
1182 transmission (146). In addition to standard, contact, and droplet precautions, airborne precautions
1183 should be applied for aerosol-generating procedures such as intubation, non-invasive ventilation,
1184 manual ventilation before intubation, bronchoscopy, tracheostomy, and suctioning of the airway
1185 (244,
1186 http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1).
1187 Designated healthcare workers and disposable equipments for managing laboratory-confirmed
1188 cases in adequately ventilated single rooms or airborne infection isolation rooms should be
1189 considered to limit the number of exposed contacts. All healthcare workers caring for patients
1190 with suspected or confirmed MERS should undergo medical surveillance with daily temperature
1191 checks and monitoring of the development of acute respiratory symptoms. Quarantine after
1192 unprotected exposure is necessary to prevent unrecognized asymptomatic infection that may
1193 serve as the source of nosocomial and community outbreaks (70). The duration of observation
1194 should last for at least two incubation periods as applied in the medical surveillance of other
1195 respiratory tract infections such as pandemic influenza A/H1N1/2009 (245). Although it has been
1196 suggested that transmission-based precautions for MERS patients may be stopped 24 hours after
1197 the resolution of symptoms, laboratory testing to exclude persistent virus shedding should be
1198 conducted as viral RNA can be detected in the respiratory tract specimens and/or blood of
1199 critically ill patients for over three weeks after symptom onset (88, 176, 182, 184, 211). Rarely,
1200 asymptomatic cases may also have prolonged virus shedding for more than five weeks after case
1201 contact (246). The infectivity of such prolonged viral shedding should be further evaluated to

1202 optimize infection control strategies. Patients who have no evidence of pneumonia or who have
1203 recovered from pneumonia but remain positive for MERS-CoV RNA by RT-PCR may be
1204 discharged from the hospital and isolated at home under appropriate supervision (247).
1205 Collection of potentially infectious specimens should be performed by trained staff wearing
1206 appropriate personal protective equipment. The specimens should be transported in leak-proof
1207 double containers by hand instead of pneumatic-tube systems
1208 (http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1).
1209 To prevent laboratory-related outbreaks as reported in SARS, all laboratories handling live
1210 MERS-CoV should strictly comply with WHO standards for BSL-3 laboratories.

1211

1212 **VACCINATION**

1213 **Active Immunization**

1214 Active immunization to protect at-risk humans and camels is a research priority in the control of
1215 MERS because of the lack of herd immunity and effective antivirals for humans. Based on
1216 previous experience gained from vaccine design for SARS, which shows the S protein to be **one**
1217 **of the major** immunogenic components of CoVs, a number of vaccines that target the S protein
1218 of MERS-CoV are being developed and evaluated in cell culture or animal experiments (Table
1219 11). A viral vector-based vaccine using recombinant modified vaccinia virus Ankara expressing
1220 full-length MERS-CoV S protein induced high levels of neutralizing antibodies in BALB/c mice
1221 after intramuscular immunization (248). The possibility of induction of immunopathology as in
1222 the case of a similar viral vector-based vaccine for SARS that led to enhanced hepatitis in ferrets
1223 needs to be carefully assessed in subsequent investigations (222). Alternatively, several **candidate**

1224 recombinant vaccines containing either full-length MERS-CoV S protein or the RBD of the S1
1225 subunit have been studied for their theoretical advantages of safety and ease of consistent
1226 production based on constant conditions and well-defined immunogenic fragments. A
1227 baculovirus-based expression system and a Venezuelan Equine Encephalitis Replicon Particles
1228 approach have been successfully applied for the development of full-length MERS-CoV S
1229 protein-based recombinant vaccines (174, 249). Identification and exclusion of non-neutralizing
1230 epitopes in the immunopredominant domain of the MERS-CoV S protein may help to reduce the
1231 risk of antibody-mediated disease enhancement during future optimization of these vaccines
1232 (250). RBD-based subunit vaccines have elicited neutralizing activity against MERS-CoV in cell
1233 culture-based assays, BALB/c mice, and rabbits (31, 34, 36, 42, 251). Among five different
1234 available RBD constructs, a truncated 212-aa fragment at residues 377 to 588 of RBD fused with
1235 human IgG Fc fragment (S377-588-Fc) showed the highest **DPP4-binding** affinity and induced
1236 the highest titers of IgG and neutralizing antibodies in BALB/c mice and rabbits respectively
1237 (36). Intranasal vaccination of this S377-588-Fc showed stronger systemic cellular and local
1238 mucosal responses as compared to subcutaneous vaccination (43). Future research directions for
1239 these promising subunit vaccine candidates include the optimization of adjuvant substances
1240 which are required to increase the immunogenicity of subunit vaccines (252), and the inclusion
1241 of chimeric S proteins containing multiple neutralizing epitopes from divergent subgroups, as
1242 there are considerable **variations** in the receptor-binding subdomain region of S1 within
1243 subgroups of MERS-CoV and across different CoV groups (202).

1244

1245 **Passive Immunization**

1246 Passive immunization using convalescent plasma or hyperimmune globulin with high titers of
1247 neutralizing antibody has been used for emerging respiratory viral infections including SARS
1248 and pandemic influenza A/H1N1/2009 with relatively few side effects (253-256). The clinical
1249 use of such therapy for MERS has not yet been evaluated in randomized controlled trials.
1250 **MERS-CoV-S-driven transduction in Caco-2 cells is inhibited by convalescent patient serum in a**
1251 **concentration-dependent manner (51).** In BALB/c mice transduced by adenoviral vectors
1252 expressing human DPP4, adoptive transfer of sera containing anti-MERS-CoV-S antibodies
1253 blocked virus attachment and accelerated virus clearance (174). The increasing number of
1254 patients recovering from MERS and enhanced international collaboration for the preparation of
1255 convalescent plasma samples will accelerate the availability of passive immunization before
1256 neutralizing monoclonal antibodies become commercially available.

1257

1258 **ANIMAL MODELS AND ANIMALS SUSCEPTIBLE TO MERS-CoV**

1259 Contrary to SARS-CoV which can cause infection in a diverse range of susceptible mammalian
1260 species, studies on MERS-CoV have been limited by the lack of animal models which are
1261 representative of MERS in humans (Table 12). The Koch's postulates for MERS-CoV as a
1262 causative agent of MERS were fulfilled with a primate model using rhesus macaques, which
1263 demonstrated mild to moderate clinical and histopathological features as compared to the
1264 infection in humans (165). However, clinical signs varied between animals, and were usually
1265 transient, lasting for only 3 days or less in most animals, which corroborated with the robust but
1266 self-limiting inflammatory response and leukocyte activation in blood and lungs of tested
1267 animals (166). Recently, common marmosets were also found to be susceptible to MERS-CoV
1268 infection and resembled moderate to severe MERS in humans with viremia and disseminated

1269 infection as evidenced by the presence of viral RNA in blood and multiple organs (168).
1270 Nevertheless, extrapulmonary manifestations that are commonly seen in human cases of MERS,
1271 such as acute renal failure and diarrhea, were absent in both the rhesus macaque and common
1272 marmoset models. Jamaican fruit bats infected with MERS-CoV do not develop clinical signs of
1273 infection despite having respiratory and intestinal tract virus shedding up to day 9 post-infection
1274 (257). Large animals including camels and goats were also found to be susceptible to MERS-
1275 CoV infection, but they developed predominantly upper respiratory tract symptoms without
1276 pneumonia (257-259). Unlike human infection in which feces and urine might be positive for
1277 viral RNA, the extrapulmonary specimens of infected camels and goats were negative. Most
1278 small animal models that worked for SARS-CoV, including BALB/c mouse, Syrian hamster, and
1279 ferret, were not susceptible to MERS-CoV infection. Infected animals had minimal clinical signs,
1280 no detectable virus in respiratory tract and extrapulmonary specimens, and did not have
1281 seroconversion. These findings suggest that MERS-CoV fails to enter these host cells because of
1282 variable DPP4 binding affinities for MERS-CoV S RBD among different species (48). A mouse
1283 model using C57BL/6 and BALB/c mice with prior transduction of respiratory epithelial cells
1284 with adenoviral vectors expressing human DPP4 inoculated with MERS-CoV intranasally
1285 showed virological, immunological, and histopathological features compatible with interstitial
1286 pneumonia, but the clinical signs were mild and evidence of infection was confined to the lungs
1287 without extrapulmonary involvement (174). Furthermore, it requires infection of the mice with
1288 the adenoviral vectors prior to every experiment, and it is unknown whether the differences in
1289 the targeted cells between the murine and human lungs may affect the immunological response
1290 and clinical progress after infection. Nonetheless, this inhaled-adenoviral vector method allows
1291 the quick use of a wide variety of pre-existing genetically modulated mice with

1292 immunodeficiencies to dissect the elements of host responses to MERS-CoV, and can be used to
1293 test candidate drugs and vaccines *in vivo*. It also provides a rapid model for any novel emerging
1294 respiratory viruses before appropriate receptor-transgenic mouse models become available.
1295 Further refinement of small animal models that are more representative of MERS in humans is
1296 urgently needed for evaluation of the efficacy of therapeutic and immunization options with *in*
1297 *vitro* activity.

1298

1299 **CONCLUSIONS**

1300 In contrast to the public health chaos in the early phase of the SARS outbreak, the global health
1301 community has demonstrated efficient and collaborative efforts to handle the MERS epidemic.
1302 The clinical experience gained in SARS and the genomic data accumulated for other human and
1303 animal CoVs discovered after SARS have facilitated the rapid development of diagnostic assays,
1304 design of candidate antiviral agents and vaccines, rationalization of infection control measures,
1305 and identification of zoonotic reservoirs for MERS (93, 104-107, 260-271). The MERS epidemic
1306 has greatly enhanced our understanding of coronavirology and provided lessons that will be
1307 useful for tackling future CoV outbreaks. Camels are now recognized as an important animal
1308 reservoir for lineage A and C β CoVs and other viruses (140, 272, 273). Continued surveillance of
1309 novel CoVs among different animal species, especially bats and mammals with frequent close
1310 contact with humans, will strengthen our preparedness to face other emerging CoVs resulting
1311 from interspecies transmissions in the future. The identification of DPP4 as a functional receptor
1312 of MERS-CoV has expanded the list of membrane ectopeptidases known to be targeted by CoVs
1313 and has increased our understanding on the pathogenesis of CoV infections. Finally, the newly
1314 identified antiviral agents in drug-repurposing programs for MERS represent additional drug

1315 candidates that can be evaluated for novel CoVs that lack specific treatment options. Looking
1316 ahead, the successful control of the expanding MERS epidemic will depend on the development
1317 of an effective camel vaccine to stop ongoing camel-to-human transmissions, compliance with
1318 infection control measures, and **timely contacting tracing** to prevent secondary healthcare-
1319 associated outbreaks. The key research priorities to optimize the clinical outcomes of MERS
1320 include more in-depth understanding on the pathogenesis from post-mortem studies and serial
1321 patient samples, testing of antiviral and vaccine candidates in more representative small animal
1322 models, and evaluation of the efficacy of currently available therapeutic options in randomized
1323 controlled trials in humans. Monitoring of the molecular evolution of MERS-CoV will facilitate
1324 early recognition of further viral adaptations for efficient person-to-person transmission.

1325 **ACKNOWLEDGEMENTS**

1326

1327 **We thank Patrick Lane of ScEYence Studios for graphic enhancement.** We are grateful to Hayes
1328 Luk for technical assistance and Siddharth Sridhar for proofreading the work. This work is partly
1329 supported by the donations of Hui Hoy and Chow Sin Lan Charity Fund Limited, the National
1330 Natural Science Foundation of China / Research Grants Council Joint Research Scheme (Project
1331 Code: N_HKU728/14), the Consultancy Service for Enhancing Laboratory Surveillance of
1332 Emerging Infectious Disease of the Department of Health, and the Research Fund for the Control
1333 of Infectious Diseases commissioned grant, the Food and Health Bureau, Hong Kong Special
1334 Administrative Region, China.

1335 **Table 1** Comparison between MERS and SARS

Characteristics	Middle East respiratory syndrome (MERS)	Severe acute respiratory syndrome (SARS)	References
Epidemiology			
Year of first identification	2012	2003	(2, 9)
Geographical origin	Middle East with imported cases in Europe, Africa, Asia, & North America	South China with imported cases causing large outbreaks in Canada & Asia	(a, 3)
Natural reservoir ^b	?Bats (<i>Neoromicia</i> sp. in Africa)	Chinese horse-shoe bats (<i>Rhinolophus sinicus</i> & other <i>Rhinolophus</i> sp. in China)	(3, 102, 110, 111, 274, 275)
Amplification or intermediate host ^b	Dromedary camels (Middle East & Africa)	Game food mammals (civets & raccoon dogs in southern China)	(3, 12, 114, 121, 133)
Epidemic centers of outbreaks or premises of acquisition	1. ?Camel farms 2. Hospital or household with MERS patients	1. Wild life markets & restaurants 2. Hospitals & laboratories 3. Housing estate with faulty sewage system & hotels 4. Planes	(3, 12, 75, 138, 139, 276-278)
Seasonality	May be related to camel breeding season	Winter	(c, d, 3)
Main types of transmission ^c	1. Animal-to-human 2. Person-to-person	1. Person-to-person 2. Animal-to-human	(3, 73, 138)
In-flight transmission	Not yet documented	Numerous episodes, related to physical proximity to the index patient	(3, 278)
Modes of transmission	?Droplet, contact, airborne	Contact, droplet, airborne	(3, 75, 234)
Infection control measures	Standard, contact, & droplet precautions; airborne precautions for aerosol-generating procedures	Standard, contact, & droplet precautions; airborne precautions for aerosol-generating procedures	(3, 75, 234)
Incubation period (days)	2-15	2-14, occasionally up to 21 days	(3, 63, 75, 234)
Basic reproduction number (R_0)	0.3-1.3	0.3-4.1	(3, 90, 150, 151, 279-281)
Virus-host interaction			
Causative virus	MERS-CoV	SARS-CoV	(2, 9, 165, 282)
Viral phylogeny	Lineage C β CoV	Lineage B β CoV	(2, 9)
Host receptor	DPP4 (CD26)	ACE2	(46, 283)
Major host proteases that activate spike protein	1. TMPRSS2 2. Cathepsin L 3. Furin	1. Cathepsin L 2. TMPRSS2 3. HAT	(44, 51, 52, 54, 284-287)
Dominant cell entry pathway	Cell membrane fusion	Endosomal fusion	(44, 51, 284, 288)
Cytopathic effects	Prominent syncytium formation	Few if any syncytia	(2, 3, 23,

Spectrum of cell line susceptibility ^f	Broad range of animal & human tissue cells	Only a few human & primate cell lines can be infected	60, 116) (3, 116-118)
Viral proteins with interferon antagonist activity	PLpro, accessory proteins 4a, 4b, & 5, & membrane protein	nsp1 protein, PLpro, accessory proteins 3b & 6, & nucleocapsid & membrane proteins	(3, 24, 25, 27, 28, 172, 289-292)
Rapid evolution of virus in human	Not yet detected	Overall Ka/Ks ratio of >1 suggests rapid evolution with strong positive selection in human strains with deletion of 29bp signature sequence or 82bp in ORF8	(3, 114, 146, 293)
Clinical features			
Presenting clinical syndrome	1. Acute community- or hospital-acquired pneumonia in elderly & patients with multiple comorbidities 2. Upper respiratory tract infection, influenza-like illness or asymptomatic infection in children & immunocompetent hosts	Acute community- or hospital-acquired pneumonia in immunocompetent & immunocompromised hosts	(2, 63, 294)
Common extrapulmonary manifestation	1. Acute renal failure 2. Diarrhea	Diarrhea	(63, 160, 196)
Radiological changes	Focal to diffuse interstitial ground glass opacities and/or consolidations	Focal to diffuse ground glass opacities and/or consolidations with pneumomediastinum	(3, 63, 152)
Common changes in blood tests	Leukopenia, lymphopenia, thrombocytopenia, impaired liver function at presentation; renal function impairment, leukocytosis & neutrophilia with progressive illness	leukopenia, lymphopenia, thrombocytopenia, ↑ alanine & aspartate aminotransferase levels	(3, 63)
Severe complications	ARDS, acute renal failure	ARDS	(3, 63)
Case-fatality rate	>35%	~10%	(g, 3, 63)
Peak viral load in respiratory secretion	Unclear	~Day 10 after symptom onset	(3, 160, 196)
Onset of neutralizing antibody	≤12 days after symptom onset	~Day 5-10 after symptom onset	(3, 66, 72, 81, 183, 295)
Specimens for diagnosis with positive viral RNA (reverse transcription-polymerase chain reaction) or culture (cell culture)	1. Lower respiratory tract: sputum, endotracheal aspirate, and/or bronchoalveolar lavage 2. Upper respiratory tract: nasopharyngeal aspirate or swab, nasal and/or throat swab 3. Extra-pulmonary: urine, feces, and/or blood 4. Tissue: biopsied and/or autopsied specimens (findings not yet reported)	1. Lower respiratory tract: sputum, endotracheal aspirate, and/or bronchoalveolar lavage 2. Upper respiratory tract: nasopharyngeal aspirate or swab, nasal and/or throat swab 3. Extra-pulmonary: urine, feces, blood, and/or cerebrospinal fluid 4. Tissue: biopsied and/or autopsied specimens	(3, 195, 296)
Criteria for positive RT-PCR test	Follow WHO criteria	Follow WHO criteria	(h, 3)

Criteria for positive antibody testing	No international standard	4-fold rise in serum (taken at least 14 days apart) neutralizing anti-SARS-CoV antibody titer (often just 4-fold rise in immunofluorescence antibody against fixed whole SARS-CoV if BSL-3 facility was not available)	(h, 3)
Key treatment measures	Ventilatory support & intensive care (ECMO & hemodialysis)	Ventilatory support & intensive care	(3, 88, 204, 234)
Antivirals used in humans in non-randomized trials	Ribavirin & interferon- α 2b	Interferons (infacon1, interferon-b, leukocytic interferons) Combinations of protease inhibitor with ribavirin	(3, 207, 216)
Active immunization	Vaccines containing RBD of S1 (mice)	Recombinant S protein fragment (mice)	(3, 36, 252, 297)
Passive immunization	Adoptive transfer of sera containing anti-MERS-CoV-S antibodies blocked virus attachment in mice	Convalescent plasma therapy used in humans	(3, 174, 298)
Animal models for testing antivirals & vaccines ⁱ	Common marmoset; no representative small animal model of severe human disease yet	Representative models using various mammalian species including small animal models	(3, 168)

1336 Abbreviations: ACE2, angiotensin-converting enzyme 2; ARDS, acute respiratory distress syndrome; BSL, Biosafety Level; CoV,
1337 coronavirus; DPP4, dipeptidyl peptidase-4; ECMO, extracorporeal membrane oxygenation; HAT, human airway trypsin-like protease;
1338 MERS, Middle East respiratory syndrome; ORF, open reading frame; PLpro, papain-like protease; RBD, receptor-binding domain; S,
1339 spike; SARS, severe acute respiratory syndrome; TMPRSS2, transmembrane protease serine protease-2.

1340 ^a http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1

1341 ^b Please refer to Table 5 for details on animal reservoirs of MERS-CoV

1342 ^c http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf

1343 ^d http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1

1344 ^e Both animal (especially dromedary camels)-to-human and person-to-person transmission in nosocomial outbreaks are considered to
1345 be important factors for the persistent MERS outbreak. Person-to-person transmission of SARS-CoV in “super-spreading events” and

1346 major nosocomial outbreaks is considered to be the major transmission type in the large-scale epidemic of SARS.

1347 ^f Please refer to Table 6 for details on tissue and host tropism of MERS-CoV

1348 ^g <http://www.who.int/csr/don/17-december-2014-mers/en/>

1349 ^h http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1

1350 ⁱ Please refer to Table 12 for details on other animal modes of MERS

1351 **TABLE 2** Nomenclature and putative functional characteristics of MERS-CoV gene products with analogy to SARS-CoV^a

Gene nomenclature (no. of amino acid residues in product)	Gene product and/or putative functional domain(s)	Characteristics and/or effect on cellular response of host	References
ORF1a/b			
nsp1 (193)	Unknown	May induce template-dependent endonucleolytic cleavage of host mRNA but not viral RNA; & may interact with cyclophilins which may be blocked by cyclosporine A.	(16, 20-22, 252, 299, 300)
nsp2 (660)	Unknown	May interact with prohibitin 1 & 2, & disrupts intracellular signaling.	(16, 20-22, 252, 301)
nsp3 (1887)	Papain-like protease	Structurally similar to the papain-like protease of SARS-CoV albeit only 30% sequence identity, consisting of a right-hand-like architecture with palm, thumb, & fingers domains. Specific conserved structural features include the ubiquitin-like domain, a catalytic triad consisting of C1594-H1761-D1776, & the ubiquitin-binding domain at the zinc finger.	(16, 20-22, 28, 172, 173, 252, 302-305)
		<p>Functions:</p> <ol style="list-style-type: none"> 1. Proteolytic processing of the viral replicase polyprotein at 3 sites (nsp1-2, 2-3, & 3-4) to generate nsps that contribute to subgenomic RNA synthesis. 2. DeISGylating (ISG15-linked ISGylation) & deubiquitinating (K48- & K63-linked ubiquitination) activities 3. Interferon antagonist: reduces induction of NF-κB, blocks phosphorylation & nuclear translocation of IRF3, & blocks upregulation of cytokines CCL5, interferon-β, & CXCL10 in HEK293T cells. 	
	ADP-ribose 1''-phosphatase	Putative dephosphorylation of Appr-1''-p, a side product of cellular tRNA splicing, to ADP-ribose.	(16, 20-22, 252)
	Transmembrane domain 1	Uncertain function, but may be similar to other CoVs including SARS-CoV in anchoring the viral replication complex through recruitment of intracellular membranes to form a reticulovesicular network of CMs & DMVs interconnected via the outer membrane with the rough endoplasmic reticulum.	(16, 20-22, 252, 306)
nsp4 (507)	Transmembrane domain 2	Similar to nsp3 & may help to form part of the viral replication complex.	(16, 20-22, 252, 306)
nsp5 (306)	Main, chymotrypsin-like, or 3C-like protease	Proteolytic processing of the replicative polyprotein at specific sites & forming key functional enzymes such as replicase & helicase.	(16, 20, 22, 252)
nsp6 (292)	Transmembrane domain 3	Membrane-spanning integral component of the viral replication complex involved in DMV formation; substitutions lead to resistance to the viral RNA synthesis inhibitor K22.	(16, 20-22, 252, 306)
nsp7 (83)	Unknown	In SARS-CoV, nsp7 & -8 are part of a unique multimeric RNA polymerase complex.	(16, 20-22, 252, 307)
nsp8 (199)	Primase		(16, 20-22, 252)

nsp9 (110)	Unknown	In SARS-CoV, nsp9 is an essential protein dimer with RNA/DNA binding activity.	(16, 20-22, 253, 308)
nsp10 (140)	Unknown	In SARS-CoV, nsp10 is required for nsp16 to bind both m7GpppA-RNA substrate & S-adenosyl-L-methionine cofactor; nsp16 possesses the canonical scaffold of MTase & associates with nsp10 at 1:1 ratio.	(16, 20-22, 253, 309)
nsp11 (14)	Unknown	Unknown	(16, 20-22, 252)
nsp12 (933)	RNA-dependent RNA polymerase	Replication & transcription to produce genome- & subgenome-sized RNAs of both polarities.	(16, 20-22, 252)
nsp13 (598)	Superfamily 1 helicase	Putative dNTPase & RNA 5'-triphosphatase activities.	(16, 20-22, 252)
	Zinc-binding domain		(16, 20-22, 252)
nsp14 (524)	3'-to'5' exonuclease	Putative endoribonuclease activity in the replication of the giant RNA genome.	(16, 20-22, 252)
	N7-methyltransferase		(16, 20-22, 252)
nsp15 (343)	Nidoviral endoribonuclease specific for U	Putative RNA endonuclease that is essential in the CoV replication cycle.	(16, 20-22, 252)
nsp16 (303)	S-adenosylmethionine-dependent ribose 2'-O-methyltransferase	In SARS-CoV, nsp16 is critical for capping of viral mRNA & prevents recognition by host sensor molecules.	(16, 20-22, 252, 310)
ORF2 (1353)	Spike (S) protein	A type I transmembrane glycoprotein displayed on viral membrane surface critical for receptor binding & membrane fusion.	(16, 20-22, 252)
ORF3 (103)	Accessory protein 3 (single transmembrane domain)	Deletion of ORF3, -4, & -5 accessory cluster showed ~1.5 logs reduction in viral titer compared with recombinant MERS-CoV, & resulted in enhanced expression of subgenomic gRNA2 encoding the S protein associated with an increased fusion phenotype; not essential for virus replication in Vero A66 & Huh-7 cells.	(16, 20-22, 188, 252, 311)
ORF4a (109)	Accessory protein 4a (dsRNA-binding motif)	A dsRNA-binding protein of with the dsRNA-binding domain (residues 3 to 83) that potently antagonizes host interferon response via inhibition of interferon production (interferon-β promoter activity, IRF-3/7 & NF-κB activation), ISRE promoter element signaling pathways, and/or suppression of PACT-induced activation of RIG-I & MDA5 in an RNA-dependent manner; not essential for virus replication in Vero A66 & Huh-7 cells.	(16, 20-22, 24, 25, 252, 311)
ORF4b (246)	Accessory protein 4b (single transmembrane domain)	May have interferon antagonist activity; not essential for virus replication in Vero A66 & Huh-7 cells.	(16, 20-22, 24-27, 252, 311)
ORF5 (224)	Accessory protein 5 (three transmembrane domains)	Interferon antagonist with no effect on interferon-β promoter activation; not essential for virus replication in Vero A66 & Huh-7 cells.	(16, 20-22, 27, 188, 252, 311)

ORF6 (82)	Envelope (E) protein	Putative ion channel activity & is involved in viral budding & release; essential for efficient virus propagation in Vero A66 & Huh-7 cells.	(16, 20-22, 252, 311)
ORF7 (219)	Membrane (M) protein	Surface protein that incorporates viral components into virions & interacts with N protein in infected cells; interferon antagonist.	(16, 20-22, 24, 252)
ORF8a (413)	Nucleocapsid (N) protein	Interacts with C-terminal domain of M protein for binding & packaging of viral RNA in assembly of the virion.	(16, 20-22, 252)
ORF8b (112)	Unknown	Unknown	(16, 20-22, 252)

1352 Abbreviations: CCL5, chemokine ligand 5; CM, convoluted membrane; CoV, coronavirus; CXCL10, chemokine (C-X-C motif) ligand

1353 10; DMV, double membrane vesicle; ds, double-stranded; IRF3, interferon regulatory factor 3; ISG, Interferon-Stimulated Gene; nsp,

1354 non-structural protein.

1355 ^a The putative functions of the accessory gene products of MERS-CoV and SARS-CoV may not directly correlate as the accessory

1356 genes of these two viruses are not homologous.

1357 **TABLE 3** Sequence of events with epidemiological importance related to MERS

Date ^a	Place or Institution	Important event	References
19 April 2012	Zarqa, Jordan	1st healthcare-associated cluster: an outbreak of severe respiratory disease among 13 patients & healthcare workers in an ICU. The index patient & a close contact (ICU nurse) were subsequently confirmed to be infected with MERS-CoV in November 2012.	(66)
6 to 24 June 2012	Jeddah, KSA	1st laboratory-confirmed case: a 60-year-old man was admitted to a regional hospital for severe acute community-acquired pneumonia complicated with acute renal failure & later died. A novel CoV was isolated in cell culture of a sputum sample obtained on admission. The virus was initially named human coronavirus-Erasmus Medical Center (HCoV-EMC) .	(9)
3 September 2012	London, UK	1st imported case in UK: a 49-year-old man in Qatar with travel history to KSA was transferred from Doha, Qatar to an ICU in London, UK on 11 September 2012 for severe acute community-acquired pneumonia. A novel CoV was detected in combined nose & throat swab, sputum, & tracheal aspirate samples. The replicase gene fragment of this strain shared 99.5% identity with the 1 st HCoV-EMC strain.	(18, 84)
23 September 2012	WHO	WHO Disease Outbreak News: report of the first 2 laboratory-confirmed cases.	c
25 September 2012	WHO	1st interim case definition for HCoV-EMC infection was issued.	d
26 September 2012	EMC, Rotterdam, the Netherlands	1st complete genome of HCoV-EMC was available in GenBank (accession number: JX869059).	(16)
27 September 2012	ECDC	Protocols for real-time RT-PCR (upE & ORF1b) assays published in <i>Eurosurveillance</i> .	(312)
5 October to 14 November 2012	KSA	1st household cluster: three household family members of a 70-year-old man with laboratory-confirmed HCoV-EMC infection were hospitalized for severe respiratory disease.	(67)
9 October 2012	Riyadh, KSA	1st survived case: a 45-year-old man who was admitted for severe respiratory disease & renal failure recovered from HCoV-EMC infection.	(64)
13 October 2012	Essen, Germany	1st imported case in Germany	(69)
21 December 2012	WHO	1st interim recommendations for laboratory testing for HCoV-EMC were issued.	e
24 January to 16 February 2013	UK	1st cluster outside of the Middle East: a 60-year old man with recent travel history to KSA was admitted to an ICU for laboratory-confirmed HCoV-EMC. Two of his relatives who were close contacts also developed laboratory-confirmed MERS.	(73)
5 February 2013	UK	1st mild case: the 30-year-old female relative in the cluster only had mild, influenza-like illness symptoms & spontaneously recovered.	(73)
8 March 2013	UAE	1st case in UAE	(72)
8 April to May 2013	Al-Hasa, KSA	1st large-scale cluster: >20 laboratory-confirmed cases of HCoV-EMC were reported in household & hospital contacts in the eastern province of KSA.	(75)
22 April 2013	Valenciennes, France	1st imported case in France	(68, 71)
6 May 2013	Tunisia	1st imported cases in Tunisia	(74)
15 May 2013	Coronavirus Study Group, ICTV	Formal naming of the novel CoV as Middle East respiratory syndrome coronavirus .	(17)
25 May 2013	Italy	1st imported case in Italy	f

2 June 2013 ^b	Italy	1st pediatric case: a 2-year-old girl who was a close contact of the 1 st imported case in Italy (subsequently reclassified as a probable case).	(313)
9 August 2013	Oman	1 st report on the detection of anti-MERS-CoV antibodies in dromedaries in the Middle East.	(121)
23 August 2013	CDC	1 st report on the detection of a short (182-nt) fragment of the viral RdRp gene from a fecal pellet of a <i>Taphozous perforatus</i> bat in KSA which showed 100% identity to that of MERS-CoV (strain HCoV-EMC/2012).	(109)
16 September 2013	CDC	1 st report on the detection of a MERS-CoV-like virus (<i>Neoromicia</i> coronavirus) with 85.6% nt identity (complete genome) in the fecal sample of a <i>Neoromicia capensis</i> bat in South Africa.	(110, 111)
26 October 2013	Oman	1st case in Oman	g
17 December 2013	Qatar	1 st report on the detection of MERS-CoV RNA in nose swabs from dromedaries by RT-PCR.	(133)
13 February 2014	Kuwait	1st case in Kuwait	h
17 March 2014	Yemen	1st case in Yemen	i
9 April 2014	Malaysia	1st imported case in Malaysia	(78)
13 April 2014	The Philippines	1st imported case in the Philippines	j
17 April 2014	Greece	1st imported case in Greece	(76)
18 April 2014	USA	1st imported case in USA	(77, 81)
22 April 2014	Egypt	1st imported case in Egypt	k
mid-March to May 2014	KSA & UAE	Sudden surge of >400 cases associated with an increase in the number of primary cases amplified by several large healthcare-associated outbreaks in KSA & UAE.	l, m
22 April 2014	Lebanon	1st case in Lebanon	n
1 May 2014	The Netherlands	1st imported case in the Netherlands	(79)
11 May 2014	Iran	1st cases in Iran	o
23 May 2014	Algeria	1st imported cases in Algeria	p
4 June 2014	KSA	1 st report on camel-to-human transmission of MERS-CoV.	
22 September 2014	Austria	1st imported case in Austria	q
25 September 2014	Turkey	1st imported case in Turkey	r
17 December 2014	WHO	A total of 938 laboratory-confirmed cases of MERS including at least 343 deaths were reported.	s

1358 Abbreviations: CoV, coronavirus; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention
1359 and Control; ICTV, International Committee on Taxonomy of Viruses; ICU, intensive care unit; KSA, Kingdom of Saudi Arabia;
1360 UAE, United Arab Emirates; UK, United Kingdom; USA, the United States of America; WHO, World Health Organization.

1361 ^a The date of reported cases represents the date of symptom onset unless otherwise specified.

1362 ^b The date of reporting by WHO.

1363 ^c http://www.who.int/csr/don/2012_09_23/en/

1364 ^d http://www.who.int/csr/don/2012_09_25/en/

1365 ^e http://www.who.int/csr/disease/coronavirus_infections/LaboratoryTestingNovelCoronavirus_21Dec12.pdf?ua=1

1366 ^f http://www.who.int/csr/don/2013_06_01_ncov/en/
1367 ^g http://www.who.int/csr/don/2013_10_31/en/
1368 ^h http://www.who.int/csr/don/2014_03_20_mers/en/
1369 ⁱ http://www.who.int/csr/don/2014_05_07_mers_yemen/en/
1370 ^j http://www.who.int/csr/don/2014_04_17_mers/en/
1371 ^k http://www.who.int/csr/don/2014_05_01_mers/en/
1372 ^l http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf
1373 ^m http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1
1374 ⁿ http://www.who.int/csr/don/2014_05_15_mers/en/
1375 ^o http://www.who.int/csr/don/2014_06_11_mers/en/
1376 ^p http://www.who.int/csr/don/2014_06_14_mers/en/
1377 ^q <http://www.who.int/csr/don/02-october-2014-mers-austria/en/>
1378 ^r <http://www.who.int/csr/don/24-october-2014-mers/en/>
1379 ^s <http://www.who.int/csr/don/17-december-2014-mers/en/>
1380

1381 **TABLE 4** Underlying comorbidities of patients with laboratory-confirmed MERS

Underlying comorbidities	Clinical cohorts (references)							
	(87)	(66)	(63)	(75)	(80)	(88)	(314)	Others (86, 152)
Time period	April 2012 to 22 October 2013	April 2012	1 September 2012 to 15 June 2013	1 March 2013 to 19 April 2013	1 April 2013 to 3 June 2013	May 2013 to August 2013	1 October 2012 to 31 May 2014	
Setting / Data source	161 cases reported to WHO	Retrospective outbreak investigation in Jordan	All cases reported by the KSA Ministry of Health to WHO	Outbreak investigation in 4 hospitals in Al-Hasa, KSA	A 350-bed general hospital in KSA	3 intensive care units in KSA	70 cases at a single center in Riyadh, KSA	Case reports or case series
Any comorbidity	91/120 (75.8%); fatal (86.8%) > non-fatal (42.4%) cases	NA	45/47 (95.7%); 28/45 (62.2%) fatal	NA	12/12 (100%)	NA	57/70 (81.4%)	Fatal (40/55; 72.7%) > non-fatal (30/73; 41.1%) cases
Chronic pulmonary disease	NA	NA	12/47 (25.6%); 10/12 (83.3%) fatal	10/23 (43.5%)	6/15 (40.0%)	Asthma (1/12; 8.3%)	NA	NA
Chronic renal disease	16/120 (13.3%); 20.8% of fatal cases; 2° (23.0%) > 1° (4.3%) cases	NA	23/47 (48.9%); 17/23 (73.9%) fatal	NA	5/15 (33.3%)	5/12 (41.7%); 1/12 (8.3%) required dialysis	NA	NA
Chronic cardiac disease	9/120 (7.5%); at least 2 fatal; 1° (7/47, 14.9%) > 2° (2/61, 3.3%) cases	1/8 (12.5%)	13/47 (27.7%); 10/13 (76.9%) fatal	9/23 (39.1%)	8/15 (53.3%) including 3/15 (20.0%) with CHF	MI (4/12; 33.3%), cardiac surgery (3/12; 25.0%), CHF (2/12; 16.7%), valvular disease (1/12; 8.3%), & PVD (2/12; 16.7%)	NA	Chemotherapy-induced cardiomyopathy (1/7; 14.3%)

Diabetes mellitus	12/120 (10.0%); 3.8% of fatal cases; 1° (11/47, 23.4%) > 2° (1/61, 1.6%) cases	NA	32/47 (68.1%); 21/32 (65.6%) fatal	17/23 (73.9%)	13/15 (86.7%)	8/12 (66.7%)	NA	3/7 (42.9%)
Hypertension	NA	2/8 (25.0%)	16/47 (34.0%); 13/16 (81.3%) fatal	NA	NA	6/12 (50.0%)	NA	3/7 (42.9%)
Obesity	NA	NA	8/47 (17.0%); 5/8 (62.5%) fatal	5/21 (23.8%)	Mean BMI: 32.02±6.78 kg/m ²	Median BMI: 31.8 (21.6 to 46.1) kg/m ² ; 3/12 (33.3%) were obese	7/70 (10.0%)	1/7 (14.3%)
Smoking	NA	2/8 (25.0%)	11/47 (23.4%); 7/11 (63.6%) fatal	NA	NA	4/12 (33.3%)	9/70 (12.9%)	2/7 (28.6%)
Malignancy	NA	NA	1/47 (2.1%); fatal	NA	1/15 (6.7%)	1/12 (8.3%)	NA	2/7 (28.6%)
Others	NA	Pregnancy	Immunosuppressive therapy (3/47, 6.4%; all 3 fatal)	NA	NA	Stroke, kidney & liver transplant, & neuromuscular disease	Pregnancy	Dyslipidemia (1/7; 14.3%)

1382 Abbreviations: BMI, body mass index; CHF, congestive heart failure; KSA, Kingdom of Saudi Arabia; MI, myocardial infarction;

1383 NA, not available; PVD, peripheral vascular disease; vs, versus; WHO, World Health Organization.

1384 **TABLE 5** Evidence of zoonotic sources of MERS-CoV and closely related CoVs

Animal species (virus)	Country (area) / Specimen collection date	Main findings	References
Bats			
Superfamily Vespertilionoidea			
Family Vespertilionidae			
Asia			
<i>Tylonycteris pachypus</i> (Ty-BatCoV HKU4)	China (Hong Kong) / April 2005 to August 2012	Detected in 29/99 (29.3%) alimentary samples; shared 90.0% (RdRp), 67.4% (S), & 72.3% (N) aa identities with MERS-CoV (HCoV-EMC/2012)	(13, 99)
<i>Pipistrellus abramus</i> (Pi-BatCoV HKU5)	China (Hong Kong) / April 2005 to August 2012	Detected in 55/216 (25.5%) alimentary samples; shared 92.3% (RdRp), 64.5% (S), & 70.5% (N) aa identities with MERS-CoV (HCoV-EMC/2012)	(13, 99)
<i>Vespertilio superans</i> (Bat CoV-BetaCoV/SC2013)	China (Southwestern part) / June 2013	Detected in 5/32 (15.6%) anal swabs; shared 75.7% (complete genome of 1 strain) nt identity; & 96.7% (816-nt RdRp fragment) & 69.0% (S) aa identities with MERS-CoV (HCoV-EMC/2012)	(315)
Africa			
<i>Neoromicia capensis</i> (NeoCoV)	South Africa (KwaZulu-Natal & Western Cape Provinces) / 2011	Detected in 1/62 (1.6%) fecal sample; shared 85.6% (complete genome) nt identity; & 64.6% (S), 89.0% (E), 94.5% (M), & 91.7% (N) aa identities with MERS-CoV from humans & camels; placing them in the same viral species based on taxonomic criteria.	(110, 111)
Europe			
<i>Pipistrellus pipistrellus</i> , <i>Pipistrellus nathusii</i> , & <i>Pipistrellus pygmaeus</i> (<i>Pipistrellus</i> bat β CoVs)	Romania (Tulcea county) & Ukraine (Kiev region) / 2009-2011	Detected in 40/272 (14.7%) fecal samples; shared 98.2% (816-nt RdRp fragment) aa identity with MERS-CoV (HCoV-EMC/2012)	(316)
<i>Pipistrellus kuhlii</i> , <i>Hypsugo savii</i> , <i>Nyctalus noctula</i> , & an unknown <i>Pipistrellus</i> sp. (β CoVs)	Italy (Lombardia & Emilia regions) / 2010-2012	10 β CoVs detected in fecal specimens of <i>Pipistrellus kuhlii</i> (7), <i>Hypsugo savii</i> (1), <i>Nyctalus noctula</i> (1), & an unknown <i>Pipistrellus</i> sp. (1) bats; shared 85.2% to 87% nt identity & 95.3% to 96.1% (329-nt RdRp fragment) aa identity with MERS-CoV (HCoV-EMC/2012)	(317)
Superfamily Emballonuroidea			
Family Emballonuridae			
<i>Taphozous perforatus</i>	KSA (Bisha) / October 2012	A β CoV detected in 1/29 (3.4%) fecal sample; shared 100% nt identity (182-nt RdRp fragment) with MERS-CoV (HCoV-	(109)

(betaCoV)		EMC/2012)
Superfamily Molossoidea		
Family Molossidae		
<i>Nyctinomops laticaudatus</i> (Mex_CoV-9)	Mexico (Campeche) / 2012	Detected in 1/5 (20.0%) rectal swabs; shared 96.5% (329-nt RdRp fragment) aa identity with MERS-CoV (HCoV-EMC/2012) (318)
Superfamily Noctilionoidea		
Family Mormoopidae		
<i>Pteronotus davyi</i> (BatCoV-P.davyi49/Mexico/2012)	Mexico (La Huerta) / 2007-2010	Detected in 1/4 (25.0%) intestinal sample; shared 71.0% (439-nt RdRp fragment) nt identity with MERS-CoV (HCoV-EMC/2012) (319)
Superfamily Rhinolophoidea		
Family Nycteridae		
<i>Nycteris gambiensis</i> (<i>Nycteris</i> bat CoV)	Ghana (Bouyem, Forikrom, & Kwamang) / 2009-2011	Detected in 46/185 (24.9%) fecal samples; shared 92.5% aa identity (816-nt RdRp fragment) with MERS-CoV (HCoV-EMC/2012) (316)
Hedgehogs		
Europe		
<i>Erinaceus europaeus</i> (<i>Erinaceus</i> CoV)	Northern Germany / unknown date	Two clades detected in 146/248 (58.9%) fecal samples; shared 89.4% (816-nt RdRp fragment), 58.2% (S), 72.0% (E), 79.4% (M), & 72.1% (N) aa identities with MERS-CoV (HCoV-EMC/2012); RNA concentration was higher in the intestine & fecal samples than other solid organs, blood, or urine, suggestive of viral replication in the lower intestine & fecal-oral transmission; 13/27 (48.2%) sera contained non-neutralizing antibodies (113)
Camelids		
Middle East		
<i>Camelus dromedarius</i>	KSA (countrywide) / 1992 to 2010; & November to December 2013	Serum Ab: 150/203 (73.9%) (2013) & 72%-100% (1992 to 2010); adults (95%) > juveniles (55%) (123, 137) Viral RNA: nasal > rectal swabs; juveniles (36/104; 34.6%) > adults (15/98; 15.3%) Virus isolation: two nasal swabs cultured in Vero E6 cells

<i>Camelus dromedarius</i>	KSA (Riyadh & Al Ahsa) / 2012 to 2013	Serum nAb: 280/310 (90.3% with titer \geq 1:20) adults (233/245; 95.1%) > juveniles (47/65; 72.3%)	(127)
<i>Camelus dromedarius</i>	KSA (Jeddah) / 3 November 2013	Direct camel-to-human transmission: phylogenetical (identical full genome sequences of patient strain & an epidemiologically-linked camel strain) & serological (the virus was circulating in the epidemiologically-linked camels but not in the patient before the human infection occurred) evidence	(138)
<i>Camelus dromedarius</i>	KSA (Jeddah) / 14 November to 9 December 2013	Serum Ab: 4-fold rise in paired sera in 2/9 (22.2%)	(128)
<i>Camelus dromedarius</i>	KSA (Al-Hasa) / November 2013 to February 2014 (peak calving season)	Viral RNA: detected in nasal swabs of both camels (upE & ORF1a) Serum nAb: 280/310 (90.3%) Viral RNA: nasal > fecal specimens Viral genome: highly stable with an estimated mutation rate of 0 nt substitutions per site per day Clinical: both calves & adults could be infected; symptoms included mild respiratory symptoms (cough, sneezing, respiratory discharge), \uparrow body temperature, & \downarrow appetite; acute infection was not associated with prolonged viremia or viral shedding	(320)
<i>Camelus dromedarius</i>	UAE (Dubai) / 2003 & 2013	Serum Ab: 151/151 (100%) (2003) & 481/500 (96.2%) (2013); high titers of nAb >1:640 in 509/651 (78.2%)	(124)
<i>Camelus dromedarius</i>	UAE (Dubai) / February to October 2005	Serum nAb: 9/11 (81.8%)	(125)
<i>Camelus dromedarius</i>	Oman / March 2013 & Spain (Canary Islands) / April 2012 to May 2013	Serum Ab: 50/50 (100%) of Omani & 15/105 (14.3%) of Spanish camels; all 50/50 (100%) of Omani (titers 1/320 to 1/2560) & 9/105 (9%) of Spanish camels had nAb (titers 1/20 to 1/320)	(121)
<i>Camelus dromedarius</i>	Oman (countrywide) / December 2013	Viral RNA: high concentrations in nasal & conjunctival swabs of 5/76 (6.6%) camels (\geq 2 gene targets)	(321)
<i>Camelus dromedarius</i>	Jordan (al Zarqa governorate) / June to September 2013	Serum nAb: 11/11 (100%)	(126)
<i>Camelus dromedarius</i>	Qatar / 17 October 2013	Serum nAb: 14/14 (100%); titers 1/160 to 1/5120 Viral RNA: 5/14 (35.7%) nasal swabs by 3 gene targets (upE, N, & ORF1a), 1/14 (7.1%) by 2 gene targets, & 5/14 (35.7%) by 1 gene target Viral genome: 3/5 samples shared 100% identity (357-nt S fragment) with sequences from 2 epidemiologically-linked patients; further sequencing of 4.2kb concatenated fragments of a camel	(133)

		strain & 2 epidemiologically-linked patient strains: only 1 nt difference in ORF1a & 1 nt difference in ORF4b	
<i>Camelus dromedarius</i>	Qatar (Doha) / February 2014	Viral RNA: 1/53 (1.9%) nasal swab from an 8-month-old camel (1/53, 1.9%) (upE & N)	(131)
		Viral genome: complete genome (MERS-CoV camel/Qatar_2_2014) shared 99.5% to 99.9% nt identities with other camel & patient strains	
<i>Camelus dromedarius</i>	Qatar (Al Shahaniya & Dukhan) / April 2014	Serum & milk Ab: all 33 camels had IgG in serum & milk	(144)
		Viral RNA: detected in the nose swabs and/or feces of 7/12 camels, & the milk of 5/7 of these camels in Al Shahaniya	
<i>Camelus dromedarius</i>	KSA (Al Hasa, As Sulayyil, Hafar Al-Batin, Medina) / 1993, Egypt / 2014, & Australia (central Australia & Queensland) / 2014	Serum nAb: 118/131 (90.1%) of KSA camels & 0/25 (0%) of Australian camels	(322)
Africa			
<i>Camelus dromedarius</i>	Somalia / 1983 to 1984, Sudan / June & July 1983, Egypt / June & July 1997	Serum nAb: Somalia (70/86, 81.4%), Sudan (49/60, 81.0%) & Egypt (34/43, 79.1%) by MNT	(132)
<i>Camelus dromedarius</i>	Kenya / 1992 to 2013	Serum Ab: 213/774 (27.5%); including 119/774 (15.4%) with nAb; seropositive camels were found in all sampling sites throughout the study period; ↑ seroprevalence was significantly correlated with ↑ camel population density	(130)
<i>Camelus dromedarius</i>	Nigeria / 2010 to 2011, Tunisia / 2009 & 2013, & Ethiopia / 2011 to 2013	Serum Ab: Nigeria (94.0% of adults) & Ethiopia (93.0% of juveniles & 97.0% of adults); lower rates in Tunisia (54.0% of adults & 30.0% of juveniles)	(323)
<i>Camelus dromedarius</i>	Egypt (Cairo & Qalyubia governorate) / June 2013	Serum nAb: 103/110 (93.6% with titer ≥1:20) by MNT & 108/110 (98% with titer ≥1:20) by spike ppNT	(122)
<i>Camelus dromedarius</i>	Egypt (Alexandra, Cairo, & Nile Delta region) / June to December 2013	Serum nAb: 48/52 (92.3% with titers between 1:20 to ≥1:640); 0/179 abattoir workers	(134)
		Viral RNA: 4/110 (3.6%) nasal swabs (upE & ORF1a)	

1385 Abbreviations: aa, amino acid; KSA, Kingdom of Saudi Arabia; N, nucleocapsid; nAb, neutralizing antibody; nt, nucleotide; ORF,

1386 open reading frame; MNT, micro-neutralization test; RT-PCR, reverse transcription polymerase chain reaction; ppNT, pseudoparticle

1387 neutralization test; RBD, receptor-binding domain; RdRp; RNA-dependent RNA polymerase; S, spike; UAE, United Arab Emirates.

1388 **TABLE 6** Tissue and host tropism of MERS-CoV demonstrated in cell culture systems

Cell culture system	Anatomic site or animal species	Main findings ^a	References
Cell lines			
Human cell types			
Lower respiratory tract			
A549	Lung adenocarcinoma	Replication with ↑ viral load (~1-2), N protein expression & CPE	(116)
Calu-3	Polarized bronchial epithelia	Replication with ↑ viral load (~4-5), N protein expression & CPE (cell rounding, detachment, & prominent syncytia formation)	(116)
		Replication in Calu-3 cells with ↑ viral load (~5-6) & CPE at 24 hpi; infection & release of virions through both the apical & basolateral routes	(185)
HFL	Embryonic lung fibroblasts	Replication with ↑ viral load (~4-5), N protein expression & CPE	(116)
Differentiated HTBE	Human tracheobronchial epithelia	Replication with ↑ viral load (~2.5-4.5) in differentiated HTBE cells; virions released exclusively from the apical but not the basolateral side	(186)
Nondifferentiated HTBE	Human tracheobronchial epithelia	Replication with ↑ viral load (<1) in nondifferentiated but much less than that observed in differentiated HTBE cells	(186)
HAE	Pseudostratified human airway epithelia	Productive infection in HAE cultures peaks at 48 hpi: host cell factors required for cell entry, RNA synthesis, & virus assembly & release are available in human	(187)
		Replication in HAE, lung fibroblasts, type II pneumocytes, & microvascular endothelial cells; most efficient in HAE & lung fibroblasts	(188)
HBEpC	Human primary bronchial epithelium	Replication with ↑ viral load (~0.5-1) (~1000-fold lower concentrations of virus progeny than in HREpC) & without CPE	(157)
Kidney			
HEK 293	Human embryonic kidney	Replication with ↑ viral load (~4-5), N protein expression & CPE	(116)
769-P	Renal cell adenocarcinoma	Replication with ↑ viral load (~3-4)	(117)
HREpC	Human primary kidney epithelium	Replication with ↑ viral load (~3-4) (~1000-fold higher concentrations of virus progeny than in HBEpC) & CPE (rounding & detachment of cells with cell death in the majority of cells after only 20 hpi)	(157)
Colon			
Caco-2	Colorectal adenocarcinoma	Replication with ↑ viral load (~4-5), N protein expression & CPE (cell rounding, detachment, & prominent syncytia formation)	(116)
LoVo	Metastatic colonic adenocarcinoma	Replication in LoVo cells with ↑ viral load (~5-6) & CPE at 4 dpi	(185)
Liver			
Huh-7	Hepatocellular carcinoma	Replication with ↑ viral load (~4-5), N protein expression & CPE (cell aggregates with marked shrinkage)	(116)
Neuromuscular cells			

NT2	Neuro-committed teratocarcinoma	Replication with ↑ viral load (~2-3), but no N protein expression & CPE	(116)
Immune cells			
THP-1	Peripheral blood monocytes from AML	Replication with ↑ viral load (<1), but no N protein expression & CPE	(116)
U937	Monocytes from histiocytic lymphoma	Replication with ↑ viral load (<0.5), but no N protein expression & CPE	(116)
H9	T lymphocytes from T-cell leukemia	Replication with ↑ viral load (<0.5), but no N protein expression & CPE.	(116)
Jurkat_CD26DPP4+	Human T lymphocytes transfected with a human DPP4-encoded plasmid	Conversion from non-susceptible state to susceptible state with productive viral infection after plasmid transfection	(185)
His-1	Malignant histiocytoma	Replication with ↑ viral load (~3-4), N protein expression & CPE	(116)
Nonhuman cell types			
Primates			
LLC-MK2	Rhesus monkey kidney	Replication with ↑ viral load (~4-5), N protein expression & CPE	(116)
Vero	African green monkey kidney	Replication with ↑ viral load (~4-5), N protein expression & CPE	(116)
Vero-TMPRSS2	African green monkey kidney cells expressing TMPRSS2	Early appearance of large syncytia at 18hpi & virus particle-induced cell-cell fusion at 3hpi	(52)
Vero E6	African green monkey kidney	Replication with ↑ viral load (~4-5) & N protein expression; slower & less obvious CPE than those in Vero cells	(58, 116)
COS-7 with DPP4	African green monkey fibroblasts transfected with a human DPP4-encoded plasmid	Conversion from non-susceptible state to susceptible state with productive viral infection after plasmid transfection	(46)
Bats			
RoNi/7	Old World bat (<i>Rousettus aegyptiacus</i>) kidney	Replication with ↑ viral load (~3-4)	(117)
PipNi/1	Old World bat (<i>Pipistrellus pipistrellus</i>) kidney	Replication with ↑ viral load (~1-2)	(117)
PipNi/3	Old World bat (<i>Pipistrellus pipistrellus</i>) kidney	Replication with ↑ viral load (~1-2)	(117)
RhiLu	Old World bat (<i>Rhinolophus landeri</i>) lung	Replication with ↑ viral load (~2-3)	(117)
MyDauNi/2	Old World bat (<i>Myotis daubentonii</i>) kidney	Replication with ↑ viral load (~1-2)	(117)
CarNi/1	New World bat (<i>Carollia perspicillata</i>) kidney	Replication with ↑ viral load (<0.5)	(117)
EFF	New World bat (<i>Eptesicus fuscus</i>) embryo	Susceptible to MERS-CoV pseudovirus infection	(23)
EidNi/41.3	Old World bat (<i>Eidolon helvum</i>) adult kidney	Replication with ↑ viral load (~10 ⁶ PFU/ml)	(324)

EpoNi/22.1	Old World bat (<i>Epomops buettikoferi</i>) adult kidney	Replication with ↑ viral load (~10 ⁴ PFU/ml)	(324)
HypLu/45.1	Old World bat (<i>Hypsignathus monstrosus</i>) fetal lung	Replication with ↑ viral load (~10 ⁵ PFU/ml)	(324)
HypNi/1.1	Old World bat (<i>Hypsignathus monstrosus</i>) fetal kidney	Replication with ↑ viral load (~10 ⁵ PFU/ml)	(324)
PESU-B5L	New World bat (<i>Pipistrellus subflavus</i>) adult lung	Did not support productive MERS-CoV infection unless transfected with a plasmid expressing human DPP4	(324)
RO5T	Old World bat (<i>Rousettus aegyptiacus</i>) embryo	Did not support productive MERS-CoV infection unless transfected with a plasmid expressing human DPP4	(324)
RO6E	Old World bat (<i>Rousettus aegyptiacus</i>) embryo	Did not support productive MERS-CoV infection unless transfected with a plasmid expressing human DPP4	(324)
RoNi/7.1	Old World bat (<i>Rousettus aegyptiacus</i>) adult kidney	Replication with ↑ viral load (~10 ⁶ PFU/ml)	(324)
RoNi/7.2	Old World bat (<i>Rousettus aegyptiacus</i>) adult kidney	Replication with ↑ viral load (~10 ⁶ PFU/ml)	(324)
Tb1Lu	New World bat (<i>Tadarida brasiliensis</i>) adult lung	Did not support productive MERS-CoV infection unless transfected with a plasmid expressing human DPP4	(324)
Camelids			
TT-R.B	Arabian camel (<i>Camelus dromedarius</i>) umbilical cord	Replication with ↑ viral load (~1) but without production of infectious virus particles	(118)
LGK-1-R	Alpaca (<i>Llama pacos</i>) kidney	Replication with ↑ viral load (~2-3) & production of infectious virus particles	(118)
Other mammals			
ZLu-R	Goat (<i>Capra hircus</i>) lung	Replication with ↑ viral load (~1-2) & production of infectious virus particles	(118)
ZN-R	Goat (<i>Capra hircus</i>) kidney	Replication with ↑ viral load (~3-4) & production of infectious virus particles	(118)
PK-15	Pig kidney	Replication with ↑ viral load (~4-5), N protein expression & CPE	(116)
PS	Pig kidney	Replication with ↑ viral load (<1)	(117)
RK-13	Rabbit kidney	Replication with ↑ viral load (~1-2), but no N protein expression & CPE	(116)
CL-1	Civet lung fibroblasts	Replication with ↑ viral load (~1-2), N protein expression & CPE	(116)
MDCK with human DPP4	Dog kidney transfected with a human DPP4-encoded plasmid	Conversion from non-susceptible state to susceptible state with productive viral infection after plasmid transfection	(46)
LR7 with human DPP4	Mouse fibroblasts transfected with a human DPP4-encoded plasmid	Conversion from non-susceptible state to susceptible state with productive viral infection after plasmid transfection	(46)
CRFK with human DPP4	Cat kidney cortex epithelium transfected with a human DPP4-encoded plasmid	Conversion from non-susceptible state to susceptible state with productive viral infection after plasmid transfection	(46)

BHK with human DPP4	Baby hamster kidney cells expressing human DPP4	Conversion from non-susceptible state to susceptible state after transfection with a human but not hamster or ferret DPP4-encoded expression vector	(325)
Primary ferret kidney with human DPP4	Primary ferret kidney cells expressing human DPP4	Conversion from non-susceptible state to susceptible state with after transfection with a human but not hamster or ferret DPP4-encoded expression vector	(325)
Ex-vivo organ or cell cultures			
Respiratory tract			
Lower respiratory tract	Human lung	Infection & replication in most cell types of the human alveolar compartment (ciliated & non-ciliated cells in simple columnar & simple bronchial epithelium, types I & II pneumocytes, endothelial cells of large & small pulmonary vessels, but not alveolar macrophages)	(189)
	Human bronchus & lung	Productive replication in both human bronchial & lung <i>ex vivo</i> organ cultures (non-ciliated bronchial epithelium, bronchiolar epithelial cells, alveolar epithelial cells, & endothelial cells); virions were found within the cytoplasm of bronchial epithelial cells & budding virions were found in alveolar epithelial cells (type II)	(190)
	Human lung	Infection of airway epithelial cells (pneumocytes & epithelial cells of terminal bronchioles, endothelial cells, & lung macrophages)	(191)
Immune cells			
Peripheral blood mononuclear cells	Human monocyte-derived macrophages (MDMs)	Productively infection & replication in MDMs with ↑ viral load (~3-4) & aberrant induction of inflammatory cytokines & chemokines (higher expression levels of IL-12, IFN-γ, IP-10, MCP-1, MIP-1α, IL-8, CCL-5, MHC class I & costimulatory molecules > SARS-CoV-infected MDMs)	(191)
	Human monocyte-derived dendritic cells (MoDCs)	Productive infection of MoDCs with ↑ viral load (~2-3) & significantly higher expression levels inflammatory cytokines & chemokines (IL-12, IFN-γ, IP-10, CCL-5, MHC class II & the costimulatory molecule CD86) than SARS-CoV-infected MoDCs	(193)

- 1389 Abbreviations: AML, acute monocytic leukemia; CCL, chemokine C-C motif ligand; CPE, cytopathic effects; dpi, days post infection;
- 1390 hpi, hours post infection; IFN, interferon; IL, interleukin; IP, interferon-γ-induced protein; MCP, monocyte chemotactic protein; MHC,
- 1391 major histocompatibility complex; MIP, macrophage inflammatory protein; N, nucleocapsid; PFU, plaque-forming unit; TMPRSS2,
- 1392 transmembrane protease serine protease-2.

1393 ^aValues of viral loads are presented in \log_{10} virus RNA genome copies equivalents per mL of cell culture supernatant unless otherwise
1394 specified.

1395 **TABLE 7** Clinical, laboratory, and radiological features of MERS

Clinical, laboratory, and radiological features	Clinical cohorts (references)						
	(66)	(63)	(75)	(80)	(88)	(314)	Others (9, 18, 64, 67, 69, 71-73, 86, 152, 157, 326)
Time period	April 2012	1 September 2012 to 15 June 2013	1 March 2013 to 19 April 2013	1 April 2013 to 3 June 2013	May 2013 to August 2013	1 October 2012 to 31 May 2014	
Setting / Data source	Retrospective outbreak investigation in Jordan	All cases reported by the KSA Ministry of Health to WHO	Outbreak investigation in 4 hospitals in Al-Hasa, KSA	A 350-bed general hospital in KSA	3 intensive care units in KSA	70 cases at a single center in Riyadh, KSA	Case reports or case series
Clinical features							
Systemic							
Fever >38°C	8/9 (88.9%)	46/47 (97.9%)	20/23 (87.0%)	6/15 (40.0%)	8/12 (66.7%)	43/70 (61.4%)	6/7 (85.7%)
Chills and/or rigors	1/9 (11.1%)	41/47 (87.2%)	NA	1/15 (6.7%)	NA	NA	NA
Respiratory							
Rhinorrhea	1/9 (11.1%)	2/47 (4.3%)	NA	NA	1/12 (8.3%)	NA	NA
Sore throat	NA	10/47 (21.3%)	20/23 (87.0%)	1/15 (6.7%)	1/12 (8.3%)	NA	NA
Cough	8/9 (88.9%)	39/47 (83.0%)	NA	NA	10/12 (83.3%)	38/70 (54.3%)	7/7 (100%)
Sputum	NA	17/47 (36.2%)	NA	NA	2/12 (16.7%)	23/70 (23.9%)	3/7 (42.9%)
Hemoptysis	NA	8/47 (17.0%)	NA	1/15 (6.7%)	1/12 (8.3%)	NA	NA
Wheezing	NA	NA	NA	2/15 (13.3%)	2/12 (16.7%)	6/70 (8.6%)	NA
Chest pain	4/9 (44.4%)	7/47 (14.9%)	NA	1/15 (6.7%)	NA	NA	NA
Dyspnea	5/9 (55.6%)	34/47 (72.3%)	11/23 (47.8%)	10/15 (66.7%)	11/12 (91.7%)	42/70 (60.0%)	4/7 (57.1%)
Renal							
Acute renal failure	NA	NA	NA	NA	7/12 (58.3%)	30/70 (42.9%)	7/7 (100%) in one cohort; & 9/12 (75.0%) in another with at least 6/9 (75.0%) fatal; median time = 11±2 days from symptom onset

Gastrointestinal							
Nausea	NA	10/47 (21.3%)	NA	NA	1/12 (8.3%)	NA	NA
Vomiting	NA	10/47 (21.3%)	4/23 (17.4%)	1/15 (6.7%)	NA	21/70 (30.0%)	NA
Diarrhea	NA	12/47 (25.5%)	5/23 (21.7%)	1/15 (6.7%)	2/12 (16.7%)	21/70 (30.0%)	NA
Abdominal pain	NA	8/47 (17.0%)	NA	NA	Acute abdomen (3/12, 25.0%): ischemic bowel requiring hemicolectomy (1) & negative laparotomies (2)	17/70 (24.3%)	1/7 (14.3%)
Other symptoms							
Myalgia	NA	15/47 (31.9%)	NA	1/15 (6.7%)	NA	14/70 (20.0%)	1/7 (14.3%)
Headache	NA	6/47 (12.8%)	NA	1/15 (6.7%)	2/12 (16.7%)	9/70 (12.9%)	
Malaise	3/9 (33.3%)	NA	NA	NA	2/12 (16.7%)	29/70 (41.4%)	1/7 (14.3%)
Complications							
Co-infections							
Bacterial & fungal	NA	0/47 (0%)	NA	NA	<i>Staphylococcus aureus</i> (1/12, 8.3%) & <i>Streptococcus pneumoniae</i> (1/12, 8.3%)	<i>Clostridium difficile</i> , multidrug-resistant bacteria (22/70, 31.4%) including CRAB, VRE, MRSA, & candidemia	<i>Klebsiella pneumoniae</i> , <i>S. aureus</i> , <i>S. epidermidis</i> , <i>Acinetobacter</i> sp., <i>Pseudomonas aeruginosa</i> ; <i>Aspergillus fumigatus</i> , & candidemia (<i>Candida albicans</i> & <i>C. glabrata</i>)
Viral	NA	0/47 (0%)	NA	NA	Influenza B (1/12, 8.3%)	0/70 (0%)	Influenza A(H1N1)pdm09 (1) & type 2 parainfluenza (2)
ICU admission ^a	4/8 (50.0%)	42/47 (89.4%)	18/23 (78.3%); time from symptom onset	8/15 (53.3%)	12/12 (100%); time from symptom onset	49/70 (70.0%)	60/133 (45.1%)

			= 5 days (1 to 10 days)		to ICU admission = 2 days; duration = 30 days (7 to 104 days)		
Mechanical ventilation ^a	2/8 (25.0%)	34/47 (72.3%); time from presentation = 7 days (3 to 11 days)	18/23 (78.3%); time from symptom onset = 7 days (3 to 11 days)	NA	12/12 (100%); time from symptom onset to mechanical ventilation = 4.5 days; duration = 16 days (4 to 30 days)	49/70 (70.0%)	NA
Others	Pericarditis, pleural & pericardial effusions, arrhythmias (SVT & VT), & delirium	NA	NA	NA	Vasopressors: (8/12, 66.7%)	Delirium: (18/70, 25.7%), seizure (6/70; 8.6%), arrhythmias (11/70, 15.7%), pneumothorax (5/70, 7.1%), rhabdomyolysis (10/70, 14.3%)	2 nd trimester stillbirth at 5 months of gestation
Death ^a	2/8 (25.0%); time from symptom onset = 16.5 day	28/47 (59.6%); time from presentation = 14 days (5 to 36 days); CFR ↑ with ↑ age	At least 15/23 (65.2%); time from symptom onset = 11 days (5 to 27 days)	13/17 (76.5%)	7/12 (58.3%) at day 90 of symptom onset	42/70 (60.0%)	291/837 (34.8%) (April 2012 to 23 July 2014) (86)
Laboratory features							
Hematological abnormalities							
Leukocytosis	NA	NA	3/23 (13.0%)	2/17 (11.8%)	NA	Yes	NA
Leukopenia	2/7 (28.6%)	7/47 (14.9%)	2/23 (8.7%)	1/17 (5.9%)	NA	NA	3/7 (42.9%)
Normal neutrophil count	NA	43/47 (91.5%)	NA	NA	NA	Yes	NA
Lymphocytosis	NA	5/47 (10.6%)	NA	NA	NA	NA	NA
Lymphopenia	6/7 (85.7%)	16/47 (34.0%)	NA	6/17 (35.3%)	9/12 (75.0%) on ICU admission & 11/12	Yes (median lymphocyte count,	7/7 (100%)

					(91.7%) during ICU stay	0.85x10 ⁹ /l	
Thrombocytosis	NA	NA	1/23 (4.3%)	NA	NA	NA	NA
Thrombocytopenia	NA	17/47 (36.2%)	4/23 (17.4%)	NA	2/12 (16.7%) on ICU admission & 7/12 (58.3%) during ICU stay	NA	3/7 (42.9%)
Others	DIC	NA	NA	NA	NA	DIC (10, 14.3%), anemia (median 10.7 g/dl), neutropenia	Anemia, ↑PT, ↑APTT, ↑INR, & DIC
Biochemical abnormalities							
Elevated serum ALT	NA	5 (10.6%)	NA	3/17 (17.6%)	2/12 (16.7%) on ICU admission & 5/12 (41.7%) during ICU stay	22/70 (31.4%)	NA
Elevated serum AST	NA	7/47 (14.9%)	3/13 (23.1%)	9/17 (52.9%)	2/12 (16.7%) on ICU admission & 8/12 (66.7%) during ICU stay	22/70 (31.4%); median 59 IU/l	NA
Elevated serum LDH	NA	23/47 (48.9%)	NA	8/17 (47.1%)	NA	NA	NA
Others	NA	NA	NA	NA	NA	Hypoalbuminemia	Hyponatremia, hyperkalemia, hypoalbuminemia, & ↑ serum urea, creatine kinase, troponin, C-reactive protein, & procalcitonin levels
Radiological findings	7/7 (100%) had CXR lesions in ≤3 days of presentation (uni- / bilateral ↑ bronchovascular	47/47 (100%) had CXR lesions (mild to extensive uni- / bilateral ↑ bronchovascular markings, air-	20/23 (87.0%) had CXR lesions at presentation (↑ bronchovascular markings, uni- / bilateral	Single (6/15; 40.0%) & multiple (9/15; 60.0%) CXR infiltrates; interstitial infiltrates	12/12 (100%) had CXR lesions (unilobar to bilateral diffuse air-space infiltrates)	Bi- (53/66; 80.3%) & unilateral (10/66; 15.2%) had CXR lesions	Bi- (6/7; 85.7%) & unilateral (1/7; 14.3%) had CT lesions; ground-glass opacities & consolidations

markings, consolidation, elevated diaphragm, & cardiomegaly with pericardial effusion)	space opacities, patchy infiltrates, interstitial changes, patchy to confluent air-space consolidation, nodular opacities, reticular opacities, reticulonodular shadows, pleural effusion, & total opacification of lung segments & lobes)	infiltrates, & diffuse reticulonodular shadows)	(10/15; 66.7%) & cardiomegaly (8/15; 53.3%)	(5/7; 71.4%), isolated ground-glass opacities (1/7; 14.3%); isolated consolidation (1/7; 14.3%); smooth septal thickening (3/7; 42.9%); lower lung-predominant (5/7; 71.4%); none had tree-in-bud pattern, cavitation, or intrathoracic lymphadeopathy
--	--	---	---	--

1396 Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CFR, 1397 case-fatality rate; CRAB, carbapenem-resistant *Acinetobacter baumannii*, CT, computerized tomography scan; CXR, chest 1398 radiograph; DIC, disseminated intravascular coagulation; ICU, intensive care unit; INR, international normalized ratio; KSA, the 1399 Kingdom of Saudi Arabia; LDH, lactate dehydrogenase; MRSA, methicillin-resistant *Staphylococcus aureus*, NA, not available; SVT, 1400 supraventricular tachycardia; UK, the United Kingdom; VRE, vancomycin-resistant enterococci, VT, ventricular tachycardia; WHO, 1401 World Health Organization. 1402 ^a Values represent median time intervals

1403 **TABLE 8** Characteristics of nucleic acid amplification tests for laboratory diagnosis of MERS

Diagnostic method and target gene	Clinical specimen(s)	Recommended use	Technical LOD	Remarks	References
Nucleic acid amplification					
upE assay (upstream of E gene)	Respiratory swab, sputum, & endotracheal aspirate	Screening	1.6 to 3.4 RNA copies/reaction	Most widely used test globally	(312)
ORF1a assay (ORF1a gene)	BAL, NPA	Confirmatory for upE-positive samples	4.1 RNA copies/reaction	As sensitive as upE assay	(62, 69)
RealStar® MERS-CoV RT-PCR kit 1.0	Aspiration tube flushed with PBS, BAL, mouth exudates, nose exudates, stool, urine, CVC flushed with PBS	Screening	upE assay: 5.3 copies/reaction ORF1a assay: 9.3 copies/reaction	As sensitive as the in-house upE & 1A assays; rapid & less labor-intensive than the in-house assays	(327)
ORF1b assay (ORF1b gene)	Respiratory swab, sputum, & endotracheal aspirate	Confirmatory for upE positive samples	64 RNA copies/reaction	Less sensitive than upE & 1A assays; no overlap with those of known pan-CoV assays	(312)
RdRpSeq assay (RdRp gene & sequencing)	BAL, NPA	Screening (pan-CoV RT-PCR) & confirmatory (sequencing)	0.3 to 3.0 PFU/ml	May cross-react with other β CoVs as the gene target is highly conserved	(62, 69)
NSeq assay (N gene & sequencing)	BAL, NPA	Screening (RT-PCR) & confirmatory (sequencing)	0.03 to 0.3 PFU/ml	Highly sensitive & specific for MERS-CoV; may have deletion or mutation in the amplified fragment	(62, 69)
N2 assay (N gene)	URT, LRT, serum, stool	Screening with upE to enhance sensitivity & specificity	5 to 10 RNA copies/reaction	As sensitive as upE assay	(328)
N3 assay (N gene)	URT, LRT, serum, stool	Confirmatory of upE- or N2-positive samples	5 to 10 RNA copies/reaction	As sensitive as upE assay	(328)
RT-RPA assay (N gene)	No clinical specimen: culture supernatant	Field use (point-of-care test)	10 RNA copies/reaction	As sensitive as RT-PCR, faster TAT (≤ 30 minutes), & mobile	(200)
RT-LAMP	Medium containing pharyngeal swabs (healthy adults) mixed with MERS-CoV	Field use	3.4 RNA copies/reaction	As sensitive as upE & ORF1a assays, faster TAT (≤ 30 minutes)	(201)

1404 Abbreviations: BAL, bronchoalveolar lavage; CoV, coronavirus; CVC, central venous catheter; Ig, immunoglobulin; LOD, lower limit
1405 of detection; LRT, lower respiratory tract; PCR, polymerase chain reaction; N, nucleocapsid; NPA, nasopharyngeal aspirate; ORF,
1406 open reading frame; RdRp, RNA-dependent RNA polymerase; RT-LAMP, reverse transcription loop-mediated isothermal
1407 amplification; RT-PCR, reverse transcription polymerase chain reaction; RT-PRA, reverse transcription isothermal Recombinase
1408 Polymerase Amplification; TAT, turnaround time; URT, upper respiratory tract.

1409 **TABLE 9** Characteristics of antibody detection assays for laboratory diagnosis of MERS and related seroepidemiological data in
 1410 human

Diagnostic method and detection target	Antigen used	Source of tested sera	Cross-reactivity	Main findings	References
IFA					
Indirect IFA (anti-MERS-CoV Ab)	Whole virus	2 laboratory-confirmed cases & blood donors	1/85 (1.2%) cross-reactive IgM in blood donors; detected in cells overexpressing recombinant S or N proteins	Better cell morphology; used as a screening test in a 2-stage protocol	(62, 69, 183)
		130 blood donors & 226 slaughterhouse workers (Jeddah & Makkah, KSA)	8/226 slaughterhouse workers had cross-reactive Ab in IFA	No evidence of widespread circulation of MERS-CoV in Jeddah & Makkah, KSA	(98)
Indirect IFA (anti-MERS-CoV Ab)	Whole virus	Animal handlers, SARS patients, & healthy blood donors in southern China	2/94 (2.1%) of animal handlers, 17/28 (60.7%) SARS patients, & 0/152 (0%) of healthy blood donors had cross-reactive anti-MERS-CoV Ab	An epitope around HR2 domain of S2 subunit may induce cross-reactivity in IFA against β CoVs.	(203)
IFA on Vero B4 cells (anti-MERS-CoV Ab)	Recombinant S & N proteins	2 serum samples from 1 patient (weeks 3 & 8)	None in samples from a few German blood donors; detected in cells overexpressing recombinant S or N proteins	Does not require optimization of infection dose & duration, & BSL-3 containment	(62, 69)
		1 laboratory-confirmed case & 85 contacts	None	Helps to confirm the positive tests in conventional IFA	(183)
ELISA					
ELISA (anti-S & anti-N Ab)	S & N proteins expressed in VRP	Mouse sera	Cross-reactive anti-N Ab against MERS-CoV & other lineage 2c β CoVs; little cross-reactive anti-S Ab; no cross-reactive anti-N or anti-S Ab between MERS-CoV & SARS-	Strain specific anti-S responses with very low level of cross-reactivity within or across CoV subgroups; cross-reactive anti-N Ab within but not across CoV subgroups	(202)

CoV or α CoVs					
Western blot					
Western blot (anti-S & anti-N Ab)	Recombinant S & N proteins	2 serum samples from 1 patient (weeks 3 & 8)	Not tested	Confirms the presence of anti-S & anti-N Ab detected in IFA	(62)
Western blot (anti-S & anti-N Ab)	S & N proteins expressed in VRP	Mouse sera	Cross-reactive anti-N Ab against MERS-CoV & other lineage C β CoVs, little cross-reactive anti-S Ab; no cross-reactive anti-N or anti-S Ab between MERS-CoV & SARS-CoV or α CoVs	Strain specific anti-S responses with very low level of cross-reactivity within or across CoV subgroups; cross-reactive anti-N Ab within but not across CoV subgroups	(202)
Protein microarray	Soluble S1 subunit of S protein	Patients with MERS, SARS, and/or other human CoV infections; & sera from cynomolgus macaques & rabbit infected with MERS-CoV	None	Allows 1-stage, high-throughput, testing with minimal sample requirement & can use dried blood spots for testing to facilitate sample transfer	(329)
Neutralization test					
PRNT (anti-MERS-CoV Ab)	Whole virus	1 laboratory-confirmed case & 85 contacts	None	Used as a confirmatory test in a 2-stage protocol	(183)
		130 blood donors & 226 slaughterhouse workers (Jeddah & Makkah, KSA)	8/226 slaughterhouse workers had cross-reactive Ab in IFA but not PRNT	PRNT is more specific than IFA	(98)
PRNT (anti-MERS-CoV Ab)	Whole virus	Patients with MERS, SARS, and/or other human CoV infections; & sera from camels & other animals	None in human samples	Used as a confirmatory test in a 2-stage protocol	(121)
PRNT (anti-S & anti-N Ab)	S & N proteins expressed from VRP	Mouse sera & 1 patient with MERS	Very low levels of cross-neutralization of MERS-CoV by mouse antisera to SARS-CoV using high concentrations of serum	S but not N protein is the major determinant of neutralizing Ab response to MERS-CoV; N proteins of CoVs cross-react within but not between subgroups; S proteins of CoVs have little cross-neutralization or cross-reactivity within subgroup 2c or any other subgroup	(202)

Neutralization of MERS-CoV-S-driven transduction (anti-S Ab)	S proteins expressed by lentiviral vectors	Sear from hospitalized children & male blood donors in KSA	None	Estimated MERS-CoV seroprevalence in the study area was <2.3% in children during 2010 to 2011, & <3.3% in male adults in 2012	(51, 97)
Microneutralization assay (neutralizing anti-MERS-CoV Ab)	Whole virus	Animal handlers, SARS patients, & healthy blood donors in southern China	0/94 (0%), 7/28 (25.0%) of SARS patients, & 0/152 (0%) of healthy blood donors had low-titer cross-reactive neutralizing anti-MERS-CoV Ab	An epitope around HR2 domain of S2 subunit may induce cross-reactive neutralizing Ab against β CoVs	(203)
Microneutralization assay (neutralizing anti-MERS-CoV Ab)	Whole virus	Human sera from general populations in Egypt & Hong Kong; MERS & SARS patients; & animal sera from Egypt	None in human samples	10 times less sensitive than the ppNT assay	(122)
ppNT assay (neutralizing anti-S Ab)	S pseudoparticle expressed by a replication-incompetent HIV virus containing a luciferase reporter gene	Human sera from general populations in Egypt & Hong Kong; MERS & SARS patients; & animal sera from Egypt	None in human samples	10 times more sensitive than the conventional microneutralization assay, does not require BSL-3 containment	(122)

1411 Abbreviations: Ab, antibody; BAL, bronchoalveolar lavage; BSL, Biosafety Level; CPE, cytopathic effects; CVC, central venous
1412 catheter; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; HR2, heptad repeat 2; Ig,
1413 immunoglobulin; IFA, immunofluorescence assay; KSA, Kingdom of Saudi Arabia; LRT, lower respiratory tract; MNT,
1414 microneutralization test; N, nucleocapsid protein; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; ppNT,
1415 pseudoparticle neutralization; PNRT, plaque reduction neutralization test; RT-PRA, reverse transcription isothermal Recombinase
1416 Polymerase Amplification; S, Spike; TAT, turnaround time; TCID₅₀, 50% tissue culture infective dose; URT, upper respiratory tract;
1417 VRP, Venezuelan equine encephalitis virus replicons.

1418 **TABLE 10** Antiviral agents and immunomodulators against MERS-CoV

Antiviral agents and/or immunomodulator(s)	Drug target and/or proposed mechanism	Study setting and methods (virus strain)	Main findings	References
<i>In vitro</i> studies				
Interferons				
IFN-universal type 1	Exogenous IFN	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 113.8 U/ml	(330)
Pegylated IFN- α	Exogenous IFN	Vero (HCoV-EMC/2012)	↓ CPE at ≥ 1 ng/ml	(58)
IFN- $\alpha 2a$	Exogenous IFN	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 160.8 U/ml	(330)
IFN- $\alpha 2b$	Exogenous IFN	Vero (HCoV-EMC/2012)	IC ₅₀ = 58.08 μ g/ml	(209)
		LLC-MK2 (HCoV-EMC/2012)	IC ₅₀ = 13.26 μ g/ml	(209)
IFN- $\alpha 2b$ (Intron A)	Exogenous IFN	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 21.4 U/ml	(330)
		Vero (HCoV-EMC/2012)	IC ₅₀ = 6709.79 IU/ml	(210)
IFN- $\beta 1a$ (Avonex)	Exogenous IFN	Vero (HCoV-EMC/2012)	IC ₅₀ = 5073.33 IU/ml	(210)
IFN- $\beta 1a$ (Rebif)	Exogenous IFN	Vero (HCoV-EMC/2012)	IC ₅₀ = 480.54 IU/ml	(210)
IFN- $\beta 1b$ (Betaferon)	Exogenous IFN	Vero (HCoV-EMC/2012)	IC ₅₀ = 17.64 IU/ml	(210)
		Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 1.37 U/ml	(330)
IFN- γ	Exogenous IFN	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 56.5 U/ml	(330)
Cyclophilin inhibitors				
Cyclosporin A	Inhibitor of cyclophilins & their interactions with Nsp1	Vero (HCoV-EMC/2012)	Complete inhibition of infection at 9 μ M of cyclosporin A	(58)
		Huh-7 (HCoV-EMC/2012)	Partial & complete inhibition of infection at 7.5 μ M & 15 μ M of cyclosporin A respectively	(58)
Viral protease inhibitors				
Lopinavir	3C-like protease inhibitor	Huh-7 (HCoV-EMC/2012)	IC ₅₀ = 8.0 μ M, SI = 3.1; 2 other MERS-CoV strains (MERS-HCoV/KSA/UK/Eng-2/2012 & MERS-HCoV/Qatar/UK/Eng-1/2012) tested were less sensitive; inhibition of a post-entry step	(213)
N3	3C-like protease inhibitor	Not available	IC ₅₀ = 0.28 μ mol/l	(223)
CE-5	3C-like protease inhibitor	HEK293T (HCoV-EMC/2012)	IC ₅₀ = 12.5 μ M	(224)

GRL-001	3C-like protease inhibitor	Vero (Hu/England-N1/2012)	Completely blocked viral replication at early time points (<24 hpi), ↓ viral replication by ~100-fold at 24 hpi, & ↓ virus-induced cytopathology in infected cells	(225)
Helicase inhibitors				
SSYA10-001	Helicase inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 25 μM, SI ≥ 20	(226)
Cellular protease inhibitors				
Camostat mesylate	TMPRSS2 inhibitor	Vero-TMPRSS2 (HCoV-EMC/2012)	↓ cell entry by ~15-fold (10 μM) & inhibited syncytia formation in a dose-dependent manner (1 to 100 μM)	(52)
		Calu-3 (HCoV-EMC/2012)	↓ cell entry by ~10-fold (10 μM), inhibited the multistep growth of the virus by ~90-fold (10 μM) to ~270-fold (100 μM), & delayed virus-induced cell death by 2 (10 μM) to 5 days (100 μM)	(52)
Leupeptin	Protease inhibitor	Calu-3 (HCoV-EMC/2012)	↓ virus entry into cells (10 & 100 μM)	(52)
E-64-D	Broad-spectrum cathepsin inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 1.275 μM	(212)
EST	Cathepsin inhibitor	Vero-TMPRSS2 (HCoV-EMC/2012)	↓ virus entry into cells by ~3-fold (10 μM)	(52)
Cathepsin L inhibitor III	Cathepsin L-specific inhibitor	Vero E6 & LLC-MK2 (HCoV-EMC/2012)	↓ entry of MERS-CoV pseudovirus by 97%	(23)
MDL-28170	Cathepsins B & L inhibitor	MRC5 (HCoV-EMC/2012)	MERS-CoV-S mediated transduction was blocked	(51)
Nucleic acid and/or protein synthesis inhibitors				
Anisomycin	Protein & DNA synthesis inhibitor by inhibiting peptidyl transferase or 80S ribosome system	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 0.003 μM	(212)
Cycloheximide	Protein synthesis inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 0.189 μM	(212)
Dasatinib	Tyrosine kinase inhibitor (ABL1 pathway)	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 5.468 μM	(212)
Emetine dihydrochloride	Protein synthesis inhibitor by binding	Vero E6 (Hu/Jordan-	IC ₅₀ = 0.014 μM	(212)

hydrate	to 40S ribosomal subunit	N3/2012)		
Gemcitabine hydrochloride	Nucleoside analog & DNA synthesis inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 1.216 μM	(212)
Homoharringtonine (omacetaxine mepesuccinate)	Protein synthesis inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 0.0718 μM	(212)
Imatinib mesylate	Tyrosine kinase inhibitor (ABL1 pathway)	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 17.689 μM	(212)
K22	Specifically targets membrane-bound viral RNA synthesis	HAE (HCoV-EMC/2012)	↓ viral replication by >4-log & substantial reduction of dsRNA (50 μM)	(306)
Mycophenolic acid	Inhibitor of IMPDH & depletion of guanosine & deoxyguanosine nucleotide pools	Vero (HCoV-EMC/2012)	IC ₅₀ = 0.17 μg/ml	(210)
		Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 2.87 μM	(330)
Ribavirin	Nucleoside polymerase inhibitor	Vero (HCoV-EMC/2012)	IC ₅₀ = 41.45 μg/ml	(209)
		Vero (HCoV-EMC/2012)	IC ₅₀ = 9.99 μg/ml	(210)
		LLC-MK2 (EMC/2012)	IC ₅₀ = 16.33 μg/ml	(209)
		Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ ≥ 250 μM	(330)
mAb against Spike protein				
Mersmab1	mAb against RBD of S1 subunit of S protein	Huh-7 (HCoV-EMC/2012)	Blocked entry of MERS-CoV-S-mediated pseudovirus into cells with ND ₅₀ < 0.16 μg/ml	(37)
		Vero E6 (HCoV-EMC/2012)	Neutralizing inhibitory activity with ND ₅₀ < 2 μg/ml	(37)
		Calu-3 (HCoV-EMC/2012)	Neutralizing activity with CPE inhibition	(37)
MERS-4 mAb	mAb against RBD of S1 subunit of S protein	Huh-7 (IC ₅₀) & COS7 (syncytia formation) (HCoV-EMC/2012)	Inhibited syncytia formation & neutralizing inhibitory activity with IC ₅₀ = 0.37 nM (pseudovirus) & 3.33nM (live)	(39)
MERS-27 mAb	mAb against RBD of S1 subunit of S protein	Huh-7 (IC ₅₀) & COS7 (syncytia formation) (HCoV-EMC/2012)	Neutralizing inhibitory activity with IC ₅₀ = 63.96 nM (pseudovirus) & 13.33nM (live)	(39)
m336 mAb	mAb against RBD of S1 subunit of S protein	Vero (live virus) & DPP4-expressing Huh-7 (pseudovirus) (HCoV-EMC/2012)	Neutralizing inhibitory activity with IC ₅₀ < 0.01 μg/ml (live) & 0.07 μg/ml (pseudovirus); inhibited RBD-DPP4 binding (IC ₅₀ = 0.034 μg/ml)	(38)

m337 mAb	mAb against RBD of S1 subunit of S protein	Vero (live virus) & DPP4-expressing Huh-7 (pseudovirus) (HCoV-EMC/2012)	Neutralizing inhibitory activity with $IC_{50} < 0.01 \mu\text{g/ml}$ (pseudovirus) & $< 10 \mu\text{g/ml}$ (live); inhibited RBD-DPP4 binding ($IC_{50} = 0.044 \mu\text{g/ml}$)	(38)
m337 mAb	mAb against RBD of S1 subunit of S protein	Vero (live virus) & DPP4-expressing Huh-7 (pseudovirus) (HCoV-EMC/2012)	Neutralizing inhibitory activity with $IC_{50} < 0.1 \mu\text{g/ml}$ (pseudovirus) & $< 1 \mu\text{g/ml}$ (live); inhibited RBD-DPP4 binding ($IC_{50} = 0.041 \mu\text{g/ml}$)	(38)
1E9 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 3.21 \mu\text{g/ml}$)	(40)
1F8 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 6.27 \mu\text{g/ml}$)	(40)
3A1 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 1.46 \mu\text{g/ml}$)	(40)
3B12 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 1.25 \mu\text{g/ml}$)	(40)
3C12 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 2.00 \mu\text{g/ml}$)	(40)
3B11 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 1.83 \mu\text{g/ml}$)	(40)
M14D3 scFvFc	Single-chain variable domain fragment against RBD of S1 subunit of S protein fused with hFc	Vero (live virus) & hDPP4-expressing 293T (pseudovirus) cells (HCoV-EMC/2012)	Neutralizing inhibitory activity ($IC_{50} = 4.30 \mu\text{g/ml}$)	(40)
mAb against DPP4				
Clone 2F9 mAb	mAb against DPP4	Huh-7 (?strain)	Near complete inhibition of NSP4 expression in infected cells	(50)
Clone YS110 mAb	mAb against DPP4	Huh-7 (?strain)	Partial inhibition of NSP4	(50)

			expression in infected cells	
Inhibitors of clathrin-mediated endocytosis				
Astemizole	Antihistamine & anticholinergic; inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 4.884 μM	(212, 214)
Clomipramine hydrochloride	Tricyclic antidepressant; inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 9.332 μM	(212, 214)
Chlorpromazine	Antipsychotic (phenothiazine); inhibitor of clathrin-mediated endocytosis	Huh-7 (HCoV-EMC/2012)	IC ₅₀ = 4.9 μM, SI = 4.3. Inhibition of an early step with or without another post-entry step in the replicative cycle.	(213, 214)
		Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 9.514 μM.	(212, 214)
Fluphenazine hydrochloride	Antipsychotic (piperazine); inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 5.868 μM	(212, 214)
Promethazine hydrochloride	Antihistamine & antipsychotic (phenothiazine); inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 11.802 μM	(212, 214)
Tamoxifen citrate	Estrogen receptor inhibitor; inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 10.117 μM	(212, 214)
Thiothixene	Antipsychotic (thioxanthene); inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 9.297 μM	(212, 214)
Triflupromazine hydrochloride	Antipsychotic (phenothiazine); inhibitor of clathrin-mediated endocytosis	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 5.758 μM	(212, 214)
Other cell entry inhibitors				
HR2P peptide	HR2-based fusion inhibitor; inhibitor of clathrin-mediated endocytosis	Vero (HCoV-EMC/2012)	IC ₅₀ = 0.6 μM	(44, 214)
		Calu-3 (HCoV-EMC/2012)	IC ₅₀ = 0.6 μM	(44)
		HFL (HCoV-EMC/2012)	IC ₅₀ = 13.9 μM	(44)
P1 peptide	HR2-based fusion inhibitor	Huh-7 (HCoV-EMC/2012)	Inhibited MERS-CoV pseudovirus with IC ₅₀ = 3.013 μM.	(45)
dec-RVKR-CMK	Furin inhibitor	Huh-7, MRC-5, WI-38, Vero, & NHBE cells (HCoV-EMC/2012)	Dose-dependent & significant ↓ virus infection in various cell types.	(54)
S377-588-Fc protein	Recombinant truncated RBD of S protein fused with human IgG Fc fragment	Calu-3 (HCoV-EMC/2012)	Complete CPE inhibition (25 μg/ml)	(42)

HP-HSA	3-hydroxyphthalic anhydride-modified human serum albumin targeting HIV-1 gp120 and/or CD4 receptor	Huh-7 & NBL-7 (MERS-CoV pseudovirus expressing full-length S protein of HCoV-EMC/2012)	Around 90% of pseudovirus entry inhibition (20 μ M); minimal cytotoxicity in Huh-7 cells at up to 100 μ M	(41)
ADS-J1	Small molecule entry inhibitor targeting HIV gp41	Huh-7 & NBL-7 (MERS-CoV pseudovirus expressing full-length S protein of HCoV-EMC/2012)	CC50 = 26.9 μ M, IC50 = 0.6 μ M, & SI = 45	(41)
C34	Peptidic HIV entry inhibitor	Huh-7 & NBL-7 (MERS-CoV pseudovirus expressing full-length S protein of HCoV-EMC/2012)	Around 50% of pseudovirus inhibition at 20 μ M in NBL cells but no activity in Huh-7 cells.	(41)
T20	Peptidic HIV entry inhibitor	Huh-7 & NBL-7 (MERS-CoV pseudovirus expressing full-length S protein of HCoV-EMC/2012)	Around 50% of pseudovirus inhibition at 20 μ M in NBL cells but no activity in Huh-7 cells.	(41)
Adenosine deaminase	Natural DPP4 ligand	Huh-7 (HCoV-EMC/2012)	Dose-dependent inhibition of MERS-CoV infection	(49)
		Human DPP4 plasmid-transfected MDCK (HCoV-EMC/2012)	Blocks S1 binding & MERS-CoV infection despite expression of DPP4	(49)
Miscellaneous				
Amodiaquine dihydrochloride dihydrate	Histamine N-methyltransferase inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 6.212 μ M	(212)
Benzotropine mesylate	Anticholinergic	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 16.627 μ M	(212)
Chloroquine	Anti-parasitic	Huh-7 (HCoV-EMC/2012)	IC ₅₀ = 3.0 μ M, SI = 19.4. Inhibition of an early step in the replicative cycle.	(213)
		Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 6.275 μ M.	(212)
Chlorphenoxamine hydrochloride	Antihistamine & anticholinergic	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 12.646 μ M	(212)
Dabrafenib	Raf inhibitor	Huh-7 (HCoV-EMC/2012)	45% inhibition (10 μ M)	(215)
ESI-09	Epac-specific inhibitor	Calu-3 (HCoV-EMC/2012)	Dose-dependent CPE inhibition (1 to 10 μ M) & viral yield reduction (2.5 to 40 μ M); treatment before infection unnecessary; extended therapeutic window (\geq 20 hours); inhibitory effects starts at 6 hpi;	(331)

			CC ₅₀ >50 µM; changed DPP4 expression pattern on the membrane of Calu-3 cells	
		Vero E6 (HCoV-EMC/2012)	Dose-dependent CPE inhibition & viral yield reduction	(331)
Everolimus	mTOR inhibitor	Huh-7 (HCoV-EMC/2012)	56% to 59% inhibition (10 µM)	(215)
Fluspirilene	Antipsychotic (diphenylbutylpiperidine)	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 7.477 µM	(212)
Hydroxychloroquine sulfate	Anti-parasitic	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 8.279 µM.	(212)
Loperamide	µ-opioid receptor agonist	Huh-7 (HCoV-EMC/2012)	IC ₅₀ = 4.8 µM; SI = 3.2; inhibition of an early step in the replication cycle	(213)
Mefloquine	Inhibition of heme polymerase; serotonin agonist	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 7.416 µM	(212)
Miltefosine	AKT inhibitor	Huh-7 (HCoV-EMC/2012)	28% inhibition (10 µM)	(215)
SB203580	Kinase inhibitor	Vero E6 (HCoV-EMC/2012)	Pretreatment of infected cells with SB203580 decreased 15% & 7% of the log ₁₀ viral titer at 24 hpi & 48 hpi respectively	(177)
Selumetinib	ERK/MAPK signaling inhibitor	Huh-7 (HCoV-EMC/2012)	>95% inhibition (10 µM)	(215)
Sorafenib	Raf inhibitor	Huh-7 (HCoV-EMC/2012)	93% inhibition (10 µM)	(215)
Terconazole	Sterol metabolism inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 12.203 µM	(212)
Thiethylperazine maleate	Antiemetic (phenothiazine)	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 7.865 µM	(212)
Toremifene citrate	Estrogen receptor inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 12.915 µM	(212)
Trametinib	ERK/MAPK signaling inhibitor	Huh-7 (HCoV-EMC/2012)	>95% inhibition (0.1 µM)	(215)
Triparanol	Sterol metabolism inhibitor	Vero E6 (Hu/Jordan-N3/2012)	IC ₅₀ = 5.283 µM	(212)
Combinational treatment				
Ribavirin / IFN-α2b (1:5)	Nucleoside polymerase inhibitor / exogenous IFN	Vero (HCoV-EMC/2012)	Additional ↓ viral titer by 0.40 to 2.16-logs with ribavirin	(209)
Mycophenolic acid / IFN-β1b	IMPDH inhibitor / exogenous IFN	Vero (HCoV-EMC/2012)	IC ₅₀ of mycophenolic acid = 1.7-2.8 times lower with 6.25-12.5 IU/ml of IFN-β1b; IC ₅₀ of IFN-β1b 1.1-1.8 times lower with 0.016-0.063 µg/ml of mycophenolic acid	(210)
MERS-4 & MERS-27	mAbs against RBD of S1 subunit of S	Huh-7 (HCoV-EMC/2012)	Synergistic neutralizing effect	(39)

mAbs	protein		against pseudovirus	
Animal experiments				
Ribavirin / IFN- α 2b	Nucleoside polymerase inhibitor / exogenous IFN	Rhesus macaques (HCoV-EMC/2012)	Compared to untreated, infected macaques, treated macaques had no breathing abnormalities, minimal radiological evidence of pneumonia, lower levels of serum & pulmonary proinflammatory markers, few viral genome copies, lower expression of inflammatory genes, & less severe histopathological changes in lungs	(175)
		Regimen: loading dose of 30mg/kg of ribavirin i.v. & 5 MIU/kg of IFN- α 2b s.c.; followed by 10mg/kg q8h of ribavirin i.m. & 5MIU/kg of IFN- α 2b s.c. q16h until 72 hpi		
Poly I:C	TLR3 agonist	Ad5-hDPP4-transduced mice (HCoV-EMC/2012)	Accelerated virus clearance from lungs of infected mice	(174)
Human trials				
Ribavirin / IFN- α 2b / corticosteroid	Nucleoside polymerase inhibitor / exogenous interferon / corticosteroid	5 critically ill MERS patients	Mean age = 57.6 (24-81) years; 3 males & 2 females; admitted 4 (2-10) days after symptom onset; all had co-morbidities; time between admission & antiviral treatment = 16.8 (11-21) days & corticosteroid 15.8 (6-22) days; side effects = hemolytic anemia, thrombocytopenia, pancreatitis, \uparrow lipase, & deranged liver & renal function tests; all died after a mean of 39.6 (32-52) days after admission	(332)
		Regimen: oral ribavirin, s.c. IFN- α 2b, & i.v. and/or oral corticosteroid (methylprednisolone and/or prednisolone)		
Ribavirin / IFN- α 2b \pm corticosteroid	Nucleoside polymerase inhibitor / exogenous IFN \pm corticosteroid	2 epidemiologically-linked MERS patients	Both the index case (treatment) & contact (prophylaxis) had clinical & radiological improvement after receiving ribavirin & IFN- α 2b	(211)
		Regimen: oral ribavirin & s.c. IFN- α 2b for 2 weeks (& i.v. methylprednisolone 500mg q24h for 3 days for index case)		
Ribavirin / IFN- α 2a	Nucleoside polymerase inhibitor / exogenous IFN \pm corticosteroid	20 severe MERS patients	Compared to the comparator group (28 severe MERS patients who received supportive care only), the treatment group had significantly	(207)
		Regimen: oral ribavirin for 8-10 days & pegylated IFN-		

		α 2a 180 μ g/week for 2 weeks; 11/19 (58%) patients received corticosteroid	improved survival at 14 days but not 28 days after the diagnosis of MERS; significantly greater reduction in hemoglobin level was noted in the treatment group	
Ribavirin / lopinavir / IFN- α 2a	Nucleoside polymerase inhibitor / protease inhibitor / exogenous IFN	1 severe MERS patient Regimen: oral ribavirin 1200mg q8h & lopinavir/ritonavir (400/100mg) q12h for 8 days, & pegylated IFN- α 2a 180 μ g/week for 2 weeks	Viremia resolved 2 days after initiation of antiviral treatment (started on day 13 of illness); persistent virus shedding in respiratory tract secretions until 4 th week of illness	(184)

1419 Abbreviations: ABL1, Abelson murine leukemia viral oncogene homolog 1; Ad5-hDPP4, adenovirus expressing human host-cell
1420 receptor dipeptidyl peptidase 4; AKT, protein kinase B; CC₅₀, 50% inhibition of cell survival; DPP4, dipeptidyl peptidase 4; Epac,
1421 exchange proteins directly activated by cAMP; ERK/MAPK, extracellular signal-regulated kinases/mitogen-activated protein kinases;
1422 HAE, primary human airway epithelia; hFc, constant region fragment of human IgG; hpi, hours post infection; HR, heptad repeat;
1423 IC₅₀, 50% maximal inhibitory concentration; IFN, interferon; IMPDH, inosine-5'-monophosphate dehydrogenase; i.v., intravenous;
1424 mAb, monoclonal antibody; MIU, mega international units; mTOR, mammalian target of rapamycin; ND₅₀, 50% neutralization dose;
1425 Nsp1, non-structural protein 1; RBD, receptor-binding domain; S, spike; s.c., subcutaneous; SI, selectivity index; TLR3, Toll-like
1426 receptor 3; TMPRSS2, type II transmembrane serine protease.

1427 **TABLE 11** Active and passive immunization against MERS

Vaccine	Components (virus strain)	Animal model (administration)	Main findings (animal model)	References
Active immunization				
MVA-MERS-S	Recombinant modified vaccinia virus Ankara expressing full-length MERS-CoV S protein (HCoV-EMC/2012)	BALB/c mice (2 i.m. immunizations at days 0 & 21)	High levels of nAb were induced	(248)
VRP-S	Venezuelan Equine Encephalitis Replicon Particles containing S protein of MERS-CoV (HCoV-EMC/2012)	Ad5-hDPP4-transduced BALB/c mice (2 immunizations in the footpads at days 0 & 28)	Reduction of viral titers to nearly undetectable levels by 1 dpi	(174)
Spike protein nanoparticles	Purified S protein nanoparticles produced in Sf9 cells infected with specific recombinant baculovirus cloned with MERS-CoV S protein gene sequence (Al-Hasa_1_2013)	BALB/c mice, 6 to 8 weeks old (2 i.m. immunizations on days 0 & 21)	Inducted nAb in mice receiving MERS-CoV S inoculation with adjuvants Matrix M1 or Alum, but not in those receiving MERS-CoV S inoculation alone (Matrix M1 > Alum > no adjuvant); nAb levels were not significantly different between regimens consisting of 1 µg & 3 µg, & between sera obtained on days 21 & 45	(249)
S-RBD-Fc	Recombinant protein containing RBD (residues 377 to 662) of S1 (HCoV-EMC/2012)	Mice (2 s.c. immunizations on days 0 & 14)	Sera of vaccinated mice showed neutralizing activity (>96%) against MERS-CoV pseudo- (Huh-7 cells) & live (Vero E6 cells) virus infection	(41)
358-to-588 S1-Fc	RBD (residues 358 to 588) of S1 fused with human IgG Fc fragment (HCoV-EMC/2012)	Vero cells (inoculation of sera containing polyclonal Ab raised in immunized rabbits)	Polyclonal antibodies against 358-to-588 S1-Fc variant efficiently neutralized virus infectivity	(34)
S377-588-Fc	Truncated 212-aa fragment of RBD (residues 377 to 588) of S1 fused with human IgG Fc fragment (HCoV-EMC/2012)	BALB/c mice, 6 to 8 weeks old (3 s.c. immunizations)	↑ neutralizing IgG1 (Th2) & IgG2a (Th1) Ab responses specific for the RBD in the S1 subunit were induced after each immunization with Montanide ISA 51 adjuvant	(31, 42)
		BALB/c mice, 4 to 6 weeks old (5 s.c. or i.n. immunizations at days 0, 21, 42, 3 months & 6 months)	i.n. vaccination with Poly(I:C) adjuvant induced similar degree of systemic humoral immune responses, including nAb, & more robust systemic cellular & local (lung) mucosal immune responses as comparable to those induced by s.c. vaccination with Montanide ISA 51 adjuvant	(43)

		BALB/c mice, 6 to 8 weeks old (3 s.c. immunizations); & rabbits (3 immunizations)	Among 5 versions of RBD fragments, the S377-588-Fc showed the highest DPP4-binding affinity, & induced the highest-titer IgG Ab in mice & neutralizing Ab in rabbits	(36)
rRBD (combined with different adjuvants)	Recombinant RBD protein containing a 240-aa fragment of RBD (residues 367-606) of S1(HCoV-EMC/2012) combined with different adjuvants [Alum alone, Alum plus CpG-ODNs, Alum plus Poly(I:C), or CpG-ODNs plus IFA]	BALB/c mice, 6 to 8 weeks old (3 i.m. or s.c. immunizations at days 0, 21 & 42)	The combination of rRBD and Alum plus CpG-ODNs given by the i.m. route provided the most robust RBD-specific humoral and cellular immunity.	(251)
Passive immunization				
Adoptive transfer of sera	Sera containing anti-MERS-CoV-S Ab (HCoV-EMC/2012)	Ad5-hDPP4-transduced BALB/c mice (sera obtained 2-4 weeks after immunization with VRP-S, & transferred into mice i.p. 1 day before infection)	Adoptive transfer of sera containing anti-MERS-CoV-S Ab blocked virus attachment & accelerated virus clearance to nearly undetectable levels by 5 dpi	(174)

1428 Abbreviations: aa, amino acid; Ab, antibody; Ad5-hDPP4, adenoviral vectors expressing human dipeptidyl peptidase 4; Alum,

1429 aluminium hydroxide; CpG-ODNs, cysteine-phosphate-guanine oligodeoxynucleotides; dpi, days post infection; IFA, incomplete

1430 Freund's adjuvant; i.m., intramuscular; i.n., intranasal; i.p., intraperitoneal; nAb, neutralizing antibody; Poly(I:C), polyriboinosinic

1431 acid; RBD, receptor-binding domain; S, Spike; s.c., subcutaneous.

1432

1433 **TABLE 12** Animals tested for susceptibility to MERS-CoV in experimental and natural infection

Animal species & age	Dose and route of inoculation (virus strain)	Point of evaluation (days)	Clinical, virological, & immunological findings	Histopathological & IHC results	References
Susceptible					
Rhesus macaques (<i>Macaca mulatta</i>); 6-10 years	7×10^6 TCID ₅₀ i.t., i.n., oral & ocular (HCoV-EMC/2012)	Up to 6	Clinical: mild to moderate symptoms including nasal swelling, piloerection, ↓ bowel opening, ↑ or ↓ respiratory rate, ↓ food intake, & hunched posture on 1-6 dpi; leukocytosis with neutrophilia & lymphopenia on 1 dpi Virological: viral RNA detected in upper & lower respiratory tract specimens, conjunctiva, & lymphoid tissues (mediastinal & tonsils) from 1 dpi, & in 1 macaque's urogenital swab on 1 dpi Immunological: significant up-regulation of genes associated with proinflammatory process (IL-6, CXCL1, MMP9); rapid resolution of controlled interferon-mediated innate immune response	Macroscopic: multifocal to coalescent, mild to marked interstitial pneumonia Microscopic: thickening of alveolar septae by edema fluid & fibrin with predominantly macrophages; BOOP-like changes with multinucleate syncytia formed by alveolar macrophages, fibrin aggregates, & occluded small airways by sloughed pulmonary epithelium, & perivascular infiltrates of inflammatory cells; type II pneumocyte hyperplasia; hyaline membrane formation IHC: viral Ag detected in types I & II pneumocytes, & macrophages/monocytes or dendritic cells	(165, 166)
Rhesus macaques (<i>Macaca mulatta</i>); 2-3 years	6.5×10^7 TCID ₅₀ i.t. (HCoV-EMC/2012)	Up to 28	Clinical: fever & reduced water intake on 1-2 dpi; CXR showed varying degrees of localized infiltration & interstitial markings on 3-5 dpi Virological: viral RNA detected in lungs on 3 dpi Immunological: neutralizing Ab detected at 7 dpi, & peaked at 14 dpi	Macroscopic: congestion & palpable nodules scattered in distribution Microscopic: multifocal mild-to-moderate interstitial pneumonia & exudative changes in lungs IHC: viral Ag detected in types I & II pneumocytes, & alveolar macrophages	(167)
Common marmosets (<i>Callithrix jacchus</i>); 2-6 years	5.2×10^6 TCID ₅₀ i.t., i.n., oral & ocular (HCoV-EMC/2012)	Up to 55	Clinical: moderate to severe symptoms including ↑ respiratory rate, open mouth and/or labored breathing, frothy hemorrhagic discharge from mouth, ↓ food intake, & ↓ activity level since 1-3 dpi & peaked o 4-6 dpi. Clinical scores returned to baseline by 13 dpi; 2/9 animals	Macroscopic: multifocal, extensive, severe lesions especially in lower lobes; lungs were firm, failed to collapse, & fluid filled Microscopic: multifocal to coalescing, moderate to marked acute bronchointerstitial pneumonia centered on terminal bronchioles, with influx of	(168)

			<p>were euthanized because of severe disease; CXR showed varying degrees of interstitial infiltration on 3-4 dpi</p> <p>Virological: viral RNA detected in upper (since 1 dpi) & lower respiratory tract specimens, blood, & multiple organs (conjunctiva, lymph nodes, tonsils, kidneys, heart, adrenal glands, liver, spleen, pancreas, colon, ileum, frontal lobe, cerebellum, brain stem, urinary bladder, & testes) since 3 dpi</p> <p>Immunological: tissue differentiation with development of pulmonary fibrosis as evidenced by activation of pathways associated with chemotaxis & cell migration, cell cycle progression, cell proliferation, fibrogenesis, inflammation, vascularization, endothelial activation, smooth muscle cell proliferation, & tissue repair; upregulation of innate & adaptive immune genes; induction of type I IFNs, IL-2, IL-4, & IL-6; inhibition of type II IFNs, IL-1 & TNFα</p>	<p>neutrophils & macrophages; thickening of alveolar septa; edema, hemorrhage & fibrin filled the alveolar spaces (3-4 dpi); type II pneumocyte hyperplasia & formation of hyaline membrane (6 dpi)</p> <p>IHC: viral Ag detected in affected areas, especially in type I pneumocytes & alveolar macrophages</p>	
<p>C57BL/6 & BALB/c mice with Ad5-hDPP4 transduction; 6-12 weeks (young) & 18-22 months (aged)</p>	<p>1 \times 10⁵ PFU i.n. (HCoV-EMC/2012)</p>	<p>Up to 14</p>	<p>Clinical: young BALB/C mice failed to gain weight, aged C57BL/6 & BALB/c mice lost weight</p> <p>Virological: clearance of virus by 6-8 dpi in young mice & 10-14 in aged mice</p> <p>Immunological: requirement of type I IFN induction & signaling, CD8 T cells & Ab for virus clearance; low level of cross-reactivity between MERS-CoV & SARS-CoV</p>	<p>Macroscopic: vascular congestion & inflammation</p> <p>Microscopic: perivascular & peribronchial lymphoid infiltration initially, with progression to an interstitial pneumonia</p> <p>IHC: viral Ag detected in lungs</p>	<p>(175)</p>
<p>Dromedary camels (<i>Camelus dromedarius</i>); 2-5 years (adults)</p>	<p>10⁷ TCID₅₀ i.t., i.n. & ocular (HCoV-EMC/2012)</p>		<p>Clinical: mild upper respiratory tract symptoms including rhinorrhea & mild \uparrow temperature</p> <p>Virological: infectious virus detected in nasal (up to 7 dpi & 10⁸ PFU/ml) & oral (up to 5 dpi & 10² PFU/ml) swabs; viral RNA detected in nasal (up to 35 dpi &</p>	<p>Macroscopic: lesions found in the upper respiratory tract, trachea, bronchi & bronchioles, but not in the alveoli (up to 28 dpi)</p> <p>Microscopic: mild to moderate acute intraepithelial & submucosal inflammation with multifocal necrosis, loss of</p>	<p>(259)</p>

			10 ⁶ TCID ₅₀ equivalent/ml) & oral (up to 35 dpi & 10 ⁴ TCID ₅₀ equivalent/ml) swabs Immunological: neutralizing Ab detected at 14 dpi, & peaked at 35 dpi	pseudostratified epithelial cells & infiltration of small numbers of neutrophils & macrophages (up to 28 dpi) IHC: viral Ag detected in affected areas (up to 28 dpi)	
Goats	N/A	N/A	Clinical: asymptomatic to mildly symptomatic Immunological: seroconversion in all 14 goats by 14 dpi	N/A	(258)
Jamaican fruit bats	N/A	N/A	Clinical: no clinical signs or elevation in temperature Virological: virus shedding from respiratory & intestinal tract for up to 9 dpi	N/A	(257)
Non-susceptible					
Syrian hamster (<i>Mesocricetus auratus</i>)	4 × 10 ² TCID ₅₀ aerosols, 10 ³ TCID ₅₀ i.t., or 10 ⁶ TCID ₅₀ i.t. (HCoV-EMC/2012)	Up to 21	Clinical: no significant weight loss or fever Virological: no viral RNA detected in nasal, oropharyngeal, urogenital & rectal swabs from 1-11 dpi; & lungs, spleen & mandibular lymph nodes on 2, 4, & 8 dpi Immunological: no seroconversion	Macroscopic: no gross lesions Microscopic: no lesions in trachea, heart, lung, spleen, liver, kidney, ileum, colon, urinary bladder, nasal turbinates, & brain tissues	(333)
BALB/c, 129/SvEv, & 129/SvEv STAT1 knockout mice; 8 weeks	120 or 1200 TCID ₅₀ i.n. (HCoV-EMC/2012)	Up to 9	Clinical: no significant weight loss Virological: no detectable virus in lungs	Microscopic: no sign of viral infection (apoptotic cells & syncytia formation); 129S6/SvEv & 129/SvEv STAT1 knockout mice had only minor signs of pathological lesions or inflammatory response, with a few lesions of focal interstitial pneumonitis composed of neutrophils & macrophages; BALB/c mice had perivascular cuffing with scattered neutrophils & foci of pneumonia around proximal airways	(334)
Ferret (<i>Mustela putorius furo</i>)	1 × 10 ⁶ TCID ₅₀ i.n. & i.t. (HCoV-EMC/2012)	Up to 14	Virological: no infectious virus was detected in nose & throat swabs Immunological: no seroconversion	In vitro: ferret primary kidney cells did not bind recombinant S protein S1 & could not be infected with MERS-CoV, despite DPP4 surface expression	(49)

1434 Abbreviations: Ab, antibody; Ad5-hDPP4, adenoviral vectors expressing human dipeptidyl peptidase 4; Ag, antigen; BOOP,

- 1435 bronchiolitis obliterans organizing pneumonia; CXCL1, chemokine C-X-C ligand 1; dpi, days post inoculation; IFN, interferon; IHC,
1436 immunohistochemistry; IL, interleukin; i.n., intranasal; i.t., intratracheal; MMP9, matrix metalloproteinase 9; N/A, not available; PFU,
1437 plaque-forming unit; S, spike; TCID50, 50% tissue culture infectious dose.

1438 **FIGURE LEGENDS**

1439

1440 **FIG. 1A.** Taxonomy of *Coronaviridae* according to the International Committee on Taxonomy
1441 of Viruses.

1442

1443 **FIG. 1B.** Phylogenetic tree of 50 coronaviruses with partial nucleotide sequences of RNA-
1444 dependent RNA polymerase. The tree was constructed by the neighbor-joining method using
1445 MEGA 5.0. The scale bar indicates the estimated number of substitutions per 20 nucleotides.

1446 Abbreviations (accession number): AntelopeCoV, sable antelope coronavirus (EF424621);

1447 BCoV, bovine coronavirus (NC_003045); BdCoV HKU22, bottlenose dolphin coronavirus

1448 HKU22 (KF793826); BuCoV HKU11, bulbul coronavirus HKU11 (FJ376619); BWCov-SW1,

1449 beluga whale coronavirus SW1 (NC_010646); CMCov HKU21, common moorhen coronavirus

1450 HKU21 (NC_016996); DcCoV HKU23, dromedary camel coronavirus HKU23 (KF906251);

1451 ECoV, equine coronavirus (NC_010327); ErinaceousCoV, Betacoronavirus

1452 *Erinaceus*/VMC/DEU/2012 (NC_022643); FIPV, feline infectious peritonitis virus (AY994055);

1453 HCoV-229E, human coronavirus 229E (NC_002645); HCoV-HKU1, human coronavirus HKU1

1454 (NC_006577); HCoV-NL63, human coronavirus NL63 (NC_005831); HCoV-OC43, human

1455 coronavirus OC43 (NC_005147); Hi-BatCoV HKU10, *Hipposideros* bat coronavirus HKU10

1456 (JQ989269); IBV-partridge, partridge coronavirus (AY646283); IBV-peafowl, peafowl

1457 coronavirus (AY641576); MERS-CoV, Middle East respiratory syndrome coronavirus

1458 (NC_019843.3); MERS-CoV KSA-CAMEL-363, Middle East respiratory syndrome coronavirus

1459 isolate KSA-CAMEL-363 (KJ713298); MHV, murine hepatitis virus (NC_001846); Mi-BatCoV

1460 1A, *Miniopterus* bat coronavirus 1A (NC_010437); Mi-BatCoV 1B, *Miniopterus* bat coronavirus

1461 1B (NC_010436); Mi-BatCoV HKU7, *Miniopterus* bat coronavirus HKU7 (DQ249226); Mi-
 1462 BatCoV HKU8, *Miniopterus* bat coronavirus HKU8 (NC_010438); MRCoV HKU18, magpie
 1463 robin coronavirus HKU18(NC_016993); MunCoV HKU13, munia coronavirus HKU13
 1464 (FJ376622); My-BatCoV HKU6, *Myotis* bat coronavirus HKU6 (DQ249224); NeoCoV,
 1465 coronavirus *Neoromicia*/PML-PHE1/RSA/2011 (KC869678); NHCov HKU19, night heron
 1466 coronavirus HKU19 (NC_016994); PEDV, porcine epidemic diarrhoea virus (NC_003436);
 1467 PHEV, porcine haemagglutinating encephalomyelitis virus (NC_007732); Pi-BatCoV-HKU5,
 1468 *Pipistrellus* bat coronavirus HKU5 (NC_009020); PorCoV HKU15, porcine coronavirus HKU15
 1469 (NC_016990); PRCV, porcine respiratory coronavirus (DQ811787); RbCoV HKU14, rabbit
 1470 coronavirus HKU14 (NC_017083); RCoV parker, rat coronavirus parker (NC_012936); Rh-
 1471 BatCoV HKU2, *Rhinolophus* bat coronavirus HKU2 (EF203064); Ro-BatCoV-HKU9, *Rousettus*
 1472 bat coronavirus HKU9 (NC_009021); Ro-BatCoV HKU10, *Rousettus* bat coronavirus HKU10
 1473 (JQ989270); SARS-CoV, SARS coronavirus (NC_004718); SARSr-CiCoV, SARS-related palm
 1474 civet coronavirus (AY304488); SARSr-Rh-BatCoV HKU3, SARS-related *Rhinolophus* bat
 1475 coronavirus HKU3 (DQ022305); Sc-BatCoV 512, *Scotophilus* bat coronavirus 512
 1476 (NC_009657); SpCoV HKU17, sparrow coronavirus HKU17 (NC_016992); TCoV, turkey
 1477 coronavirus (NC_010800); TGEV, transmissible gastroenteritis virus (NC_002306); ThCoV
 1478 HKU12, thrush coronavirus HKU12 (FJ376621); Ty-BatCoV-HKU4, *Tytonycteris* bat
 1479 coronavirus HKU4 (NC_009019); WECov HKU16, white-eye coronavirus HKU16
 1480 (NC_016991); WiCoV HKU20, wigeon coronavirus HKU20 (NC_016995).

1481

1482 **FIG. 2.** Genome arrangement of MERS-CoV with emphasis on the clinical applications of the
 1483 key non-structural and structural genes. * denotes furin cleavage sites. Abbreviations: 3CLpro,

1484 3C-like protease; AP, accessory protein; CP, cytoplasmic domain; E, envelope; FP, fusion
1485 peptide; Hel, helicase; HR, heptad repeat; IFN, interferon; M, membrane; mAb, monoclonal
1486 antibody; N, nucleocapsid; nsp, non-structural protein; ORF, open reading frame; pp,
1487 polyprotein; PLpro, papain-like protease; RBD, receptor binding domain; RdRp, polymerase;
1488 RT-RPA; reverse transcription isothermal Recombinase Polymerase Amplification; S, spike; SP,
1489 signal peptide; TM, transmembrane domain.

1490

1491 **FIG. 3.** Candidate antiviral agents for MERS-CoV in relation to the viral replication cycle. (+)
1492 and (-) denotes positive- and negative-strand RNA respectively. Abbreviations: AKT, protein
1493 kinase B; Cyps, cyclophilins; DPP4, dipeptidyl peptidase-4; E, envelope; ER, endoplasmic
1494 reticulum; ERGIC, endoplasmic reticulum Golgi intermediate compartment; ERK, extracellular
1495 signal-regulated kinases; HR2P, heptad repeat 2 peptide; IFN, interferon; M, membrane; mAb,
1496 monoclonal antibody; MAPK, mitogen-activated protein kinases; MPA, mycophenolic acid;
1497 mRNA, messenger RNA; mTOR, mammalian target of rapamycin; N, nucleocapsid; NFAT,
1498 nuclear factor of activated T-cells; nsp, non-structural protein; ORF, open reading frame; PI3K,
1499 phosphatidylinositide 3-kinases; S, spike; TMPRSS2, transmembrane protease serine protease-2.

1500

1501 **FIG. 4.** Phylogenetic tree of representative human and camel strains of MERS-CoV rooted by
1502 NeoCoV (KC869678.4) according to reference (111).

1503 **REFERENCES**

- 1504 1. **Chan JF, To KK, Tse H, Jin DY, Yuen KY.** 2013. Interspecies transmission and
 1505 emergence of novel viruses: lessons from bats and birds. *Trends Microbiol.* **21**:544-555.
- 1506 2. **Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW,**
 1507 **Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY.** 2003.
 1508 Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* **361**:1319-
 1509 1325.
- 1510 3. **Cheng VC, Lau SK, Woo PC, Yuen KY.** 2007. Severe acute respiratory syndrome
 1511 coronavirus as an agent of emerging and reemerging infection. *Clin. Microbiol. Rev.*
 1512 **20**:660-694.
- 1513 4. **To KK, Chan JF, Chen H, Li L, Yuen KY.** 2013. The emergence of influenza A H7N9
 1514 in human beings 16 years after influenza A H5N1: a tale of two cities. *Lancet Infect. Dis.*
 1515 **13**:809-821.
- 1516 5. **Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, Cheung PT, To**
 1517 **WK, Ho ET, Sung R, Cheng AF.** 1998. Clinical features and rapid viral diagnosis of
 1518 human disease associated with avian influenza A H5N1 virus. *Lancet* **351**:467-471.
- 1519 6. **MacNeil A, Rollin PE.** 2012. Ebola and Marburg hemorrhagic fevers: neglected tropical
 1520 diseases? *PLoS Negl. Trop. Dis.* **6**:e1546.
- 1521 7. **Marsh GA, Wang LF.** 2012. Hendra and Nipah viruses: why are they so deadly? *Curr.*
 1522 *Opin. Virol.* **2**:242-247.
- 1523 8. **To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, Yuen KY.** 2012.
 1524 Avian influenza A H5N1 virus: a continuous threat to humans. *Emerging Microbes &*
 1525 *Infections* **1**, e25.
- 1526 9. **Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA.** 2012.
 1527 Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N. Engl. J.*
 1528 *Med.* **367**:1814-1820.
- 1529 10. **Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY.** 2012. Is the discovery of the
 1530 novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another
 1531 SARS-like pandemic? *J. Infect.* **65**:477-489.
- 1532 11. **Chan JF, Lau SK, Woo PC.** 2013. The emerging novel Middle East respiratory
 1533 syndrome coronavirus: the "knowns" and "unknowns". *J. Formos Med. Assoc.* **112**:372-
 1534 381.
- 1535 12. **Woo PC, Lau SK, Yuen KY.** 2006. Infectious diseases emerging from Chinese wet-
 1536 markets: zoonotic origins of severe respiratory viral infections. *Curr. Opin. Infect. Dis.*
 1537 **19**:401-407.
- 1538 13. **Woo PC, Wang M, Lau SK, Xu H, Poon RW, Guo R, Wong BH, Gao K, Tsoi HW,**
 1539 **Huang Y, Li KS, Lam CS, Chan KH, Zheng BJ, Yuen KY.** 2007. Comparative
 1540 analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals
 1541 unique group and subgroup features. *J. Virol.* **81**:1574-1585.
- 1542 14. **Woo PC, Lau SK, Li KS, Poon RW, Wong BH, Tsoi HW, Yip BC, Huang Y, Chan**
 1543 **KH, Yuen KY.** 2006. Molecular diversity of coronaviruses in bats. *Virology* **351**:180-
 1544 187.
- 1545 15. **Woo PC, Lau SK, Huang Y, Yuen KY.** 2009. Coronavirus diversity, phylogeny and
 1546 interspecies jumping. *Exp. Biol. Med. (Maywood)* **234**:1117-1127.
- 1547 16. **van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM,**

- 1548 **Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA.** 2012.
1549 Genomic characterization of a newly discovered coronavirus associated with acute
1550 respiratory distress syndrome in humans. *mBio* **3**:e00473-12.
- 1551 17. **de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA,**
1552 **Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens**
1553 **GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J.** 2013. Middle East respiratory
1554 syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *J.*
1555 *Virology*. **87**:7790-7792.
- 1556 18. **Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K,**
1557 **Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R,**
1558 **Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M.** 2012. Severe
1559 respiratory illness caused by a novel coronavirus, in a patient transferred to the United
1560 Kingdom from the Middle East, September 2012. *Euro. Surveill.* **17**:20290.
- 1561 19. **Pollack MP, Pringle C, Madoff LC, Memish ZA.** 2013. Latest outbreak news from
1562 ProMED-mail: novel coronavirus -- Middle East. *Int. J. Infect. Dis.* **17**:e143-144.
- 1563 20. **Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, Pybus OG, Rambaut**
1564 **A, Guan Y, Pillay D, Kellam P, Nastouli E.** 2013. Full-genome deep sequencing and
1565 phylogenetic analysis of novel human betacoronavirus. *Emerg. Infect. Dis.* **19**:736-742B.
- 1566 21. **Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY.** 2012. Genetic relatedness of the novel
1567 human group C betacoronavirus to *Tylonycteris* bat coronavirus HKU4 and *Pipistrellus*
1568 bat coronavirus HKU5. *Emerging Microbes & Infections* **1**, e35.
- 1569 22. **Frey KG, Redden CL, Bishop-Lilly KA, Johnson R, Hensley LE, Raviprakash K,**
1570 **Luke T, Kochel T, Mokashi VP, Defang GN.** 2014. Full-genome sequence of human
1571 betacoronavirus 2c jordan-n3/2012 after serial passage in Mammalian cells. *Genome*
1572 *Announc.* **2**.
- 1573 23. **Qian Z, Dominguez SR, Holmes KV.** 2013. Role of the spike glycoprotein of human
1574 Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia
1575 formation. *PLoS One* **8**:e76469.
- 1576 24. **Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, Zhao Z, Tan W.** 2013. The
1577 structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East
1578 respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. *Protein*
1579 *Cell* **4**:951-961.
- 1580 25. **Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, Chan CP, Tse H, Woo PC,**
1581 **Yuen KY, Jin DY.** 2014. Middle east respiratory syndrome coronavirus 4a protein is a
1582 double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I
1583 and MDA5 in the innate antiviral response. *J. Virology*. **88**:4866-4876.
- 1584 26. **Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB.** 2014. The
1585 ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and
1586 two related bat coronaviruses localize to the nucleus and inhibit innate immune
1587 signalling. *J. Gen. Virol.* **95**:874-882.
- 1588 27. **Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, Barchet W,**
1589 **Weber F, Drosten C, Muller MA.** 2013. Middle East respiratory syndrome coronavirus
1590 accessory protein 4a is a type I interferon antagonist. *J. Virology*. **87**:12489-12495.
- 1591 28. **Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y, Chen Z.** 2014. Proteolytic processing,
1592 deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome
1593 coronavirus papain-like protease. *J. Gen. Virol.* **95**:614-626.

- 1594
1595 29. **Chen Y, Rajashankar KR, Yang Y, Agnihothram SS, Liu C, Lin YL, Baric RS, Li F.**
1596 2013. Crystal structure of the receptor-binding domain from newly emerged Middle East
1597 respiratory syndrome coronavirus. *J. Virol.* **87**:10777-10783.
- 1598 30. **Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang**
1599 **B, Shi Y, Yan J, Gao GF.** 2013. Molecular basis of binding between novel human
1600 coronavirus MERS-CoV and its receptor CD26. *Nature* **500**:227-231.
- 1601 31. **Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng**
1602 **BJ, Zhou Y, Jiang S.** 2013. Identification of a receptor-binding domain in the S protein
1603 of the novel human coronavirus Middle East respiratory syndrome coronavirus as an
1604 essential target for vaccine development. *J. Virol.* **87**:9939-9942.
- 1605 32. **Jiang S, Lu L, Du L, Debnath AK.** 2013. A predicted receptor-binding and critical
1606 neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. *J. Infect.*
1607 **66**:464-466.
- 1608 33. **Jiang S, Lu L, Du L, Debnath AK.** 2013. Putative conformations of the receptor-
1609 binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl
1610 peptidase-4. *J. Infect.* **67**:156-158.
- 1611 34. **Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ.** 2013. The
1612 receptor binding domain of the new Middle East respiratory syndrome coronavirus maps
1613 to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
1614 *J. Virol.* **87**:9379-9383.
- 1615 35. **Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X,**
1616 **Arledge KC, Chen YH, Zhang L, Wang X.** 2013. Structure of MERS-CoV spike
1617 receptor-binding domain complexed with human receptor DPP4. *Cell Res.* **23**:986-993.
- 1618 36. **Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L.**
1619 2014. Searching for an ideal vaccine candidate among different MERS coronavirus
1620 receptor-binding fragments-The importance of immunofocusing in subunit vaccine
1621 design. *Vaccine* **32**:6170-6176.
- 1622 37. **Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, Jiang**
1623 **S, Li F, Zhou Y.** 2014. A conformation-dependent neutralizing monoclonal antibody
1624 specifically targeting receptor-binding domain in middle East respiratory syndrome
1625 coronavirus spike protein. *J. Virol.* **88**:7045-7053.
- 1626 38. **Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang**
1627 **Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS.** 2014. Exceptionally potent
1628 neutralization of Middle East respiratory syndrome coronavirus by human monoclonal
1629 antibodies. *J. Virol.* **88**:7796-7805.
- 1630 39. **Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L,**
1631 **Yuen KY, Zheng BJ, Wang X, Zhang L.** 2014. Potent neutralization of MERS-CoV by
1632 human neutralizing monoclonal antibodies to the viral spike glycoprotein. *Sci. Transl.*
1633 *Med.* **6**:234ra259.
- 1634 40. **Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y,**
1635 **Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA.** 2014. Identification of
1636 human neutralizing antibodies against MERS-CoV and their role in virus adaptive
1637 evolution. *Proc. Natl. Acad. Sci. U. S. A.* **111**:E2018-2026.
- 1638 41. **Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou**
1639 **Y.** 2013. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing

- 1640 antibodies and screen for viral entry inhibitors against the novel human coronavirus
1641 MERS-CoV. *Viol. J.* **10**:266.
- 1642 42. **Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y,**
1643 **Jiang S.** 2013. A truncated receptor-binding domain of MERS-CoV spike protein
1644 potently inhibits MERS-CoV infection and induces strong neutralizing antibody
1645 responses: implication for developing therapeutics and vaccines. *PLoS One* **8**:e81587.
- 1646 43. **Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S.** 2014.
1647 Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike
1648 protein induces much stronger local mucosal immune responses than subcutaneous
1649 immunization: Implication for designing novel mucosal MERS vaccines. *Vaccine*
1650 **32**:2100-2108.
- 1651 44. **Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye**
1652 **S, Yuen KY, Zhang R, Jiang S.** 2014. Structure-based discovery of Middle East
1653 respiratory syndrome coronavirus fusion inhibitor. *Nat. Commun.* **5**:3067.
- 1654 45. **Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan**
1655 **J, Gao GF.** 2013. Structure of the fusion core and inhibition of fusion by a heptad repeat
1656 peptide derived from the S protein of Middle East respiratory syndrome coronavirus. *J.*
1657 *Virol.* **87**:13134-13140.
- 1658 46. **Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers**
1659 **JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ,**
1660 **Haagmans BL.** 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging
1661 human coronavirus-EMC. *Nature* **495**:251-254.
- 1662 47. **Lambeir AM, Durinx C, Scharpe S, De Meester I.** 2003. Dipeptidyl-peptidase IV from
1663 bench to bedside: an update on structural properties, functions, and clinical aspects of the
1664 enzyme DPP IV. *Crit. Rev. Clin. Lab. Sci.* **40**:209-294.
- 1665 48. **van Doremalen N, Miazgowiec KL, Milne-Price S, Bushmaker T, Robertson S, Scott**
1666 **D, Kinne J, McLellan JS, Zhu J, Munster VJ.** 2014. Host Species Restriction of
1667 Middle East Respiratory Syndrome Coronavirus through its Receptor Dipeptidyl
1668 Peptidase 4. *J. Virol.* **88**:9220-32.
- 1669 49. **Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ,**
1670 **Bestebroer TM, Spronken MI, van Amerongen G, Rottier PJ, Fouchier RA, Bosch**
1671 **BJ, Osterhaus AD, Haagmans BL.** 2014. Adenosine deaminase acts as a natural
1672 antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory
1673 syndrome coronavirus. *J. Virol.* **88**:1834-1838.
- 1674 50. **Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch**
1675 **BJ, Morimoto C.** 2013. Inhibition of Middle East respiratory syndrome coronavirus
1676 infection by anti-CD26 monoclonal antibody. *J. Virol.* **87**:13892-13899.
- 1677 51. **Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K,**
1678 **Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H,**
1679 **Pohlmann S.** 2013. The spike protein of the emerging betacoronavirus EMC uses a novel
1680 coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by
1681 neutralizing antibodies. *J. Virol.* **87**:5502-5511.
- 1682 52. **Shirato K, Kawase M, Matsuyama S.** 2013. Middle East respiratory syndrome
1683 coronavirus infection mediated by the transmembrane serine protease TMPRSS2. *J.*
1684 *Virol.* **87**:12552-12561.
- 1685 53. **Gierer S, Muller MA, Heurich A, Ritz D, Springstein B, Karsten CB, Schendzielorz**

- 1686 **A, Gnirss K, Drosten C, Pohlmann S.** 2014. Inhibition of proprotein convertases
1687 abrogates processing of the MERS-coronavirus spike protein in infected cells but does
1688 not reduce viral infectivity. *J. Infect. Dis.* pii: jiu407. [Epub ahead of print]
- 1689 54. **Millet JK, Whittaker GR.** 2014. Host cell entry of Middle East respiratory syndrome
1690 coronavirus after two-step, furin-mediated activation of the spike protein. *Proc. Natl.*
1691 *Acad. Sci. U. S. A.* **111**:15214-15219.
- 1692 55. **Thomas G.** 2002. Furin at the cutting edge: from protein traffic to embryogenesis and
1693 disease. *Nat. Rev. Mol. Cell Biol.* **3**:753-766.
- 1694 56. **Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W.** 1992. Inhibition
1695 of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. *Nature* **360**:358-361.
- 1696 57. **Shiryayev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M,**
1697 **Rega MF, Parent A, Desjardins R, Fugere M, Day R, Sabet M, Pellicchia M,**
1698 **Liddington RC, Smith JW, Mustelin T, Guiney DG, Lebl M, Strongin AY.** 2007.
1699 Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial
1700 toxins and viral pathogens. *J. Biol. Chem.* **282**:20847-20853.
- 1701 58. **de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens**
1702 **RW, Posthuma CC, van der Meer Y, Barcena M, Haagmans BL, Snijder EJ, van den**
1703 **Hoogen BG.** 2013. MERS-coronavirus replication induces severe in vitro cytopathology
1704 and is strongly inhibited by cyclosporin A or interferon-alpha treatment. *J. Gen. Virol.*
1705 **94**:1749-1760.
- 1706 59. **Lu L, Liu Q, Du L, Jiang S.** 2013. Middle East respiratory syndrome coronavirus
1707 (MERS-CoV): challenges in identifying its source and controlling its spread. *Microbes*
1708 *Infect.* **15**:625-629.
- 1709 60. **Lei J, Mesters JR, Drosten C, Anemuller S, Ma Q, Hilgenfeld R.** 2014. Crystal
1710 structure of the papain-like protease of MERS coronavirus reveals unusual, potentially
1711 druggable active-site features. *Antiviral Res.* **109C**:72-82.
- 1712 61. **Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli**
1713 **R.** 2003. SARS--beginning to understand a new virus. *Nat. Rev. Microbiol.* **1**:209-218.
- 1714 62. **Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P,**
1715 **Lattwein E, Eschbach-Bludau M, Nitsche A, Bleicker T, Landt O, Schweiger B,**
1716 **Drexler JF, Osterhaus AD, Haagmans BL, Dittmer U, Bonin F, Wolff T, Drosten C.**
1717 2012. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC)
1718 infections. *Euro. Surveill.* **17.** pii: 20334.
- 1719 63. **Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A,**
1720 **Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI,**
1721 **Memish ZA.** 2013. Epidemiological, demographic, and clinical characteristics of 47
1722 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a
1723 descriptive study. *Lancet Infect. Dis.* **13**:752-761.
- 1724 64. **Albarrak AM, Stephens GM, Hewson R, Memish ZA.** 2012. Recovery from severe
1725 novel coronavirus infection. *Saudi Med. J.* **33**:1265-1269.
- 1726 65. **Memish ZA, Zumla AI, Assiri A.** 2013. Middle East respiratory syndrome coronavirus
1727 infections in health care workers. *N. Engl. J. Med.* **369**:884-886.
- 1728 66. **Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour**
1729 **M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL,**
1730 **Kuhar DT, Swerdlow DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI.**
1731 2014. Hospital-associated outbreak of middle East respiratory syndrome coronavirus: a

- 1732 serologic, epidemiologic, and clinical description. *Clin. Infect. Dis.* **59**:1225-1233.
- 1733 67. **Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM.** 2013. Family
1734 cluster of Middle East respiratory syndrome coronavirus infections. *N. Engl. J. Med.*
1735 **368**:2487-2494.
- 1736 68. **Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C,**
1737 **Guery B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettahar N,**
1738 **Noel H, Behillil S, Hendricx S, Manuguerra JC, Enouf V, La Ruche G, Semaille C,**
1739 **Coignard B, Levy-Bruhl D, Weber F, Saura C, Che D.** 2013. First cases of Middle
1740 East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France,
1741 investigations and implications for the prevention of human-to-human transmission,
1742 France, May 2013. *Euro. Surveill.* **18**. pii: 20502.
- 1743 69. **Guberina H, Witzke O, Timm J, Dittmer U, Muller MA, Drosten C, Bonin F.** 2014. A
1744 patient with severe respiratory failure caused by novel human coronavirus. *Infection*
1745 **42**:203-206.
- 1746 70. **Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM.** 2013.
1747 A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a
1748 likely unrecognized asymptomatic or mild case. *Int. J. Infect. Dis.* **17**:e668-672.
- 1749 71. **Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, Vuotto F,**
1750 **Goffard A, Behillil S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu**
1751 **D, Fontanet A, van der Werf S.** 2013. Clinical features and viral diagnosis of two cases
1752 of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial
1753 transmission. *Lancet* **381**:2265-2272.
- 1754 72. **Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos**
1755 **W, Kallies R, Muth D, Junglen S, Muller MA, Haas W, Guberina H, Rohnisch T,**
1756 **Schmid-Wendtner M, Aldabbagh S, Dittmer U, Gold H, Graf P, Bonin F, Rambaut**
1757 **A, Wendtner CM.** 2013. Clinical features and virological analysis of a case of Middle
1758 East respiratory syndrome coronavirus infection. *Lancet Infect. Dis.* **13**:745-751.
- 1759 73. **Health Protection Agency (HPA) UK Novel Coronavirus Investigation team.** 2013.
1760 Evidence of person-to-person transmission within a family cluster of novel coronavirus
1761 infections, United Kingdom, February 2013. *Euro. Surveill.* **18**:20427.
- 1762 74. **Abroug F, Slim A, Ouanes-Besbes L, Hadj Kacem MA, Dachraoui F, Ouanes I, Lu**
1763 **X, Tao Y, Paden C, Caidi H, Miao C, Al-Hajri MM, Zorruga M, Ghaouar W,**
1764 **BenSalah A, Gerber SI; World Health Organization Global Outbreak Alert and**
1765 **Response Network Middle East Respiratory Syndrome Coronavirus International**
1766 **Investigation Team.** 2014. Family cluster of Middle East respiratory syndrome
1767 coronavirus infections, Tunisia, 2013. *Emerg. Infect. Dis.* **20**:1527-1530.
- 1768 75. **Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA,**
1769 **Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-**
1770 **Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA.** 2013. Hospital
1771 outbreak of Middle East respiratory syndrome coronavirus. *N. Engl. J. Med.* **369**:407-
1772 416.
- 1773 76. **Tsiodras S, Baka A, Mentis A, Iliopoulos D, Dedoukou X, Papamavrou G, Karadima**
1774 **S, Emmanouil M, Kossyvakis A, Spanakis N, Pavli A, Maltezou H, Karageorgou A,**
1775 **Spala G, Pitiriga V, Kosmas E, Tsiagklis S, Gkatzias S, Koulouris N, Koutsoukou A,**
1776 **Bakakos P, Markozanhs E, Dionellis G, Pontikis K, Rovina N, Kyriakopoulou M,**
1777 **Efstathiou P, Papadimitriou T, Kremastinou J, Tsakris A, Saroglou G.** 2014. A case

- 1778 of imported Middle East Respiratory Syndrome coronavirus infection and public health
1779 response, Greece, April 2014. *Euro. Surveill.* **19**:20782.
- 1780 77. **Bialek SR, Allen D, Alvarado-Ramy F, Arthur R, Balajee A, Bell D, Best S,**
1781 **Blackmore C, Breakwell L, Cannons A, Brown C, Cetron M, Chea N, Chommanard**
1782 **C, Cohen N, Conover C, Crespo A, Creviston J, Curns AT, Dahl R, Dearth S,**
1783 **DeMaria A, Echols F, Erdman DD, Feikin D, Frias M, Gerber SI, Gulati R, Hale C,**
1784 **Haynes LM, Heberlein-Larson L, Holton K, Ijaz K, Kapoor M, Kohl K, Kuhar DT,**
1785 **Kumar AM, Kundich M, Lippold S, Liu L, Lovchik JC, Madoff L, Martell S,**
1786 **Matthews S, Moore J, Murray LR, Onofrey S, Pallansch MA, Pesik N, Pham H,**
1787 **Pillai S, Pontones P, Pringle K, Pritchard S, Rasmussen S, Richards S, Sandoval M,**
1788 **Schneider E, Schuchat A, Sheedy K, Sherin K, Swerdlow DL, Tappero JW, Vernon**
1789 **MO, Watkins S, Watson J.** 2014. First confirmed cases of Middle East respiratory
1790 syndrome coronavirus (MERS-CoV) infection in the United States, updated information
1791 on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians,
1792 and public health authorities - May 2014. *MMWR Morb. Mortal. Wkly. Rep.* **63**:431-
1793 436.
- 1794 78. **Premila Devi J, Noraini W, Norhayati R, Chee Kheong C, Badrul AS, Zainah S,**
1795 **Fadzilah K, Hirman I, Lokman Hakim S, Noor Hisham A.** 2014. Laboratory-
1796 confirmed case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
1797 in Malaysia: preparedness and response, April 2014. *Euro. Surveill.* **19**. pii: 20797.
- 1798 79. **Kraaij-Dirkzwager M, Timen A, Dirksen K, Gelinck L, Leyten E, Groeneveld P,**
1799 **Jansen C, Jonges M, Raj S, Thurkow I, van Gageldonk-Lafeber R, van der Eijk A,**
1800 **Koopmans M.** 2014. Middle East respiratory syndrome coronavirus (MERS-CoV)
1801 infections in two returning travellers in the Netherlands, May 2014. *Euro. Surveill.* **19**.
1802 pii: 20817.
- 1803 80. **Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Memish ZA.**
1804 2014. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized
1805 patients. *Clin. Infect. Dis.* **59**:160-165.
- 1806 81. **Kapoor M, Pringle K, Kumar A, Dearth S, Liu L, Lovchik J, Perez O, Pontones P,**
1807 **Richards S, Yeadon-Fagbohun J, Breakwell L, Chea N, Cohen NJ, Schneider E,**
1808 **Erdman D, Haynes L, Pallansch M, Tao Y, Tong S, Gerber S, Swerdlow D, Feikin**
1809 **DR.** 2014. Clinical and Laboratory Findings of the First Imported Case of Middle East
1810 Respiratory Syndrome Coronavirus to the United States. *Clin. Infect. Dis.* **59**:1511-1518.
- 1811 82. **Drosten C, Muth D, Corman V, Hussain R, Al Masri M, HajOmar W, Landt O,**
1812 **Assiri A, Eckerle I, Al Shangiti A, Al-Tawfiq JA, Albarrak A, Zumla A, Rambaut A,**
1813 **Memish Z.** 2014. An observational, laboratory-based study of outbreaks of MERS-
1814 Coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014. *Clin. Infect. Dis.* pii:
1815 ciu812. [Epub ahead of print]
- 1816 83. **Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF, Assiri A,**
1817 **Rabeeah AA, Al-Tawfiq JA.** 2014. Community case clusters of Middle East respiratory
1818 syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic
1819 study. *Int. J. Infect. Dis.* **23**:63-68.
- 1820 84. **Pebody RG, Chand MA, Thomas HL, Green HK, Boddington NL, Carvalho C,**
1821 **Brown CS, Anderson SR, Rooney C, Crawley-Boevey E, Irwin DJ, Aarons E, Tong**
1822 **C, Newsholme W, Price N, Langrish C, Tucker D, Zhao H, Phin N, Crofts J,**
1823 **Birmingham A, Gilgunn-Jones E, Brown KE, Evans B, Catchpole M, Watson JM.**

- 1824 2012. The United Kingdom public health response to an imported laboratory confirmed
 1825 case of a novel coronavirus in September 2012. *Euro. Surveill.* **17**:20292.
- 1826 85. **Drosten C, Meyer B, Muller MA, Corman VM, Al-Masri M, Hossain R, Madani H,**
 1827 **Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak**
 1828 **AM, Al-Tawfiq JA, Zumla AI, Memish ZA.** 2014. Transmission of MERS-coronavirus
 1829 in household contacts. *N. Engl. J. Med.* **371**:828-835.
- 1830 86. **Penttinen PM, Kaasik-Aaslav K, Friaux A, Donachie A, Sudre B, Amato-Gauci AJ,**
 1831 **Memish ZA, Coulombier D.** 2013. Taking stock of the first 133 MERS coronavirus
 1832 cases globally--Is the epidemic changing? *Euro. Surveill.* **18**. pii: 20596.
- 1833 87. **WHO MERS-CoV Research Group.** 2013. State of Knowledge and Data Gaps of
 1834 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. *PLoS Curr.* **5**.
 1835 pii: ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
- 1836 88. **Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Hawa H,**
 1837 **Alothman A, Khaldi A, Al Raiy B.** 2014. Clinical course and outcomes of critically ill
 1838 patients with Middle East respiratory syndrome coronavirus infection. *Ann. Intern. Med.*
 1839 **160**:389-397.
- 1840 89. **Alghamdi IG, Hussain, II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy**
 1841 **MA.** 2014. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia:
 1842 a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int. J.*
 1843 *Gen. Med.* **7**:417-423.
- 1844 90. **Breban R, Riou J, Fontanet A.** 2013. Interhuman transmissibility of Middle East
 1845 respiratory syndrome coronavirus: estimation of pandemic risk. *Lancet* **382**:694-699.
- 1846 91. **Alqurashi KA, Aljabri KS, Bokhari SA.** 2011. Prevalence of diabetes mellitus in a
 1847 Saudi community. *Ann. Saudi Med.* **31**:19-23.
- 1848 92. **Zumla AI, Memish ZA.** 2014. Middle East respiratory syndrome coronavirus: epidemic
 1849 potential or a storm in a teacup? *Eur. Respir. J.* **43**:1243-1248.
- 1850 93. **Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Wong BH, Poon RW, Cai**
 1851 **JJ, Luk WK, Poon LL, Wong SS, Guan Y, Peiris JS, Yuen KY.** 2005. Characterization
 1852 and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients
 1853 with pneumonia. *J. Virol.* **79**:884-895.
- 1854 94. **Woo PC, Lau SK, Tsoi HW, Huang Y, Poon RW, Chu CM, Lee RA, Luk WK, Wong**
 1855 **GK, Wong BH, Cheng VC, Tang BS, Wu AK, Yung RW, Chen H, Guan Y, Chan KH,**
 1856 **Yuen KY.** 2005. Clinical and molecular epidemiological features of coronavirus HKU1-
 1857 associated community-acquired pneumonia. *J. Infect. Dis.* **192**:1898-1907.
- 1858 95. **Lau SK, Woo PC, Yip CC, Tse H, Tsoi HW, Cheng VC, Lee P, Tang BS, Cheung CH,**
 1859 **Lee RA, So LY, Lau YL, Chan KH, Yuen KY.** 2006. Coronavirus HKU1 and other
 1860 coronavirus infections in Hong Kong. *J. Clin. Microbiol.* **44**:2063-2071.
- 1861 96. **Chan CM, Tse H, Wong SS, Woo PC, Lau SK, Chen L, Zheng BJ, Huang JD, Yuen**
 1862 **KY.** 2009. Examination of seroprevalence of coronavirus HKU1 infection with S protein-
 1863 based ELISA and neutralization assay against viral spike pseudotyped virus. *J. Clin.*
 1864 *Virol.* **45**:54-60.
- 1865 97. **Gierer S, Hofmann-Winkler H, Albuali WH, Bertram S, Al-Rubaish AM, Yousef**
 1866 **AA, Al-Nafaie AN, Al-Ali AK, Obeid OE, Alkharsah KR, Pohlmann S.** 2013. Lack of
 1867 MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia.
 1868 *Emerg. Infect. Dis.* **19**:2034-2036.
- 1869 98. **Aburizaiza AS, Mattes FM, Azhar EI, Hassan AM, Memish ZA, Muth D, Meyer B,**

- 1870 **Lattwein E, Muller MA, Drosten C.** 2014. Investigation of anti-middle East respiratory
1871 syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah,
1872 Saudi Arabia, fall 2012. *J. Infect. Dis.* **209**:243-246.
- 1873 99. **Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, Chan KH, Woo PC, Yuen**
1874 **KY.** 2013. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals
1875 marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in
1876 Japanese pipistrelle: implications for the origin of the novel Middle East respiratory
1877 syndrome coronavirus. *J. Virol.* **87**:8638-8650.
- 1878 100. **Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F.** 2014. Receptor
1879 usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human
1880 transmission of MERS coronavirus. *Proc. Natl. Acad. Sci. U. S. A.* **111**:12516-12521.
- 1881 101. **Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, Ji W, Li Y, Wu Y, Wang J, Iwamoto**
1882 **A, Woo PC, Yuen KY, Yan J, Lu G, Gao GF.** 2014. Bat origins of MERS-CoV
1883 supported by bat coronavirus HKU4 usage of human receptor CD26. *Cell Host Microbe*
1884 **16**:328-337.
- 1885 102. **Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan**
1886 **KH, Yuen KY.** 2005. Severe acute respiratory syndrome coronavirus-like virus in
1887 Chinese horseshoe bats. *Proc. Natl. Acad. Sci. U. S. A.* **102**:14040-14045.
- 1888 103. **Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC,**
1889 **Wang M, Zheng BJ, Chan KH, Yuen KY.** 2012. Discovery of seven novel Mammalian
1890 and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the
1891 gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene
1892 source of gammacoronavirus and deltacoronavirus. *J. Virol.* **86**:3995-4008.
- 1893 104. **Lau SK, Woo PC, Li KS, Huang Y, Wang M, Lam CS, Xu H, Guo R, Chan KH,**
1894 **Zheng BJ, Yuen KY.** 2007. Complete genome sequence of bat coronavirus HKU2 from
1895 Chinese horseshoe bats revealed a much smaller spike gene with a different evolutionary
1896 lineage from the rest of the genome. *Virology* **367**:428-439.
- 1897 105. **Lau SK, Li KS, Huang Y, Shek CT, Tse H, Wang M, Choi GK, Xu H, Lam CS, Guo**
1898 **R, Chan KH, Zheng BJ, Woo PC, Yuen KY.** 2010. Ecoepidemiology and complete
1899 genome comparison of different strains of severe acute respiratory syndrome-related
1900 Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting
1901 infection that allows recombination events. *J. Virol.* **84**:2808-2819.
- 1902 106. **Lau SK, Poon RW, Wong BH, Wang M, Huang Y, Xu H, Guo R, Li KS, Gao K,**
1903 **Chan KH, Zheng BJ, Woo PC, Yuen KY.** 2010. Coexistence of different genotypes in
1904 the same bat and serological characterization of Rousettus bat coronavirus HKU9
1905 belonging to a novel Betacoronavirus subgroup. *J. Virol.* **84**:11385-11394.
- 1906 107. **Lau SK, Li KS, Tsang AK, Shek CT, Wang M, Choi GK, Guo R, Wong BH, Poon**
1907 **RW, Lam CS, Wang SY, Fan RY, Chan KH, Zheng BJ, Woo PC, Yuen KY.** 2012.
1908 Recent transmission of a novel alphacoronavirus, bat coronavirus HKU10, from
1909 Leschenault's rousettes to pomona leaf-nosed bats: first evidence of interspecies
1910 transmission of coronavirus between bats of different suborders. *J. Virol.* **86**:11906-
1911 11918.
- 1912 108. **Cui J, Eden JS, Holmes EC, Wang LF.** 2013. Adaptive evolution of bat dipeptidyl
1913 peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory
1914 syndrome coronavirus. *Virol. J.* **10**:304.
- 1915 109. **Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH, Alhakeem R,**

- 1916 **Durosinloun A, Al Asmari M, Islam A, Kapoor A, Briese T, Daszak P, Al Rabeeah**
1917 **AA, Lipkin WI.** 2013. Middle East respiratory syndrome coronavirus in bats, Saudi
1918 Arabia. *Emerg. Infect. Dis.* **19**:1819-1823.
- 1919 110. **Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC,**
1920 **Drosten C, Drexler JF, Preiser W.** 2013. Close relative of human Middle East
1921 respiratory syndrome coronavirus in bat, South Africa. *Emerg. Infect. Dis.* **19**:1697-1699.
- 1922 111. **Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C,**
1923 **Drexler JF.** 2014. Rooting the phylogenetic tree of middle East respiratory syndrome
1924 coronavirus by characterization of a conspecific virus from an African bat. *J. Virol.*
1925 **88**:11297-11303.
- 1926 112. **Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, Al-**
1927 **Tawfiq JA, Alhakeem RF, Madani H, AlRabiah FA, Al Hajjar S, Al-nassir WN,**
1928 **Albarrak A, Flemban H, Balkhy HH, Alsubaie S, Palser AL, Gall A, Bashford-**
1929 **Rogers R, Rambaut A, Zumla AI, Memish ZA.** 2013. Transmission and evolution of
1930 the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic
1931 study. *Lancet* **382**:1993-2002.
- 1932 113. **Corman VM, Kallies R, Philipps H, Gopner G, Muller MA, Eckerle I, Brunink S,**
1933 **Drosten C, Drexler JF.** 2014. Characterization of a novel betacoronavirus related to
1934 middle East respiratory syndrome coronavirus in European hedgehogs. *J. Virol.* **88**:717-
1935 724.
- 1936 114. **Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH,**
1937 **Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen**
1938 **KY, Peiris JS, Poon LL.** 2003. Isolation and characterization of viruses related to the
1939 SARS coronavirus from animals in southern China. *Science* **302**:276-278.
- 1940 115. **Wong S, Lau S, Woo P, Yuen KY.** 2007. Bats as a continuing source of emerging
1941 infections in humans. *Rev. Med. Virol.* **17**:67-91.
- 1942 116. **Chan JF, Chan KH, Choi GK, To KK, Tse H, Cai JP, Yeung ML, Cheng VC, Chen**
1943 **H, Che XY, Lau SK, Woo PC, Yuen KY.** 2013. Differential cell line susceptibility to the
1944 emerging novel human betacoronavirus 2c EMC/2012: implications for disease
1945 pathogenesis and clinical manifestation. *J. Infect. Dis.* **207**:1743-1752.
- 1946 117. **Muller MA, Raj VS, Muth D, Meyer B, Kallies S, Smits SL, Wollny R, Bestebroer**
1947 **TM, Specht S, Suliman T, Zimmermann K, Binger T, Eckerle I, Tschapka M, Zaki**
1948 **AM, Osterhaus AD, Fouchier RA, Haagmans BL, Drosten C.** 2012. Human
1949 coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad
1950 replicative capability in mammalian cell lines. *mBio* **3**:e00515-12.
- 1951 118. **Eckerle I, Corman VM, Muller MA, Lenk M, Ulrich RG, Drosten C.** 2014.
1952 Replicative Capacity of MERS Coronavirus in Livestock Cell Lines. *Emerg. Infect. Dis.*
1953 **20**:276-279.
- 1954 119. **Cockrell AS, Peck KM, Yount BL, Agnihothram SS, Scobey T, Curnes NR, Baric**
1955 **RS, Heise MT.** 2014. Mouse dipeptidyl peptidase 4 is not a functional receptor for
1956 Middle East respiratory syndrome coronavirus infection. *J. Virol.* **88**:5195-5199.
- 1957 120. **Barlan A, Zhao J, Sarkar MK, Li K, McCray PB, Jr., Perlman S, Gallagher T.** 2014.
1958 Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus
1959 infection. *J. Virol.* **88**:4953-4961.
- 1960 121. **Reusken CB, Haagmans BL, Muller MA, Gutierrez C, Godeke GJ, Meyer B, Muth**
1961 **D, Raj VS, Smits-De Vries L, Corman VM, Drexler JF, Smits SL, El Tahir YE, De**

- 1962 **Sousa R, van Beek J, Nowotny N, van Maanen K, Hidalgo-Hermoso E, Bosch BJ,**
1963 **Rottier P, Osterhaus A, Gortazar-Schmidt C, Drosten C, Koopmans MP.** 2013.
1964 Middle East respiratory syndrome coronavirus neutralising serum antibodies in
1965 dromedary camels: a comparative serological study. *Lancet Infect. Dis.* **13**:859-866.
- 1966 122. **Perera RA, Wang P, Goma MR, El-Shesheny R, Kandeil A, Bagato O, Siu LY,**
1967 **Shehata MM, Kayed AS, Moatasim Y, Li M, Poon LL, Guan Y, Webby RJ, Ali MA,**
1968 **Peiris JS, Kayali G.** 2013. Seroepidemiology for MERS coronavirus using
1969 microneutralisation and pseudoparticle virus neutralisation assays reveal a high
1970 prevalence of antibody in dromedary camels in Egypt, June 2013. *Euro. Surveill.* **18**. pii:
1971 20574.
- 1972 123. **Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, de Wit E,**
1973 **Munster VJ, Hensley LE, Zalmout IS, Kapoor A, Epstein JH, Karesh WB, Daszak P,**
1974 **Mohammed OB, Lipkin WI.** 2014. Middle East respiratory syndrome coronavirus
1975 infection in dromedary camels in Saudi Arabia. *mBio* **5**:e00884-00814.
- 1976 124. **Meyer B, Muller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, Lattwein E,**
1977 **Kallies S, Siemens A, van Beek J, Drexler JF, Muth D, Bosch BJ, Wernery U,**
1978 **Koopmans MP, Wernery R, Drosten C.** 2014. Antibodies against MERS coronavirus in
1979 dromedary camels, United Arab Emirates, 2003 and 2013. *Emerg. Infect. Dis.* **20**:552-
1980 559.
- 1981 125. **Alexandersen S, Kobinger GP, Soule G, Wernery U.** 2014. Middle East respiratory
1982 syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates,
1983 in 2005. *Transbound. Emerg. Dis.* **61**:105-108.
- 1984 126. **Reusken CB, Ababneh M, Raj VS, Meyer B, Eljarah A, Abutarbush S, Godeke GJ,**
1985 **Bestebroer TM, Zutt I, Muller MA, Bosch BJ, Rottier PJ, Osterhaus AD, Drosten C,**
1986 **Haagmans BL, Koopmans MP.** 2013. Middle East Respiratory Syndrome coronavirus
1987 (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to
1988 September 2013. *Euro. Surveill.* **18**:20662.
- 1989 127. **Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Li M, Poon LL, Saif L,**
1990 **Alnaeem A, Peiris M.** 2013. Middle East Respiratory Syndrome (MERS) coronavirus
1991 seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. *Euro. Surveill.*
1992 **18**:20659.
- 1993 128. **Memish ZA, Cotten M, Meyer B, Watson SJ, Alshafi AJ, Al Rabeeah AA, Corman**
1994 **VM, Sieberg A, Makhdoom HQ, Assiri A, Al Masri M, Aldabbagh S, Bosch BJ, Beer**
1995 **M, Muller MA, Kellam P, Drosten C.** 2014. Human infection with MERS coronavirus
1996 after exposure to infected camels, Saudi Arabia, 2013. *Emerg. Infect. Dis.* **20**:1012-1015.
- 1997 129. **Hemida MG, Chu DK, Poon LL, Perera RA, Alhammadi MA, Ng HY, Siu LY, Guan**
1998 **Y, Alnaeem A, Peiris M.** 2014. MERS Coronavirus in Dromedary Camel Herd, Saudi
1999 Arabia. *Emerg. Infect. Dis.* **20**: 1231-1234.
- 2000 130. **Corman VM, Jores J, Meyer B, Younan M, Liljander A, Said MY, Gluecks I,**
2001 **Lattwein E, Bosch BJ, Drexler JF, Bornstein S, Drosten C, Muller MA.** 2014.
2002 Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992-2013.
2003 *Emerg. Infect. Dis.* **20**: 1319-1322.
- 2004 131. **Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, Smits SL,**
2005 **Osterhaus AD, Al-Mawlawi N, Al-Romaihi HE, AlHajri MM, El-Sayed AM, Mohran**
2006 **KA, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, El-Maghraby MM,**
2007 **Koopmans MP, Haagmans BL.** 2014. Isolation of MERS Coronavirus from a

- 2008 Dromedary Camel, Qatar, 2014. *Emerg. Infect. Dis.* **20**: 1339-1342.
- 2009 132. **Müller MA, Corman VM, Jores J, Meyer B, Younan M, Liljander A, Bosch BJ,**
- 2010 **Lattwein E, Hilali M, Musa BE, Bornstein S, Drosten C.** 2014. MERS Coronavirus
- 2011 Neutralizing Antibodies in Camels, Eastern Africa, 1983-1997. *Emerg. Infect. Dis.* **20**:
- 2012 doi: 10.3201/eid2012.141026. [Epub ahead of print]
- 2013 133. **Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke**
- 2014 **GJ, Jonges M, Farag E, Diab A, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA,**
- 2015 **Al Romaihi HE, Al Khal A, Bermingham A, Osterhaus AD, AlHajri MM, Koopmans**
- 2016 **MP.** 2014. Middle East respiratory syndrome coronavirus in dromedary camels: an
- 2017 outbreak investigation. *Lancet Infect. Dis.* **14**:140-145.
- 2018 134. **Chu DK, Poon LL, Gomaa MM, Shehata MM, Perera RA, Abu Zeid D, El Rifay AS,**
- 2019 **Siu LY, Guan Y, Webby RJ, Ali MA, Peiris M, Kayali G.** 2014. MERS Coronaviruses
- 2020 in Dromedary Camels, Egypt. *Emerg. Infect. Dis.* **20**:1049-1053.
- 2021 135. **Hemida M, Perera R, Al Jassim R, Kayali G, Siu L, Wang P, Chu K, Perlman S, Ali**
- 2022 **M, Alnaeem A, Guan Y, Poon L, Saif L, Peiris M.** 2014. Seroepidemiology of Middle
- 2023 East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia
- 2024 (2014) and characterisation of assay specificity. *Euro. Surveill.* **19**. pii: 20828.
- 2025 136. **Memish ZA, Alsahly A, Masri MA, Heil GL, Anderson BD, Peiris M, Khan SU,**
- 2026 **Gray GC.** 2014. Sparse evidence of MERS-CoV infection among animal workers living
- 2027 in Southern Saudi Arabia during 2012. *Influenza Other Respir. Viruses* doi:
- 2028 10.1111/irv.12287. [Epub ahead of print]
- 2029 137. **Briese T, Mishra N, Jain K, Zalmout IS, Jabado OJ, Karesh WB, Daszak P,**
- 2030 **Mohammed OB, Alagaili AN, Lipkin WI.** 2014. Middle East respiratory syndrome
- 2031 coronavirus quasispecies that include homologues of human isolates revealed through
- 2032 whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. *mBio*
- 2033 **5**:e01146-01114.
- 2034 138. **Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM,**
- 2035 **Madani TA.** 2014. Evidence for camel-to-human transmission of MERS coronavirus. *N.*
- 2036 *Engl. J. Med.* **370**:2499-2505.
- 2037 139. **Azhar EI, Hashem AM, El-Kafrawy SA, Sohrab SS, Aburizaiza AS, Farraj SA,**
- 2038 **Hassan AM, Al-Saeed MS, Jamjoom GA, Madani TA.** 2014. Detection of the Middle
- 2039 East respiratory syndrome coronavirus genome in an air sample originating from a camel
- 2040 barn owned by an infected patient. *mBio* **5**:e01450-01414.
- 2041 140. **Woo PC, Lau SK, Wernery U, Wong EY, Tsang AK, Johnson B, Yip CC, Lau CC,**
- 2042 **Sivakumar S, Cai JP, Fan RY, Chan KH, Mareena R, Yuen KY.** 2014. Novel
- 2043 betacoronavirus in dromedaries of the Middle East, 2013. *Emerg. Infect. Dis.* **20**:560-
- 2044 572.
- 2045 141. **Muyldermans S.** 2001. Single domain camel antibodies: current status. *J. Biotechnol.*
- 2046 **74**:277-302.
- 2047 142. **Fanoy EB, van der Sande MA, Kraaij-Dirkzwager M, Dirksen K, Jonges M, van der**
- 2048 **Hoek W, Koopmans MP, van der Werf D, Sonder G, van der Weijden C, van der**
- 2049 **Heuvel J, Gelinck L, Bouwhuis JW, van Gageldonk-Lafeber AB.** 2014. Travel-related
- 2050 MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch
- 2051 travellers returning from the Kingdom of Saudi Arabia, May 2014. *Emerg. Themes*
- 2052 *Epidemiol.* **11**:16.
- 2053 143. **van Doremalen N, Bushmaker T, Karesh WB, Munster VJ.** 2014. Stability of Middle

- 2054 East respiratory syndrome coronavirus in milk. *Emerg. Infect. Dis.* **20**:1263-1264.
- 2055 144. **Reusken CB, Farag EA, Jonges M, Godeke GJ, El-Sayed AM, Pas SD, Raj VS,**
- 2056 **Mohran KA, Moussa HA, Ghobashy H, Alhajri F, Ibrahim AK, Bosch BJ, Pasha**
- 2057 **SK, Al-Romaihi HE, Al-Thani M, Al-Marri SA, AlHajri MM, Haagmans BL,**
- 2058 **Koopmans MP.** 2014. Middle East respiratory syndrome coronavirus (MERS-CoV)
- 2059 RNA and neutralising antibodies in milk collected according to local customs from
- 2060 dromedary camels, Qatar, April 2014. *Euro. Surveill.* **19**. pii: 20829.
- 2061 145. **van Doremalen N, Bushmaker T, Munster VJ.** 2013. Stability of Middle East
- 2062 respiratory syndrome coronavirus (MERS-CoV) under different environmental
- 2063 conditions. *Euro surveillance* **18**. pii: 20590.
- 2064 146. **Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah**
- 2065 **AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, Albarrak A, Barry M, Shibl A, Alrabiah**
- 2066 **FA, Hajjar S, Balkhy HH, Flemban H, Rambaut A, Kellam P, Memish ZA.** 2014.
- 2067 Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus.
- 2068 *mBio* **5**:e01062-13.
- 2069 147. **Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K,**
- 2070 **Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M.** 2005.
- 2071 Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.
- 2072 *EMBO J.* **24**:1634-1643.
- 2073 148. **Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R.** 2008.
- 2074 Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range
- 2075 expansion in human airway epithelium. *J. Virol.* **82**:2274-2285.
- 2076 149. **McRoy WC, Baric RS.** 2008. Amino acid substitutions in the S2 subunit of mouse
- 2077 hepatitis virus variant V51 encode determinants of host range expansion. *J. Virol.*
- 2078 **82**:1414-1424.
- 2079 150. **Poletto C, Pelat C, Levy-Bruhl D, Yazdanpanah Y, Boelle PY, Colizza V.** 2014.
- 2080 Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic
- 2081 in the Middle East and risk of international spread using a novel maximum likelihood
- 2082 analysis approach. *Euro. Surveill.* **19**. pii: 20824.
- 2083 151. **Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A,**
- 2084 **Enouf V, van der Werf S, Ferguson NM.** 2014. Middle East respiratory syndrome
- 2085 coronavirus: quantification of the extent of the epidemic, surveillance biases, and
- 2086 transmissibility. *Lancet Infect. Dis.* **14**:50-56.
- 2087 152. **Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA.** 2014. Middle East
- 2088 Respiratory Syndrome Coronavirus (MERS-CoV) Infection: Chest CT Findings. *AJR*
- 2089 *Am. J. Roentgenol.* **203**:782-787.
- 2090 153. **Cheng VC, To KK, Tse H, Hung IF, Yuen KY.** 2012. Two years after pandemic
- 2091 influenza A/2009/H1N1: what have we learned? *Clin. Microbiol. Rev.* **25**:223-263.
- 2092 154. **To KK, Chan JF, Yuen KY.** 2014. Viral lung infections: epidemiology, virology, clinical
- 2093 features, and management of avian influenza A(H7N9). *Curr. Opin. Pulm. Med.* **20**:225-
- 2094 232.
- 2095 155. **Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JF, To KK, Chen H, Yang Y, Liang W,**
- 2096 **Zheng S, Yao H, Yang S, Cao H, Dai X, Zhao H, Li J, Bao Q, Chen P, Hou X, Li L,**
- 2097 **Yuen KY.** 2013. Clinical, virological, and histopathological manifestations of fatal
- 2098 human infections by avian influenza A(H7N9) virus. *Clin. Infect. Dis.* **57**:1449-1457.
- 2099 156. **To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt**

- 2100 **CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, Zheng B,**
 2101 **Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY.** 2010. Delayed clearance of
 2102 viral load and marked cytokine activation in severe cases of pandemic H1N1 2009
 2103 influenza virus infection. *Clin. Infect. Dis.* **50**:850-859.
- 2104 157. **Eckerle I, Muller MA, Kallies S, Gotthardt DN, Drosten C.** 2013. In-vitro renal
 2105 epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute
 2106 renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection.
 2107 *Virology* **10**:359.
- 2108 158. **Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, Fung KS, Tang HL, Yan**
 2109 **WW, Chan HW, Lai TS, Tong KL, Lai KN.** 2005. Acute renal impairment in
 2110 coronavirus-associated severe acute respiratory syndrome. *Kidney Int.* **67**:698-705.
- 2111 159. **Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, Stewart**
 2112 **TE.** 2003. Critically ill patients with severe acute respiratory syndrome. *JAMA* **290**:367-
 2113 373.
- 2114 160. **Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, Wong MM, Hui WT,**
 2115 **Poon LL, Tse DM, Chan KS, Woo PC, Lau SK, Peiris JS, Yuen KY.** 2004. Viral loads
 2116 in clinical specimens and SARS manifestations. *Emerg. Infect. Dis.* **10**:1550-1557.
- 2117 161. **Park SJ, Kim GY, Choy HE, Hong YJ, Saif LJ, Jeong JH, Park SI, Kim HH, Kim**
 2118 **SK, Shin SS, Kang MI, Cho KO.** 2007. Dual enteric and respiratory tropisms of winter
 2119 dysentery bovine coronavirus in calves. *Arch. Virol.* **152**:1885-1900.
- 2120 162. **Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour**
 2121 **M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL,**
 2122 **Kuhar DT, Swerdlow DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI.**
 2123 2014. Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus:
 2124 A Serologic, Epidemiologic, and Clinical Description. *Clin. Infect. Dis.* **59**:1225-1233.
- 2125 163. **Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon**
 2126 **TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY.**
 2127 2003. Clinical progression and viral load in a community outbreak of coronavirus-
 2128 associated SARS pneumonia: a prospective study. *Lancet* **361**:1767-1772.
- 2129 164. **Memish ZA, Al-Tawfiq JA, Assiri A, Alrabiah FA, Hajjar SA, Albarrak A, Flemban**
 2130 **H, Alhakeem RF, Makhdoom HQ, Alsubaie S, Al-Rabeeah AA.** 2014. Middle East
 2131 Respiratory Syndrome Coronavirus Disease in Children. *Pediatr. Infect. Dis. J.* **33**:904-
 2132 906.
- 2133 165. **Munster VJ, de Wit E, Feldmann H.** 2013. Pneumonia from human coronavirus in a
 2134 macaque model. *N. Engl. J. Med.* **368**:1560-1562.
- 2135 166. **de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL,**
 2136 **Fischer ER, Martellaro C, Okumura A, Chang J, Scott D, Benecke AG, Katze MG,**
 2137 **Feldmann H, Munster VJ.** 2013. Middle East respiratory syndrome coronavirus
 2138 (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. *Proc.*
 2139 *Natl. Acad. Sci. U. S. A.* **110**:16598-16603.
- 2140 167. **Yao Y, Bao L, Deng W, Xu L, Li F, Lv Q, Yu P, Chen T, Xu Y, Zhu H, Yuan J, Gu S,**
 2141 **Wei Q, Chen H, Yuen KY, Qin C.** 2014. An animal model of MERS produced by
 2142 infection of rhesus macaques with MERS coronavirus. *J. Infect. Dis.* **209**:236-242.
- 2143 168. **Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, Thomas**
 2144 **MJ, van Doremalen N, Haddock E, Nagy L, LaCasse R, Liu T, Zhu J, McLellan JS,**
 2145 **Scott DP, Katze MG, Feldmann H, Munster VJ.** 2014. Infection with MERS-CoV

- 2146 causes lethal pneumonia in the common marmoset. *PLoS Pathog.* **10**:e1004250.
- 2147 169. **Prescott J, de Wit E, Falzarano D, Scott DP, Feldmann H, Munster VJ.** 2014.
- 2148 Defining the effects of immunosuppression in the rhesus model of Middle East
- 2149 respiratory syndrome (MERS). Final Program 33rd Annual Meeting American Society
- 2150 for Virology, Fort Collins, CO.
- 2151 170. **Menachery VD, Eisfeld AJ, Schafer A, Josset L, Sims AC, Proll S, Fan S, Li C,**
- 2152 **Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green R, Williams CM,**
- 2153 **Weiss J, Matzke MM, Webb-Robertson BJ, Schepmoes AA, Shukla AK, Metz TO,**
- 2154 **Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS.** 2014. Pathogenic influenza
- 2155 viruses and coronaviruses utilize similar and contrasting approaches to control interferon-
- 2156 stimulated gene responses. *mBio* **5**:e01174-01114.
- 2157 171. **Lau SK, Lau CC, Chan KH, Li CP, Chen H, Jin DY, Chan JF, Woo PC, Yuen KY.**
- 2158 2013. Delayed induction of proinflammatory cytokines and suppression of innate
- 2159 antiviral response by the novel Middle East respiratory syndrome coronavirus:
- 2160 implications for pathogenesis and treatment. *J. Gen. Virol.* **94**:2679-2690.
- 2161 172. **Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC.** 2014. MERS-
- 2162 CoV papain-like protease has deISGylating and deubiquitinating activities. *Virology* **450-**
- 2163 **451**:64-70.
- 2164 173. **Deng X, Agnihothram S, Mielech AM, Nichols DB, Wilson MW, StJohn SE, Larsen**
- 2165 **SD, Mesecar AD, Lenschow DJ, Baric RS, Baker SC.** 2014. A chimeric virus-mouse
- 2166 model system for evaluating the function and inhibition of papain-like proteases of
- 2167 emerging coronaviruses. *J. Virol.* **88**:11825-11833.
- 2168 174. **Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Gale MJ, Jr., Baric RS,**
- 2169 **Enjuanes L, Gallagher T, McCray PB, Jr., Perlman S.** 2014. Rapid generation of a
- 2170 mouse model for Middle East respiratory syndrome. *Proc. Natl. Acad. Sci. U. S. A.*
- 2171 **111**:4970-4975.
- 2172 175. **Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining**
- 2173 **D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ,**
- 2174 **Feldmann H.** 2013. Treatment with interferon-alpha2b and ribavirin improves outcome
- 2175 in MERS-CoV-infected rhesus macaques. *Nat. Med.* **19**:1313-1317.
- 2176 176. **Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, Bortolotti P,**
- 2177 **Martinez L, Dubucquoi S, Dessein R, Gosset P, Mathieu D, Guery B.** 2014. Distinct
- 2178 immune response in two MERS-CoV-infected patients: can we go from bench to
- 2179 bedside? *PLoS One* **9**:e88716.
- 2180 177. **Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, Yount**
- 2181 **BL, Graham RL, Baric RS, Katze MG.** 2013. Cell host response to infection with
- 2182 novel human coronavirus EMC predicts potential antivirals and important differences
- 2183 with SARS coronavirus. *mBio* **4**:e00165-00113.
- 2184 178. **Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller**
- 2185 **MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y,**
- 2186 **Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar**
- 2187 **A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Kelvin DJ.** 2007.
- 2188 Interferon-mediated immunopathological events are associated with atypical innate and
- 2189 adaptive immune responses in patients with severe acute respiratory syndrome. *J. Virol.*
- 2190 **81**:8692-8706.
- 2191 179. **Perlman S, Netland J.** 2009. Coronaviruses post-SARS: update on replication and

- 2192 pathogenesis. *Nat. Rev. Microbiol.* **7**:439-450.
- 2193 180. **Ryzhakov G, Lai CC, Blazek K, To KW, Hussell T, Udalova I.** 2011. IL-17 boosts
2194 proinflammatory outcome of antiviral response in human cells. *J. Immunol.* **187**:5357-
2195 5362.
- 2196 181. **Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, Enelow RI, Ross TM,**
2197 **Witztum JL, Kolls JK.** 2009. Critical role of IL-17RA in immunopathology of influenza
2198 infection. *J. Immunol.* **183**:5301-5310.
- 2199 182. **Poissy J, Goffard A, Parmentier-Decrucq E, Favory R, Kauh M, Kipnis E, Mathieu**
2200 **D, Guery B.** 2014. Kinetics and pattern of viral excretion in biological specimens of two
2201 MERS-CoV cases. *J. Clin. Virol.* **61**:275-278.
- 2202 183. **Buchholz U, Muller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, Bonin**
2203 **F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G, Schaade**
2204 **L, Haas W.** 2013. Contact investigation of a case of human novel coronavirus infection
2205 treated in a German hospital, October-November 2012. *Euro. Surveill.* **18**. pii 20406.
- 2206 184. **Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A,**
2207 **Koulouris NG, Osterhaus AD, Koopmans MP, Tsakris A.** 2014. Virological and
2208 serological analysis of a recent Middle East respiratory syndrome coronavirus infection
2209 case on a triple combination antiviral regimen. *Int. J. Antimicrob. Agents* **44**:528-532.
- 2210 185. **Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, Tseng CT.** 2013. Bilateral entry
2211 and release of Middle East respiratory syndrome coronavirus induces profound apoptosis
2212 of human bronchial epithelial cells. *J. Virol.* **87**:9953-9958.
- 2213 186. **Zielecki F, Weber M, Eickmann M, Spiegelberg L, Zaki AM, Matrosovich M,**
2214 **Becker S, Weber F.** 2013. Human cell tropism and innate immune system interactions of
2215 human respiratory coronavirus EMC compared to those of severe acute respiratory
2216 syndrome coronavirus. *J. Virol.* **87**:5300-5304.
- 2217 187. **Kindler E, Jonsdottir HR, Muth D, Hamming OJ, Hartmann R, Rodriguez R,**
2218 **Geffers R, Fouchier RA, Drosten C, Muller MA, Dijkman R, Thiel V.** 2013. Efficient
2219 replication of the novel human betacoronavirus EMC on primary human epithelium
2220 highlights its zoonotic potential. *mBio* **4**:e00611-00612.
- 2221 188. **Scobey T, Yount BL, Sims AC, Donaldson EF, Agnihothram SS, Menachery VD,**
2222 **Graham RL, Swanstrom J, Bove PF, Kim JD, Grego S, Randell SH, Baric RS.** 2013.
2223 Reverse genetics with a full-length infectious cDNA of the Middle East respiratory
2224 syndrome coronavirus. *Proc. Natl. Acad. Sci. U. S. A.* **110**:16157-16162.
- 2225 189. **Hocke AC, Becher A, Knepper J, Peter A, Holland G, Tonnies M, Bauer TT,**
2226 **Schneider P, Neudecker J, Muth D, Wendtner CM, Ruckert JC, Drosten C, Gruber**
2227 **AD, Laue M, Suttorp N, Hippenstiel S, Wolff T.** 2013. Emerging human middle East
2228 respiratory syndrome coronavirus causes widespread infection and alveolar damage in
2229 human lungs. *American journal of respiratory and critical care medicine* **188**:882-886.
- 2230 190. **Chan RW, Chan MC, Agnihothram S, Chan LL, Kuok DI, Fong JH, Guan Y, Poon**
2231 **LL, Baric RS, Nicholls JM, Peiris JS.** 2013. Tropism of and innate immune responses
2232 to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ
2233 cultures. *J. Virol.* **87**:6604-6614.
- 2234 191. **Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, Sun T, Lau CC, Wong KK,**
2235 **Chan JY, Chan JF, To KK, Chan KH, Zheng BJ, Yuen KY.** 2014. Active replication of
2236 Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory
2237 cytokines and chemokines in human macrophages: implications for pathogenesis. *J.*

- 2238 Infect. Dis. **209**:1331-1342.
- 2239 192. **Ziegler AF, Ladman BS, Dunn PA, Schneider A, Davison S, Miller PG, Lu H,**
 2240 **Weinstock D, Salem M, Eckroade RJ, Gelb J, Jr.** 2002. Nephropathogenic infectious
 2241 bronchitis in Pennsylvania chickens 1997-2000. *Avian Dis.* **46**:847-858.
- 2242 193. **Chu H, Zhou J, Wong BH, Li C, Cheng ZS, Lin X, Poon VK, Sun T, Lau CC, Chan**
 2243 **JF, To KK, Chan KH, Lu L, Zheng BJ, Yuen KY.** 2014. Productive replication of
 2244 Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells
 2245 modulates innate immune response. *Virology* **454-455**:197-205.
- 2246 194. **Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A,**
 2247 **Alsubaie S, Al-Rabeeh AA, Hajomar WH, Hussain R, Kheyami AM, Almutairi A,**
 2248 **Azhar EI, Drosten C, Watson SJ, Kellam P, Cotten M, Zumla A.** 2014. Respiratory
 2249 Tract Samples, Viral Load and Genome Fraction Yield in patients with Middle East
 2250 Respiratory Syndrome. *J. Infect. Dis.* **210**:1590-1594.
- 2251 195. **de Sousa R, Reusken C, Koopmans M.** 2014. MERS coronavirus: data gaps for
 2252 laboratory preparedness. *J. Clin. Virol.* **59**:4-11.
- 2253 196. **Cheng VC, Hung IF, Tang BS, Chu CM, Wong MM, Chan KH, Wu AK, Tse DM,**
 2254 **Chan KS, Zheng BJ, Peiris JS, Sung JJ, Yuen KY.** 2004. Viral replication in the
 2255 nasopharynx is associated with diarrhea in patients with severe acute respiratory
 2256 syndrome. *Clin. Infect. Dis.* **38**:467-475.
- 2257 197. **Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, Yam LY, Seto WH, Yuen**
 2258 **KY, Peiris JS.** 2004. Detection of SARS coronavirus in patients with suspected SARS.
 2259 *Emerg. Infect. Dis.* **10**:294-299.
- 2260 198. **Memish ZA, Assiri AM, Al-Tawfiq JA.** 2014. Middle East respiratory syndrome
 2261 coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational
 2262 analysis with infection control implications. *Int. J. Infect. Dis.* **29**:307-308.
- 2263 199. **Palm D, Pereyaslov D, Vaz J, Broberg E, Zeller H, Gross D, Brown CS, Struelens**
 2264 **MJ.** 2012. Laboratory capability for molecular detection and confirmation of novel
 2265 coronavirus in Europe, November 2012. *Euro. Surveill.* **17**. pii: 20335.
- 2266 200. **Abd El Wahed A, Patel P, Heidenreich D, Hufert FT, Weidmann M.** 2013. Reverse
 2267 transcription recombinase polymerase amplification assay for the detection of middle
 2268 East respiratory syndrome coronavirus. *PLoS Curr.* **5**. pii:
 2269 ecurrents.outbreaks.62df1c7c75ffc96cd59034531e2e8364.
- 2270 201. **Shirato K, Yano T, Senba S, Akachi S, Kobayashi T, Nishinaka T, Notomi T,**
 2271 **Matsuyama S.** 2014. Detection of Middle East respiratory syndrome coronavirus using
 2272 reverse transcription loop-mediated isothermal amplification (RT-LAMP). *Virol. J.*
 2273 **11**:139.
- 2274 202. **Agnihothram S, Gopal R, Yount BL, Jr., Donaldson EF, Menachery VD, Graham**
 2275 **RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS.** 2014. Evaluation
 2276 of serologic and antigenic relationships between middle eastern respiratory syndrome
 2277 coronavirus and other coronaviruses to develop vaccine platforms for the rapid response
 2278 to emerging coronaviruses. *J. Infect. Dis.* **209**:995-1006.
- 2279 203. **Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, Tsang AK, Xiao X, To KK, Lau**
 2280 **SK, Woo PC, Zheng BJ, Wang M, Yuen KY.** 2013. Cross-reactive antibodies in
 2281 convalescent SARS patients' sera against the emerging novel human coronavirus EMC
 2282 (2012) by both immunofluorescent and neutralizing antibody tests. *J. Infect.* **67**:130-140.
- 2283 204. **Cheng VC, Tang BS, Wu AK, Chu CM, Yuen KY.** 2004. Medical treatment of viral

- 2284 pneumonia including SARS in immunocompetent adult. *J. Infect.* **49**:262-273.
- 2285 205. **Wong SS, Yuen KY.** 2008. The management of coronavirus infections with particular
2286 reference to SARS. *J. Antimicrob. Chemother.* **62**:437-441.
- 2287 206. **Ho PL, Sin WC, Chan JF, Cheng VC, Chan KH.** 2014. Severe influenza A H7N9
2288 pneumonia with rapid virological response to intravenous zanamivir. *Eur. Respir. J.*
2289 **44**:535-537.
- 2290 207. **Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY,**
2291 **Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM.** 2014. Ribavirin and
2292 interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a
2293 retrospective cohort study. *Lancet Infect. Dis.* **14**:1090-1095.
- 2294 208. **Frausto SD, Lee E, Tang H.** 2013. Cyclophilins as modulators of viral replication.
2295 *Viruses* **5**:1684-1701.
- 2296 209. **Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H.** 2013.
2297 Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b
2298 and ribavirin. *Sci. Rep.* **3**:1686.
- 2299 210. **Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen**
2300 **H, Hayden FG, Yuen KY.** 2013. Broad-spectrum antivirals for the emerging Middle East
2301 respiratory syndrome coronavirus. *J. Infect.* **67**:606-616.
- 2302 211. **Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E.** 2014.
2303 Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle
2304 East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases.
2305 *Antivir. Ther.* doi: 10.3851/IMP2792. [Epub ahead of print]
- 2306 212. **Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J,**
2307 **Johnson RF, Olinger GG, Jr., Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney**
2308 **CM, Glass PJ, Hensley LE, Frieman MB.** 2014. Repurposing of clinically developed
2309 drugs for treatment of middle East respiratory syndrome coronavirus infection.
2310 *Antimicrob. Agents Chemother.* **58**:4885-4893.
- 2311 213. **de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop**
2312 **S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ.** 2014. Screening of an
2313 FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle
2314 East Respiratory Syndrome Coronavirus Replication in Cell Culture. *Antimicrob. Agents*
2315 *Chemother.* **58**:4875-4884.
- 2316 214. **Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L, Jiang S.** 2014. Testing of MERS-CoV
2317 replication inhibitors for their ability to block viral entry. *Antimicrob. Agents Chemother.*
2318 pii: AAC.03977-14. [Epub ahead of print]
- 2319 215. **Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D,**
2320 **Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB.** 2014. The
2321 Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for
2322 MERS-CoV Infection as Identified by Temporal Kinome Analysis. *Antimicrob. Agents*
2323 *Chemother.* pii: AAC.03659-14. [Epub ahead of print]
- 2324 216. **Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL,**
2325 **Wong CL, Guan Y, Peiris JS, Yuen KY.** 2004. Role of lopinavir/ritonavir in the
2326 treatment of SARS: initial virological and clinical findings. *Thorax* **59**:252-256.
- 2327 217. **Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah**
2328 **NG, Nichol ST.** 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection
2329 and spread. *Virology* **2**:69.

- 2330 218. **Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PK,**
2331 **Sidwell RW.** 2006. Evaluation of immunomodulators, interferons and known in vitro
2332 SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir.*
2333 *Chem. Chemother.* **17**:275-284.
- 2334 219. **Barnard DL, Kumaki Y.** 2011. Recent developments in anti-severe acute respiratory
2335 syndrome coronavirus chemotherapy. *Future Virol.* **6**:615-631.
- 2336 220. **Kilianski A, Baker SC.** 2014. Cell-based antiviral screening against coronaviruses:
2337 developing virus-specific and broad-spectrum inhibitors. *Antiviral Res.* **101**:105-112.
- 2338 221. **Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ.**
2339 2005. Evasion of antibody neutralization in emerging severe acute respiratory syndrome
2340 coronaviruses. *Proc. Natl. Acad. Sci. U. S. A.* **102**:797-801.
- 2341 222. **Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S,**
2342 **Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A,**
2343 **Dick D, Berry J, Ganske S, Manning L, Cao J.** 2004. Immunization with modified
2344 vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory
2345 syndrome is associated with enhanced hepatitis in ferrets. *J. Virol.* **78**:12672-12676.
- 2346 223. **Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z, Rao Z.** 2013. The newly emerged
2347 SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective
2348 inhibitor targeting a 3C-like protease. *Protein Cell* **4**:248-250.
- 2349 224. **Kilianski A, Mielech AM, Deng X, Baker SC.** 2013. Assessing activity and inhibition of
2350 Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using
2351 luciferase-based biosensors. *J. Virol.* **87**:11955-11962.
- 2352 225. **Agnihothram S, Yount BL, Jr., Donaldson EF, Huynh J, Menachery VD, Gralinski**
2353 **LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A,**
2354 **Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS.** 2014.
2355 A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5
2356 variant. *mBio* **5**:e00047-00014.
- 2357 226. **Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, Frieman MB,**
2358 **Sarafianos SG.** 2014. Evaluation of SSYA10-001 as a Replication Inhibitor of SARS,
2359 MHV and MERS Coronaviruses. *Antimicrob. Agents Chemother.* **58**:4894-4898.
- 2360 227. **Bosch BJ, Smits SL, Haagmans BL.** 2014. Membrane ectopeptidases targeted by
2361 human coronaviruses. *Curr. Opin. Virol.* **6**:55-60.
- 2362 228. **Reinhold D, Bank U, Tager M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U,**
2363 **Faust J, Neubert K, Brocke S.** 2008. DP IV/CD26, APN/CD13 and related enzymes as
2364 regulators of T cell immunity: implications for experimental encephalomyelitis and
2365 multiple sclerosis. *Front. Biosci.* **13**:2356-2363.
- 2366 229. **Reinhold D, Brocke S.** 2014. DPP4-directed therapeutic strategies for MERS-CoV.
2367 *Lancet Infect. Dis.* **14**:100-101.
- 2368 230. **Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM.** 2005. Endosomal
2369 proteolysis of the Ebola virus glycoprotein is necessary for infection. *Science* **308**:1643-
2370 1645.
- 2371 231. **Marzi A, Reinheckel T, Feldmann H.** 2012. Cathepsin B & L are not required for ebola
2372 virus replication. *PLoS Negl. Trop. Dis.* **6**:e1923.
- 2373 232. **Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, Yao H, Wo J, Fang Q, Cui D, Li Y,**
2374 **Yao X, Zhang Y, Wu H, Zheng S, Diao H, Xia S, Chan KH, Tsoi HW, Teng JL, Song**
2375 **W, Wang P, Lau SY, Zheng M, Chan JF, To KK, Chen H, Li L, Yuen KY.** 2013.

- 2376 Human infections with the emerging avian influenza A H7N9 virus from wet market
 2377 poultry: clinical analysis and characterisation of viral genome. *Lancet* **381**:1916-1925.
- 2378 233. **To KK, Tsang AK, Chan JF, Cheng VC, Chen H, Yuen KY.** 2014. Emergence in China
 2379 of human disease due to avian influenza A(H10N8)--cause for concern? *J. Infect.* **68**:205-
 2380 215.
- 2381 234. **Cheng VC, Chan JF, To KK, Yuen KY.** 2013. Clinical management and infection
 2382 control of SARS: lessons learned. *Antiviral Res.* **100**:407-419.
- 2383 235. **Memish ZA, Al-Tawfiq JA, Assiri A.** 2013. Hospital-associated Middle East respiratory
 2384 syndrome coronavirus infections. *The New England journal of medicine* **369**:1761-1762.
- 2385 236. **Coburn BJ, Blower S.** 2014. Predicting the potential for within-flight transmission and
 2386 global dissemination of MERS. *Lancet Infect. Dis.* **14**:99.
- 2387 237. **Thomas HL, Zhao H, Green HK, Boddington NL, Carvalho CF, Osman HK, Sadler
 2388 C, Zambon M, Bermingham A, Pebody RG.** 2014. Enhanced MERS Coronavirus
 2389 Surveillance of Travelers from the Middle East to England. *Emerg. Infect. Dis.* **20**:1562-
 2390 1564.
- 2391 238. **Leclercq I, Batejat C, Burguiere AM, Manuguerra JC.** 2014. Heat inactivation of the
 2392 Middle East respiratory syndrome coronavirus. *Influenza Other Respir. Viruses* **8**:585-
 2393 586.
- 2394 239. **Gautret P, Charrel R, Belhouchat K, Drali T, Benkouiten S, Nougairede A, Zandotti
 2395 C, Memish ZA, al Masri M, Gaillard C, Brouqui P, Parola P.** 2013. Lack of nasal
 2396 carriage of novel corona virus (HCoV-EMC) in French Hajj pilgrims returning from the
 2397 Hajj 2012, despite a high rate of respiratory symptoms. *Clin. Microbiol. Infect.* **19**:E315-
 2398 317.
- 2399 240. **Gautret P, Charrel R, Benkouiten S, Belhouchat K, Nougairede A, Drali T, Salez N,
 2400 Memish ZA, Al Masri M, Lagier JC, Million M, Raoult D, Brouqui P, Parola P.**
 2401 2014. Lack of MERS coronavirus but prevalence of influenza virus in French pilgrims
 2402 after 2013 Hajj. *Emerg. Infect. Dis.* **20**:728-730.
- 2403 241. **Memish ZA, Almasri M, Turkestani A, Al-Shangiti AM, Yezli S.** 2014. Etiology of
 2404 severe community-acquired pneumonia during the 2013 Hajj-part of the MERS-CoV
 2405 surveillance program. *Int. J. Infect. Dis.* **25**:186-190.
- 2406 242. **Memish ZA, Al-Rabeeh AA.** 2013. Health conditions of travellers to Saudi Arabia for
 2407 the pilgrimage to Mecca (Hajj and Umra) for 1434 (2013). *J. Epidemiol. Glob. Health*
 2408 **3**:59-61.
- 2409 243. **Al-Tawfiq JA, Memish ZA.** 2014. Mass gathering medicine: 2014 Hajj and Umra
 2410 preparation as a leading example. *Int. J. Infect. Dis.* **27**:26-31.
- 2411 244. **Chung SJ, Ling ML, Seto WH, Ang BS, Tambyah PA.** 2014. Debate on MERS-CoV
 2412 respiratory precautions: surgical mask or N95 respirators? *Singapore Med. J.* **55**:294-297.
- 2413 245. **Cheng VC, Tai JW, Wong LM, Chan JF, Li IW, To KK, Hung IF, Chan KH, Ho PL,
 2414 Yuen KY.** 2010. Prevention of nosocomial transmission of swine-origin pandemic
 2415 influenza virus A/H1N1 by infection control bundle. *J. Hosp. Infect.* **74**:271-277.
- 2416 246. **Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Drosten C, Memish ZA.**
 2417 2014. A case of long-term excretion and subclinical infection with MERS-Coronavirus in
 2418 a health care worker. *Clin. Infect. Dis.* pii: ciu1135. [Epub ahead of print]
- 2419 247. **Madani TA.** 2014. Case definition and management of patients with MERS coronavirus
 2420 in Saudi Arabia. *Lancet Infect. Dis.* **14**:911-913.
- 2421 248. **Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD,**

- 2422 **Haagmans BL, Sutter G.** 2013. Middle East respiratory syndrome coronavirus spike
 2423 protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing
 2424 antibodies. *J. Virol.* **87**:11950-11954.
- 2425 249. **Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith**
 2426 **GE, Frieman MB.** 2014. Purified coronavirus spike protein nanoparticles induce
 2427 coronavirus neutralizing antibodies in mice. *Vaccine* **32**:3169-3174.
- 2428 250. **He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S.** 2004. Identification of
 2429 immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS)
 2430 coronavirus: implication for developing SARS diagnostics and vaccines. *J. Immunol.*
 2431 **173**:4050-4057.
- 2432 251. **Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, Lu Z, Gao GF, Tan W.** 2014.
 2433 Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes
 2434 Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain
 2435 as an Antigen. *PLoS One* **9**:e112602.
- 2436 252. **Zhang N, Jiang S, Du L.** 2014. Current advancements and potential strategies in the
 2437 development of MERS-CoV vaccines. *Expert Rev. Vaccines* **13**:761-774.
- 2438 253. **Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung**
 2439 **CB, Cheng G.** 2005. Use of convalescent plasma therapy in SARS patients in Hong
 2440 Kong. *Eur. J. Clin. Microbiol. Infect. Dis.* **24**:44-46.
- 2441 254. **Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, Wan HL, Chen JH, Hu**
 2442 **BS, Perng CL, Lu JJ, Chang FY.** 2005. Experience of using convalescent plasma for
 2443 severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J.*
 2444 *Antimicrob. Chemother.* **56**:919-922.
- 2445 255. **Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law**
 2446 **KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY.** 2013.
 2447 Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized
 2448 controlled trial for patients with severe 2009 influenza A(H1N1) infection. *Chest*
 2449 **144**:464-473.
- 2450 256. **Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM,**
 2451 **Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS,**
 2452 **Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY.** 2011. Convalescent plasma
 2453 treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009
 2454 virus infection. *Clin. Infect. Dis.* **52**:447-456.
- 2455 257. **van Doremalen N, de Wit E, Falzarano D, Scott DP, Schountz T, Bowen D, McLellan**
 2456 **JS, Zhu J, Munster VJ.** 2014. Modeling the host ecology of Middle East respiratory
 2457 syndrome coronavirus (MERS-CoV): from host reservoir to disease. Final Program 33rd
 2458 Annual Meeting American Society for Virology, Fort Collins, CO.
- 2459 258. **Adney DR, Brown VR, Dominguez SR, Bielefeldt-Ohmann H, Bowen RA.** 2014.
 2460 Experimental infectioin of goats and insectivorous bats with MERS-CoV. Final Program
 2461 33rd Annual Meeting American Society for Virology, Fort Collins, CO.
- 2462 259. **Adney DR, van Doremalen N, Brown VR, Bushmaker T, Scott D, de Wit E, Bowen**
 2463 **RA, Munster VJ.** 2014. Replication and Shedding of MERS-CoV in Upper Respiratory
 2464 Tract of Inoculated Dromedary Camels. *Emerg. Infect. Dis.* **20**:1999-2005.
- 2465 260. **Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, Leung YH, Lau SK, Woo PC,**
 2466 **Suen KY, Yuen KY, Guan Y, Peiris JS.** 2005. Identification of a novel coronavirus in
 2467 bats. *J. Virol.* **79**:2001-2009.

- 2468 261. **Woo PC, Lau SK, Huang Y, Tsoi HW, Chan KH, Yuen KY.** 2005. Phylogenetic and
2469 recombination analysis of coronavirus HKU1, a novel coronavirus from patients with
2470 pneumonia. *Arch. Virol.* **150**:2299-2311.
- 2471 262. **Woo PC, Huang Y, Lau SK, Tsoi HW, Yuen KY.** 2005. In silico analysis of ORF1ab in
2472 coronavirus HKU1 genome reveals a unique putative cleavage site of coronavirus HKU1
2473 3C-like protease. *Microbiol. Immunol.* **49**:899-908.
- 2474 263. **Woo PC, Lau SK, Yip CC, Huang Y, Tsoi HW, Chan KH, Yuen KY.** 2006.
2475 Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and
2476 evidence of natural recombination in coronavirus HKU1. *J. Virol.* **80**:7136-7145.
- 2477 264. **Huang Y, Lau SK, Woo PC, Yuen KY.** 2008. CoVDB: a comprehensive database for
2478 comparative analysis of coronavirus genes and genomes. *Nucleic Acids Res.* **36**:D504-
2479 511.
- 2480 265. **Woo PC, Lau SK, Lam CS, Lai KK, Huang Y, Lee P, Luk GS, Dyrting KC, Chan
2481 KH, Yuen KY.** 2009. Comparative analysis of complete genome sequences of three avian
2482 coronaviruses reveals a novel group 3c coronavirus. *J. Virol.* **83**:908-917.
- 2483 266. **Woo PC, Lau SK, Yip CC, Huang Y, Yuen KY.** 2009. More and More Coronaviruses:
2484 Human Coronavirus HKU1. *Viruses* **1**:57-71.
- 2485 267. **Woo PC, Huang Y, Lau SK, Yuen KY.** 2010. Coronavirus genomics and bioinformatics
2486 analysis. *Viruses* **2**:1804-1820.
- 2487 268. **Lau SK, Lee P, Tsang AK, Yip CC, Tse H, Lee RA, So LY, Lau YL, Chan KH, Woo
2488 PC, Yuen KY.** 2011. Molecular epidemiology of human coronavirus OC43 reveals
2489 evolution of different genotypes over time and recent emergence of a novel genotype due
2490 to natural recombination. *J. Virol.* **85**:11325-11337.
- 2491 269. **Lau SK, Woo PC, Yip CC, Fan RY, Huang Y, Wang M, Guo R, Lam CS, Tsang AK,
2492 Lai KK, Chan KH, Che XY, Zheng BJ, Yuen KY.** 2012. Isolation and characterization
2493 of a novel Betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from
2494 domestic rabbits. *J. Virol.* **86**:5481-5496.
- 2495 270. **Woo PC, Lau SK, Lam CS, Tsang AK, Hui SW, Fan RY, Martelli P, Yuen KY.** 2014.
2496 Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine
2497 mammal coronavirus in Gammacoronavirus. *Journal of virology* **88**:1318-1331.
- 2498 271. **Pereyaslov D, Rosin P, Palm D, Zeller H, Gross D, Brown C, Struelens M.** 2014.
2499 Laboratory capability and surveillance testing for Middle East respiratory syndrome
2500 coronavirus infection in the WHO European Region, June 2013. *Euro. Surveill.*
2501 **19**:20923.
- 2502 272. **Woo PC, Lau SK, Teng JL, Tsang AK, Joseph M, Wong EY, Tang Y, Sivakumar S,
2503 Xie J, Bai R, Wernery R, Wernery U, Yuen KY.** 2014. New hepatitis E virus genotype
2504 in camels, the Middle East. *Emerg. Infect. Dis.* **20**:1044-1048.
- 2505 273. **Woo PC, Lau SK, Teng JL, Tsang AK, Joseph M, Wong EY, Tang Y, Sivakumar S,
2506 Bai R, Wernery R, Wernery U, Yuen KY.** 2014. Metagenomic analysis of viromes of
2507 dromedary camel fecal samples reveals large number and high diversity of circoviruses
2508 and picobirnaviruses. *Virology* **471-473C**:117-125.
- 2509 274. **Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang
2510 H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF.** 2005.
2511 Bats are natural reservoirs of SARS-like coronaviruses. *Science* **310**:676-679.
- 2512 275. **Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang
2513 W, Peng C, Zhang YJ, Luo CM, Tan B, Wang N, Zhu Y, Crameri G, Zhang SY,**



- 2514 **Wang LF, Daszak P, Shi ZL.** 2013. Isolation and characterization of a bat SARS-like
2515 coronavirus that uses the ACE2 receptor. *Nature* **503**:535-538.
- 2516 276. **Chu CM, Cheng VC, Hung IF, Chan KS, Tang BS, Tsang TH, Chan KH, Yuen KY.**
2517 2005. Viral load distribution in SARS outbreak. *Emerg. Infect. Dis.* **11**:1882-1886.
- 2518 277. **Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC, Se-Thoe SY, Oon
2519 L, Bai X, Stanton LW, Ruan Y, Miller LD, Vega VB, James L, Ooi PL, Kai CS, Olsen
2520 SJ, Ang B, Leo YS.** 2004. Laboratory-acquired severe acute respiratory syndrome. *N.
2521 Engl. J. Med.* **350**:1740-1745.
- 2522 278. **Olsen SJ, Chang HL, Cheung TY, Tang AF, Fisk TL, Ooi SP, Kuo HW, Jiang DD,
2523 Chen KT, Lando J, Hsu KH, Chen TJ, Dowell SF.** 2003. Transmission of the severe
2524 acute respiratory syndrome on aircraft. *N. Engl. J. Med.* **349**:2416-2422.
- 2525 279. **Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, Leung
2526 GM, Lam TH, Hedley AJ.** 2004. Epidemiology, transmission dynamics and control of
2527 SARS: the 2002-2003 epidemic. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **359**:1091-
2528 1105.
- 2529 280. **Wallinga J, Teunis P.** 2004. Different epidemic curves for severe acute respiratory
2530 syndrome reveal similar impacts of control measures. *Am. J. Epidemiol.* **160**:509-516.
- 2531 281. **Nishiura H, Kuratsuji T, Quy T, Phi NC, Van Ban V, Ha LE, Long HT, Yanai H,
2532 Keicho N, Kirikae T, Sasazuki T, Anderson RM.** 2005. Rapid awareness and
2533 transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam.
2534 *Am. J. Trop. Med. Hyg.* **73**:17-25.
- 2535 282. **Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den
2536 Hoogen BG, Peiris M, Lim W, Stohr K, Osterhaus AD.** 2003. Aetiology: Koch's
2537 postulates fulfilled for SARS virus. *Nature* **423**:240.
- 2538 283. **Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M,
2539 Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M.** 2003. Angiotensin-
2540 converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **426**:450-
2541 454.
- 2542 284. **Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P.** 2005.
2543 Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.
2544 *Proc. Natl. Acad. Sci. U. S. A.* **102**:11876-11881.
- 2545 285. **Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I,
2546 Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pohlmann S.**
2547 2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome
2548 coronavirus spike protein for membrane fusion and reduces viral control by the humoral
2549 immune response. *J. Virol.* **85**:4122-4134.
- 2550 286. **Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F.** 2010.
2551 Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by
2552 the transmembrane protease TMPRSS2. *J. Virol.* **84**:12658-12664.
- 2553 287. **Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.** 2014.
2554 TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2
2555 augments entry driven by the severe acute respiratory syndrome coronavirus spike
2556 protein. *J. Virol.* **88**:1293-1307.
- 2557 288. **Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS,
2558 Harrison SC, Dormitzer PR, Farzan M, Rottier PJ, Choe H.** 2006. SARS
2559 coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-



- 2560 expressing cells. *J. Biol. Chem.* **281**:3198-3203.
- 2561 289. **Siu KL, Kok KH, Ng MH, Poon VK, Yuen KY, Zheng BJ, Jin DY.** 2009. Severe acute
2562 respiratory syndrome coronavirus M protein inhibits type I interferon production by
2563 impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. *J. Biol. Chem.*
2564 **284**:16202-16209.
- 2565 290. **Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P.** 2007.
2566 Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6,
2567 and nucleocapsid proteins function as interferon antagonists. *J. Virol.* **81**:548-557.
- 2568 291. **Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng CT,**
2569 **Makino S.** 2008. Severe acute respiratory syndrome coronavirus nsp1 suppresses host
2570 gene expression, including that of type I interferon, in infected cells. *J. Virol.* **82**:4471-
2571 4479.
- 2572 292. **Devaraj SG, Wang N, Chen Z, Tseng M, Barretto N, Lin R, Peters CJ, Tseng CT,**
2573 **Baker SC, Li K.** 2007. Regulation of IRF-3-dependent innate immunity by the papain-
2574 like protease domain of the severe acute respiratory syndrome coronavirus. *J. Biol.*
2575 *Chem.* **282**:32208-32221.
- 2576 293. **Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, Guan Y,**
2577 **Rozanov M, Spaan WJ, Gorbalenya AE.** 2003. Unique and conserved features of
2578 genome and proteome of SARS-coronavirus, an early split-off from the coronavirus
2579 group 2 lineage. *J. Mol. Biol.* **331**:991-1004.
- 2580 294. **Woo PC, Lau SK, Tsoi HW, Chan KH, Wong BH, Che XY, Tam VK, Tam SC, Cheng**
2581 **VC, Hung IF, Wong SS, Zheng BJ, Guan Y, Yuen KY.** 2004. Relative rates of non-
2582 pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. *Lancet*
2583 **363**:841-845.
- 2584 295. **Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, Wang W, Lian G, Yin X, Du L, Ren L,**
2585 **Wang J, He X, Li T, Deng H, Ding M.** 2004. Neutralizing antibodies in patients with
2586 severe acute respiratory syndrome-associated coronavirus infection. *J. Infect. Dis.*
2587 **190**:1119-1126.
- 2588 296. **Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A,**
2589 **Alsubaie S, Al-Rabeeh AA, Hajomar WH, Hussain R, Kheyami AM, Almutairi A,**
2590 **Azhar EI, Drosten C, Watson SJ, Kellam P, Cotten M, Zumla A.** 2014. Respiratory
2591 tract samples, viral load, and genome fraction yield in patients with middle East
2592 respiratory syndrome. *J. Infect. Dis.* **210**:1590-1594.
- 2593 297. **Graham RL, Donaldson EF, Baric RS.** 2013. A decade after SARS: strategies for
2594 controlling emerging coronaviruses. *Nat. Rev. Microbiol.* **11**:836-848.
- 2595 298. **Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS,**
2596 **Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR.** 2014. The Effectiveness of
2597 Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe
2598 Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory
2599 Meta-analysis. *J. Infect. Dis.* **211**:80-90.
- 2600 299. **Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J,**
2601 **Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T,**
2602 **Zust R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V,**
2603 **Herrler G, Thiel HJ, Schwegmann-Wessels C, Pohlmann S, Haas J, Drosten C, von**
2604 **Brunn A.** 2011. The SARS-coronavirus-host interactome: identification of cyclophilins
2605 as target for pan-coronavirus inhibitors. *PLoS Pathog.* **7**:e1002331.

- 2606 300. **Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S.**
2607 2011. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
2608 cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. *PLoS*
2609 *Pathog.* **7**:e1002433.
- 2610 301. **Cornillez-Ty CT, Liao L, Yates JR, 3rd, Kuhn P, Buchmeier MJ.** 2009. Severe acute
2611 respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein
2612 complex involved in mitochondrial biogenesis and intracellular signaling. *J. Virol.*
2613 **83**:10314-10318.
- 2614 302. **Lin MH, Chuang SJ, Chen CC, Cheng SC, Cheng KW, Lin CH, Sun CY, Chou CY.**
2615 2014. Structural and functional characterization of MERS coronavirus papain-like
2616 protease. *J. Biomed. Sci.* **21**:54.
- 2617 303. **Baez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD.** 2014. Catalytic
2618 Function and Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the
2619 Middle East Respiratory Syndrome Coronavirus. *J. Virol.* **88**:12511-12527.
- 2620 304. **Lei J, Mesters JR, Drosten C, Anemuller S, Ma Q, Hilgenfeld R.** 2014. Crystal
2621 structure of the papain-like protease of MERS coronavirus reveals unusual, potentially
2622 druggable active-site features. *Antiviral Res.* **109**:72-82.
- 2623 305. **Bailey-Elkin BA, Knaap RC, Johnson GG, Dalebout TJ, Ninaber DK, van Kasteren**
2624 **PB, Bredenbeek PJ, Snijder EJ, Kikkert M, Mark BL.** 2014. Crystal Structure of the
2625 MERS Coronavirus Papain-Like Protease Bound to Ubiquitin Facilitates Targeted
2626 Disruption of Deubiquitinating Activity to Demonstrate its Role in Innate Immune
2627 Suppression. *J. Biol. Chem.* pii: jbc.M114.609644. [Epub ahead of print]
- 2628 306. **Lundin A, Dijkman R, Bergstrom T, Kann N, Adamiak B, Hannoun C, Kindler E,**
2629 **Jonsdottir HR, Muth D, Kint J, Forlenza M, Muller MA, Drosten C, Thiel V,**
2630 **Trybala E.** 2014. Targeting membrane-bound viral RNA synthesis reveals potent
2631 inhibition of diverse coronaviruses including the middle East respiratory syndrome virus.
2632 *PLoS Pathog.* **10**:e1004166.
- 2633 307. **te Velhuis AJ, van den Worm SH, Snijder EJ.** 2012. The SARS-coronavirus
2634 nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo
2635 initiation and primer extension. *Nucleic acids Res.* **40**:1737-1747.
- 2636 308. **Miknis ZJ, Donaldson EF, Umland TC, Rimmer RA, Baric RS, Schultz LW.** 2009.
2637 Severe acute respiratory syndrome coronavirus nsp9 dimerization is essential for efficient
2638 viral growth. *J. Virol.* **83**:3007-3018.
- 2639 309. **Chen Y, Su C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z, Tien P, Ahola T,**
2640 **Liang Y, Liu X, Guo D.** 2011. Biochemical and structural insights into the mechanisms
2641 of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex.
2642 *PLoS Pathog.* **7**:e1002294.
- 2643 310. **Menachery VD, Debbink K, Baric RS.** 2014. Coronavirus non-structural protein 16:
2644 Evasion, attenuation, and possible treatments. *Virus Res.* **194C**:191-199.
- 2645 311. **Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S,**
2646 **Andres G, Enjuanes L.** 2013. Engineering a replication-competent, propagation-
2647 defective Middle East respiratory syndrome coronavirus as a vaccine candidate. *mBio*
2648 **4**:e00650-00613.
- 2649 312. **Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van**
2650 **Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Muller MA, Drexler**
2651 **JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C.** 2012. Detection of a novel

- 2652 human coronavirus by real-time reverse-transcription polymerase chain reaction. *Euro. Surveill.* **17**. pii: 20285.
- 2653
- 2654 313. **Memish ZA, Al-Tawfiq JA, Assiri A, AlRabiah FA, Al Hajjar S, Albarrak A,**
- 2655 **Flemban H, Alhakeem RF, Makhdoom HQ, Alsubaie S, Al-Rabeeah AA.** 2014.
- 2656 Middle East respiratory syndrome coronavirus disease in children. *Pediatr. Infect. Dis. J.*
- 2657 **33:904-906.**
- 2658 314. **Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Selim MA, Mutairi**
- 2659 **MA, Nakhli DA, Aidaroos AY, Sherbeeni NA, Al-Khashan HI, Memish ZA,**
- 2660 **Albarrak AM.** 2014. Clinical aspects and outcomes of 70 patients with Middle East
- 2661 respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia.
- 2662 *Int. J. Infect. Dis.* pii: S1201-9712(14)01622-1.
- 2663 315. **Yang L, Wu Z, Ren X, Yang F, Zhang J, He G, Dong J, Sun L, Zhu Y, Zhang S, Jin**
- 2664 **Q.** 2014. MERS-related betacoronavirus in *Vespertilio superans* bats, China. *Emerg.*
- 2665 *Infect. Dis.* **20:1260-1262.**
- 2666 316. **Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, Badu EK,**
- 2667 **Anti P, Agbenyega O, Meyer B, Oppong S, Sarkodie YA, Kalko EK, Lina PH,**
- 2668 **Godlevska EV, Reusken C, Seebens A, Gloza-Rausch F, Vallo P, Tschapka M,**
- 2669 **Drosten C, Drexler JF.** 2013. Human betacoronavirus 2c EMC/2012-related viruses in
- 2670 bats, Ghana and Europe. *Emerg. Infect. Dis.* **19:456-459.**
- 2671 317. **Lelli D, Papetti A, Sabelli C, Rosti E, Moreno A, Boniotti MB.** 2013. Detection of
- 2672 coronaviruses in bats of various species in Italy. *Viruses* **5:2679-2689.**
- 2673 318. **Anthony SJ, Ojeda-Flores R, Rico-Chavez O, Navarrete-Macias I, Zambrana-**
- 2674 **Torrelío CM, Rostal MK, Epstein JH, Tipps T, Liang E, Sanchez-Leon M,**
- 2675 **Sotomayor-Bonilla J, Aguirre AA, Avila-Flores R, Medellin RA, Goldstein T, Suzan**
- 2676 **G, Daszak P, Lipkin WI.** 2013. Coronaviruses in bats from Mexico. *J. Gen. Virol.*
- 2677 **94:1028-1038.**
- 2678 319. **Goes LG, Ruvalcaba SG, Campos AA, Queiroz LH, de Carvalho C, Jerez JA,**
- 2679 **Durigon EL, Davalos LI, Dominguez SR.** 2013. Novel bat coronaviruses, Brazil and
- 2680 Mexico. *Emerg. Infect. Dis.* **19:1711-1713.**
- 2681 320. **Hemida MG, Chu DK, Poon LL, Perera RA, Alhammadi MA, Ng HY, Siu LY, Guan**
- 2682 **Y, Alnaeem A, Peiris M.** 2014. MERS coronavirus in dromedary camel herd, Saudi
- 2683 Arabia. *Emerg. Infect. Dis.* **20:1231-1234.**
- 2684 321. **Nowotny N, Kolodziejek J.** 2014. Middle East respiratory syndrome coronavirus
- 2685 (MERS-CoV) in dromedary camels, Oman, 2013. *Euro. Surveill.* **19:20781.**
- 2686 322. **Hemida MG, Perera RA, Al Jassim RA, Kayali G, Siu LY, Wang P, Chu KW,**
- 2687 **Perlman S, Ali MA, Alnaeem A, Guan Y, Poon LL, Saif L, Peiris M.** 2014.
- 2688 Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi
- 2689 Arabia (1993) and Australia (2014) and characterisation of assay specificity. *Euro.*
- 2690 *Surveill.* **19**. pii: 20828.
- 2691 323. **Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A, Dawo F,**
- 2692 **Jemli M, Melaku S, Shamaki D, Woma Y, Wungak Y, Gebremedhin EZ, Zutt I,**
- 2693 **Bosch BJ, Haagmans BL, Koopmans MP.** 2014. Geographic Distribution of MERS
- 2694 Coronavirus among Dromedary Camels, Africa. *Emerg. Infect. Dis.* **20:1370-1374.**
- 2695 324. **Cai Y, Yú SQ, Postnikova EN, Mazur S, Bernbaum JG, Burk R, Zhāng T,**
- 2696 **Radoshitzky SR, Müller MA, Jordan I, Bollinger L, Hensley LE, Jahrling PB, Kuhn**
- 2697 **JH.** 2014. CD26/DPP4 Cell-Surface Expression in Bat Cells Correlates with Bat Cell

- 2698 **Susceptibility to Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection**
2699 **and Evolution of Persistent Infection. PLoS One 9:e112060.**
- 2700 325. **van Doremalen N, Miazgowiec KL, Milne-Price S, Bushmaker T, Robertson S, Scott**
2701 **D, Kinne J, McLellan JS, Zhu J, Munster VJ.** 2014. Host species restriction of Middle
2702 East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. *J.*
2703 *Virol.* **88**:9220-9232.
- 2704 326. **Payne DC, Iblan I, Alqasrawi S, Al Nsour M, Rha B, Tohme RA, Abedi GR, Farag**
2705 **NH, Haddadin A, Al Sanhoury T, Jarour N, Swerdlow DL, Jamieson DJ, Pallansch**
2706 **MA, Haynes LM, Gerber SI, Al Abdallat MM.** 2014. Stillbirth during infection with
2707 Middle East respiratory syndrome coronavirus. *J. Infect. Dis.* **209**:1870-1872.
- 2708 327. **Corman VM, Olschlager S, Wendtner CM, Drexler JF, Hess M, Drosten C.** 2014.
2709 Performance and clinical validation of the RealStar MERS-CoV Kit for detection of
2710 Middle East respiratory syndrome coronavirus RNA. *J. Clin. Virol.* **60**:168-171.
- 2711 328. **Lu X, Whitaker B, Sakthivel SK, Kamili S, Rose LE, Lowe L, Mohareb E, Ellassal**
2712 **EM, Al-sanouri T, Haddadin A, Erdman DD.** 2014. Real-time reverse transcription-
2713 PCR assay panel for Middle East respiratory syndrome coronavirus. *J. Clin. Microbiol.*
2714 **52**:67-75.
- 2715 329. **Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, Muller MA, Haagmans**
2716 **B, de Sousa R, Schuurman N, Dittmer U, Rottier P, Osterhaus A, Drosten C, Bosch**
2717 **BJ, Koopmans M.** 2013. Specific serology for emerging human coronaviruses by protein
2718 microarray. *Euro. Surveill.* **18**:20441.
- 2719 330. **Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG,**
2720 **Jr., Frieman MB, Holbrook MR, Jahrling PB, Hensley L.** 2014. Interferon-beta and
2721 mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus
2722 in cell-based assays. *J. Gen. Virol.* **95**:571-577.
- 2723 331. **Tao X, Mei F, Agrawal A, Peters CJ, Ksiazek TG, Cheng X, Tseng CT.** 2014.
2724 Blocking of exchange proteins directly activated by cAMP leads to reduced replication of
2725 Middle East respiratory syndrome coronavirus. *J. Virol.* **88**:3902-3910.
- 2726 332. **Al-Tawfiq JA, Momattin H, Dib J, Memish ZA.** 2014. Ribavirin and interferon therapy
2727 in patients infected with the Middle East respiratory syndrome coronavirus: an
2728 observational study. *Int. J. Infect. Dis.* **20**:42-46.
- 2729 333. **de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T, Lackemeyer MG,**
2730 **Martellaro C, Milne-Price S, Haddock E, Haagmans BL, Feldmann H, Munster VJ.**
2731 2013. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not
2732 replicate in Syrian hamsters. *PLoS One* **8**:e69127.
- 2733 334. **Coleman CM, Matthews KL, Goicochea L, Frieman MB.** 2014. Wild-type and innate
2734 immune-deficient mice are not susceptible to the Middle East respiratory syndrome
2735 coronavirus. *J. Gen. Virol.* **95**:408-412.





nsp1: possibly interacts with cyclophilins
Use: antiviral target (cyclophilin inhibitors)

PLpro: proteolysis, IFN antagonist, deubiquitination and deISGylation
Use: antiviral target (PLpro inhibitors)

3CLpro: proteolysis
Use: antiviral target (3CLpro inhibitors)

Hel: viral replication
Use: antiviral target (Hel inhibitors)


RdRp: viral replication and transcription
Use: diagnostic (RdRpSeq assay) and antiviral targets (polymerase inhibitors)


S: virus-cell receptor binding
Use: diagnostic (serology), antiviral (mAbs and antiviral peptides), and vaccination targets

E: virion assembly

M: virion assembly; IFN antagonist
Use: antiviral target (exogenous IFN)

N: virion assembly
Use: diagnostic target (Nseq, N2, N3, and RT-RPA assays; serology)





0.0005